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General introduction 
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Prostate cancer is currently the most common cancer and the second leading cause of cancer 
death in Western men(1). Prostate cancer is unique among the potentially lethal malignancies 
in the huge discrepancy between the high prevalence of histological changes recognizable as 
cancer and the much lower prevalence of clinical disease. While the chance that a 50-year-old 
Dutch man will be diagnosed with prostate cancer during the rest of his lifetime is estimated 
to be 10% and his risk to die from prostate cancer is smaller than 4%(2) autopsy studies have 
shown that the estimated life-time risk of developing (histologically defined) prostate cancer 
for men over 50 is about 42%(3-6).  
In the Netherlands it is the most frequent form of cancer among men with 8800 (21%) new 
diagnoses per year in 2005 followed by lung cancer (6400 [15%] new diagnoses)(7). The 
number of men who will die from this disease each year is around 2350 and is second only to 
ȱ ȱ ȱ ǯȱ ȱ ȱ ȱ ȱ ȱ şŖȂȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ
incidence of about 40 percent (1989-1994). In the years thereafter the number stabilized to an 
incidence of around 100 per 100,000 men per year. 
A number of factors contributed to the increase in prostate cancer diagnoses over the last 
decades. The main factor has been the introduction and widespread use of serum 
measurements of Prostate Specific Antigen (PSA), followed by transrectal ultrasound guided 
needle biopsies. The PSA threshold for a biopsy has also declined gradually due to the 
detection of significant cancers in the low PSA range(8). Furthermore, the total number of 
biopsies is increasing based on the observation that the detection rate of cancer rises when 
more biopsies are taken(9). Finally, also the awareness of prostate cancer within the general 
population has increased, stimulated by the information obtained from the urologic 
profession(10). For the last two decades, unfortunately, the focus has been more on the 
detection of all prostate cancers than on the prevention of diagnoses of insignificant disease. 
It is only the last few years that witnessed a change in this focus.  
With the increasing number of prostate cancer diagnoses we also see a dramatic shift 
towards smaller and earlier stage prostate cancer(11). Between 1989 to 1990 and 2001 to 2002 
in the United States the relative distribution of T1 tumors increased from 16.7% to 48.5% and 
that of T3-4 tumors decreased from 11.8% to 3.5%(12). In that same time frame there was also a 
profound change in Gleason distribution, with the incidence of Gleason scores 6 or less 
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decreasing from 77.1% to 66.4%. However within this group the proportion of Gleason 5-6 
tumors has increased from 44.1 to 64.8 % while the Gleason 2-4 tumors have decreased from 
33.3%to 1.6%. This is probably also caused by the changes in pathological grading 
Today, most men in the United States are diagnosed with non-palpable disease (clinical stage 
T1c), with the diagnosis estimated to be 5 to 10 years earlier than with digital rectal 
examination (DRE) detection(13). In the Dutch situation it is even around 10 to 11 years(14). 
Prostate cancers detected by DRE in screened and non screened populations have been 
shown to be pathologically advanced in more than 50% of men(15) and are commonly 
associated with under-staging of the disease(16).  Therefore, the major limitation of the DRE is 
its lack of sensitivity, because it is only moderately reproducible and highly dependent on 
experience, misses a substantial proportion of cancers, and detects most cancers at a more 
advanced pathologic stage, when treatment is less likely to be effective(13-17). 
The improvements in the detection of prostate cancer along with changes in surgical 
technique have contributed to a dramatic increase in the number of prostatectomies 
performed during the last few decades(18). As a consequence, concerns remain about the over-
diagnosis and over-treatment of indolent or clinically insignificant tumors. Although with 
the current diagnostic tools (PSA, DRE, ultrasound and ultrasound guided biopsies, MRI) 
staging has improved over time as compared to DRE alone 20 years ago, it is still not 
possible to make good decisions about treatment options. 
Therefore we need better tools for prostate cancer staging and tools for better insight in the 
malignant potential of this cancer so that we can offer tailor-made treatment options for each 
patient. MRI, PCA3 and maybe even TMPRSS2-ERG may be some of the tools of the future, 
as will be discussed later in this thesis. 
However, until this is reality, patients with a life expectancy of more than 10 years will be 
offered radical therapy, such as surgery or radiotherapy. Obviously another possibility in 
these patients is active surveillance.  
The way in which a radical prostatectomy is performed has evolved during the last two 
decades. Due to a better anatomical understanding and insight there has been an 
improvement of the surgical technique resulting in better urinary continence and potency 
rates. There have also been developments in techniques like laparoscopic radical 
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prostatectomy and more recent the robot assisted laparoscopic prostatectomy. In radical 
prostatectomy, one of the above mentioned options, examination of the resected tissue, the 
so called histological examination, plays a crucial role in exact classification of a patient, for 
prognostication and subsequent additional therapy  
In this thesis the results of these pathological findings in the radical prostatectomy specimen 
are analyzed, evaluated and discussed for their clinical relevance. 
  
Outline of this thesis 
In chapter 2 a review is presented about the prognostic relevance of pathological information 
that is usually derived from radical prostatectomy specimens. Prognostic factors that are 
most relevant are Gleason score (chapter 3), pathologic stage (chapter 4) and margin status (chapter 
7, 8). 
In chapter 3 the tertiary Gleason Grade is discussed. The Gleason score is an important 
prognostic factor for patients treated with radical prostatectomy. This score is based on the 
sum of the most frequent (primary) and the second most frequent (secondary) pattern seen at 
low magnification. However, frequently more than two predominant Gleason patterns are 
present in one specimen. In this chapter we investigate the prognostic significance of tertiary 
Gleason patterns in radical prostatectomy specimens.  
In chapters 4, 5 and 6 we discuss the value of pathological staging systems and the value of 
determining cancer volume. The purpose of any clinical staging system is to provide a 
reliable estimate of the anatomical extent of the disease to predict prognosis and to guide 
adequate treatment. The role of the T2 subclassification for prostate cancer in the 2002 TNM 
staging system is evaluated for its predictive ability of biochemical recurrence in chapter 4.  
Active surveillance is more and more considered to be a reasonable treatment approach for 
prostate cancer. Especially for patients with small volume prostate cancers (<0.5cc) or 
insignificant cancers (<0.5cc and Gleason score<7) it is considered to be a good approach.  
In chapter 5 we analyze our own patient cohort to determine the biochemical recurrence rate 
of these cancers and discuss the results.  
Prostate cancer tumor volume is clearly associated with prognosis but it is still controversial 
whether it is an independent prognostic factor. Since the measurement of tumor volume is 
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complex and time-consuming we looked at an easier method to determine tumor volume in 
relation with PSA failure.  
In chapter 6 we investigate the prognostic value of maximum tumor diameter, as an easy 
proxy for tumor volume. 
In chapters 7 and 8 we evaluate the surgical margin status. As mentioned earlier in chapter 2 
the presence of positive surgical margins in radical prostatectomy specimens is an important 
negative prognostic factor. Stratification of men with a positive surgical margin, on the basis 
of the probability of post surgery recurrence, is essential in determining who might benefit 
from adjuvant therapy after RP. One of these factors for stratification may be the length of 
the positive margin. In chapter 7 we studied the correlation between the lengths of the 
positive resection margins and biochemical recurrence in our own cohort.  In chapter 8, in a 
different cohort of patients from the Université Catholique de Louvain, Brussels, the 
prognostic value of the number of positive surgical margins and bilaterality of the tumor was 
investigated to see whether this could be an easy parameter to be used to improve risk 
stratification. Another parameter that is of utmost importance in predicting the clinical 
course of this disease is the ability to metastasis. All the prognostic factors mentioned above 
have limitations with regards to this. Therefore, more accurate markers are required to 
predict clinical course. One of these markers is the epithelial cell adhesion molecule E-
cadherin(19).  
In chapter 9 we determine the value of the loss of expression of e-cadherin and cadherin 
associated molecules and analyze the correlation between expression of these molecules with 
long-term prostate cancer specific survival. 
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Algemene introductie 
Prostaatkanker is momenteel de meest voorkomende vorm van kanker en de op één na 
grootste doodsoorzaak bij mannen in West Europa(1). In het grote contrast tussen de hoge 
prevalentie van de als kanker herkenbare histologische veranderingen en de veel lagere 
prevalentie van klinische ziektes is prostaatkanker uniek onder de potentiële dodelijke 
kwaadaardige ziektes. Bij een 50-jarige man is de kans op prostaatkanker voor de rest van 
zijn geschatte levensduur 10%. Het risico dat hij aan deze ziekte zal sterven is slechts 4%. 
Autopsiestudies hebben echter aangetoond dat het geschatte levensrisico voor de 
ontwikkeling van prostaatkanker voor mannen boven de 50 jaar ongeveer 42% is(2-5). 
In Nederland is prostaatkanker de meest voorkomende vorm van kanker met 8.800 (21%) 
nieuwe diagnoses per jaar in 2005, gevolgd door longkanker met 6.400 [15%] nieuwe 
diagnoses)(6). Het aantal mannen dat elk jaar aan deze ziekte zal sterven bedraagt ongeveer 
2.350 en wordt op de voet gevolgd door longkanker. Sinds begin jaren 90 (1989-1994) heeft 
een dramatische groei van ongeveer 40% plaatsgevonden in de incidentie. In de jaren hierop 
volgend is het aantal gestabiliseerd met een actuele incidentie van ± 100 per 100.000. 
Er is een aantal factoren, dat gedurende de laatste decennia mogelijk heeft bijgedragen aan 
de toename van een prostaatkankerdiagnose. De belangrijkste factor is de introductie en het 
algemene gebruik van serummetingen van Prostaat Specifiek Antigen (PSA), aangevuld met 
transrectale echogeleide naaldbiopten. De PSA waarde voor het nemen van biopten is ook 
geleidelijk gedaald dankzij de detectie van significante kankers in de lage PSA waarden(7). 
Het feit dat meer kanker wordt gediagnosticeerd als er meer biopten worden afgenomen, 
heeft een toename in de hoeveelheid afgenomen biopten tot gevolg gehad(8). Ten slotte, de 
bekendheid van prostaatkanker is ook onder de bevolking toegenomen, wat wordt 
gestimuleerd door de voorlichting vanuit de urologische beroepsgroep(9).  
Het is een feit dat de focus de laatste 20 jaar meer gericht geweest is op de detectie van alle 
prostaatkankers dan op de preventie van de diagnose van klinisch insignificante ziekte. Met 
het toenemend aantal prostaatkankerdiagnoses, wordt ook een aanmerkelijke verschuiving 
geconstateerd naar kleinere prostaatkankers en prostaatkanker in een vroeger stadium(10). 
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Tussen 1989 - 1990 en 2001 - 2002 is de incidentie van T1 tumoren toegenomen van 16.7% tot 
48.5% terwijl de incidentie van T3-4 tumoren respectievelijk is gedaald van 11.8% tot 3.5%(11). 
In dezelfde tijdsspanne was er ook een duidelijke verschuiving in Gleason gradering, met 
een daȱȱȱ ȱȱȱ	ȱȱǂȱŜȱȱŝŝǯŗƖȱ ȱŜŜǯŚƖǯȱȱȱ
deze groep is het aandeel van Gleason 5-6 tumoren toegenomen van 44.1% naar 64.8% terwijl 
het aandeel van de Gleason 2-4 tumoren is gedaald van 33.3% naar 1.6%. Dit wordt 
waarschijnlijk veroorzaakt door veranderingen in beoordeling van het preparaat door de 
patholoog. 
Tegenwoordig worden de meeste mannen in de Verenigde Staten gediagnosticeerd met een 
niet-palpabele ziekte (klinische stadium T1c), waarbij wordt geschat dat de diagnose 5 tot 10 
jaar eerder kan worden gesteld dan via rectaal toucher (RT) detectie(12). In de Nederlandse 
situatie is dit zelfs 10-11 jaar eerder. Prostaatkanker die door middel van RT is gedetecteerd 
(in gescreende en in niet gescreende populaties)  zijn in meer dan 50% van de mannen 
pathologisch verder gevorderd(15).  Deze bevinding gaat meestal samen met pathologische 
onderstadiëring van de ziekte(14). De grootste beperking van het RT is derhalve het gebrek 
aan sensitiviteit, omdat het slechts beperkt reproduceerbaar is, sterk afhankelijk is van de 
ervaring van de onderzoeker en een substantieel aantal kankers mist. De meeste kankers 
worden pas opgespoord als deze in een meer gevorderde pathologische fase zijn en 
behandeling waarschijnlijk minder effectief zal zijn(12,15). 
In de laatste decennia hebben de verbeteringen in de detectie van prostaatkanker en de 
veranderingen in operatietechnieken bijgedragen tot een aanzienlijke toename van het aantal 
uitgevoerde prostatectomieën(16). Een gevolg hiervan is dat er bezorgdheid blijft bestaan over 
de mogelijkheid van overdiagnostisering en overbehandeling van langzaam groeiende of 
klinisch insignificante tumoren. Hoewel met de huidige diagnostische apparatuur (PSA, RT, 
echo met echogeleide biopten en MRI) de stadiering in de loop van de tijd vergeleken met 
alleen RT van 20 jaar geleden is verbeterd, is het nog steeds niet mogelijk om goede 
beslissingen over behandelingsmogelijkheden te nemen. 
Daarom wordt gezocht naar betere instrumenten om een patiënt met prostaatkanker te 
stadiëren. Er wordt gezocht naar instrumenten die een beter inzicht geeft in de 
kwaadaardigheid van deze vorm van kanker, zodat de uroloog meer verfijnde en kant en 
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klare behandelplannen aan elke patiënt kan bieden. MRI, PCA3 en misschien zelfs 
TMPRSS2-ERG kunnen deze instrumenten van de toekomst zijn.  
Zolang dit echter nog niet is gerealiseerd, zal aan iedere patiënt met een levensverwachting 
van meer dan 10 jaar een definitieve vorm van behandeling, zoals chirurgie of radiotherapie 
worden voorgesteld dan wel een waakzaam wachten protocol worden aangeboden. De wijze 
waarop de radicale prostatectomie wordt uitgevoerd is gedurende de laatste twee decennia 
geëvolueerd. Een beter anatomisch inzicht heeft geleid tot verbetering van de chirurgische 
techniek met betere resultaten voor continentie en potentie. Ook zijn er technische 
ontwikkelingen geweest zoals de laparoscopische radicale prostatectomie en de meer recente 
robot geassisteerde laparoscopische prostatectomie. In radicale prostatectomieën, een van de 
eerdere genoemde therapieën, speelt het pathologisch onderzoek van het chirurgische 
preparaat een belangrijke rol in de exacte classificatie van de patiënt voor de prognose en de 
eventuele daaropvolgende therapie.  
In dit proefschrift worden de resultaten geanalyseerd en bediscussieerd van pathologische 
bevindingen van tijdens radicale prostatectomieën afgenomen preparaten en de klinische 
waarde van deze bevindingen.  
 
Overzicht van deze thesis 
In hoofdstuk 2 wordt de relevantie en prognostische waarde van pathologische informatie 
gepresenteerd afkomstig uit preparaten van radicale prostatectomieën. Prognostische 
factoren die relevant zijn voor de prognose na radicale prostatectomie zijn Gleason score 
(hoofdstuk 3), pathologische stadiering (hoofdstuk 4) en chirurgische resectievlakken (hoofdstuk 7,8). 
In hoofdstuk 3 wordt de tertiaire Gleason gradering besproken. De Gleason score is een 
belangrijke prognostische factor voor patiënten die een radicale prostatectomie hebben 
ondergaan. Deze score is gebaseerd op de som van het meest voorkomende (primaire) en het 
op twee na meest voorkomende (secondaire) patroon dat bij een kleine prostaatvergroting 
kan worden gezien. Er zijn echter vaak meer dan twee predominante Gleason patronen in 
één preparaat aanwezig. In dit hoofdstuk onderzoeken wij de prognostische betekenis van 
tertiaire Gleason patronen in het preparaat van een radicale prostatectomie.  
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In hoofdstuk 4, 5 en 6 wordt de waarde van het pathologische stadiëringssysteem en de 
waarde van één van de factoren in gradering: tumorvolume in prostaatkanker en de 
prognostische rol hiervan besproken. Het doel van ieder klinisch stadiëringssysteem is een 
betrouwbare schatting te kunnen geven van de anatomische uitgebreidheid van de ziekte om 
een prognose te kunnen stellen en een adequate behandeling voor te stellen.  
In hoofdstuk 4 wordt de rol van de T2 subclassificatie voor prostaatkanker in het 2002 TNM 
graderingsysteem geëvalueerd ten aanzien van de waarde van dit systeem om biochemische 
recidieven te voorspellen. In dit hoofdstuk wordt besproken of de subclassificatie van de T2 
prostaatkanker prognostische waarde heeft en wordt een wijziging van het TNM systeem 
voorgesteld.  
Waakzaam wachten wordt steeds vaker beschouwd als een acceptabele behandeling voor 
prostaatkanker. Speciaal bij patiënten met een klein-volume prostaatkanker (<0.5cc) of 
insignificante kankers (0.5cc en Gleason score <7) wordt dit als een goede behandeling 
beschouwd. 
Hoofdstuk 5 geeft een analyse van ons eigen patiëntencohort waarbij de kans op 
biochemisch recidief van deze klein-volume en insignificante kankers wordt bepaald.  
Prostaatkanker en tumorvolume zijn duidelijk geassocieerd met prognose, maar het is nog 
altijd controversieel of het een onafhankelijke prognostische factor is. Aangezien het meten 
van het tumorvolume ingewikkeld en tijdrovend is, wordt in hoofdstuk 6 gekeken naar een 
eenvoudiger methode voor het vaststellen van het tumorvolume in relatie tot het 
biochemisch recidief, te weten de maximale tumordiameter. Hiervoor wordt de 
prognostische waarde van de gemakkelijk te meten parameter, de maximale tumordiameter, 
onderzocht als plaatsvervanger van tumorvolume.  
 In hoofdstuk 7 en 8 worden de chirurgische snijvlakken geëvalueerd. Zoals eerder vermeldt 
in hoofdstuk 2, is de aanwezigheid van positieve snijvlakken in een preparaat van een 
radicale prostatectomie (RP) een belangrijke negatieve prognostische factor. Stratificatie van 
mannen met een positief snijvlak op basis van de waarschijnlijkheid van postchirurgische 
recidieven, is essentieel om te bepalen wie na RP in aanmerking komt voor adjuvante 
therapie. Een van de factoren voor deze stratificatie kan de lengte van het positieve snijvlak 
zijn. 
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In hoofdstuk 7 wordt de correlatie tussen de lengte van het positieve chirurgisch snijvlak en 
het biochemisch recidief in ons eigen cohort bestudeerd.  
In hoofdstuk 8 wordt in een patiëntencohort van de Katholieke Universiteit van Leuven, 
Brussel het aantal positieve snijvlakken en de bilateraliteit van de snijvlakken onderzocht in 
correlatie met het biochemisch recidief. Deze correlatie wordt geanalyseerd om te kunnen 
vaststellen of dit een eenvoudig te meten parameter zou kunnen zijn voor risico stratificatie 
van het positieve snijvlak.  
Een andere parameter welke van belang is om het klinisch verloop te kunnen voorspellen is 
het metastaseringspotentieel. Al deze hierboven genoemde prognostische factoren hebben 
beperkingen ten aanzien van deze parameter. Daarom zijn er efficiëntere markers nodig om 
het klinisch verloop te kunnen bepalen. Een van deze markers is de epitheliale cel adhesie 
molecuul E-cadherine(17).  
 In hoofdstuk 9 wordt de waarde bepaald van het verlies van expressie van E-cadherine en 
de cadherine verwante moleculen, en wordt de correlatie geanalyseerd tussen de expressie 
van deze moleculen en de lange termijn prostaatkankerspecifieke overleving. 
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CHAPTER  2 
Prognostic factors in radical prostatectomy 
specimens: what do we need to know from our 
pathologist? 
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Abstract 
Objectives 
Pathologic information derived from the radical prostatectomy specimen contains powerful 
ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ Ȃȱ ȱ ȱ -free 
survival and to decide what treatment a patient should receive; therefore, it is important to 
get the appropriate pathological information from the pathologist. 
This review will concentrate on relevant prognostic factors in assessing radical 
prostatectomy specimens. 
Methods 
Medical literature was screened with PubMed for prognostic factors derived from radical 
prostatectomy specimens. 
Evidence synthesis: Prognostic information from radical prostatectomy specimens should at 
least include Gleason score, pathologic stage, and margins status and should be clearly 
presented by the pathologist to the urologists. Other prognostic factors such as tumor 
volume, perineural invasion, maximum tumor diameter, percentage of high-grade tumor, 
and tertiary Gleason pattern are still under debate and require more study. 
Conclusions 
The urologist should be aware of and presented with those factors that are the most 
important ones for estimating prognosis after radical prostatectomy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
van Oort IM, Hulsbergen±van de Kaa CA, Witjes JA. Prognostic factors in radical prostatectomy specimens: what do we need to know from our 
pathologist? Eur Urol. Suppl.2008 Nov; 7 (12): 715-722. 
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Introduction 
Prostate cancer is the most commonly diagnosed solid cancer and the second leading cause 
of cancer related deaths in American and European men(1-2). The most common definitive 
therapy for the treatment of clinically localized prostate cancer is radical prostatectomy. 
Pathologic information derived from the radical prostatectomy specimen, such as Gleason 
score, pathologic stage and margin status, are powerful prognostic indicators which can be 
ȱ ȱȱ ȱ ȱ ȱȱȱ ȱȱ ȱȂȱ ȱ ȱ
disease free survival(3). This pathologic information is also of importance to decide if a 
patient needs to receive adjuvant radiotherapy or hormonal treatment(4-5). Therefore it is 
important to get the appropriate pathological information from the pathologist. In this 
article, we review the results of published prognostic factors derived from radical 
prostatectomy specimen and look at the future perspectives. For this we will use the 
classification of prognostic factors developed at consensus meetings sponsored by the 
College of American Pathologists (CAP) in 1999 (6). In this classification there are 3 categories. 
In category 1 the prognostic factors are proven to be prognostically significant and useful in 
patient management (Gleason score, pathologic stage and margin status). In category 2 the 
prognostic factors show promise as predictive or prognostic factors (tumor volume). In 
category 3 the prognostic factors have some scientific evidence as prognostic factors, but the 
data are too preliminary (perineural invasion). This review will not address prognostic 
factors that are not derived from radical prostatectomy specimen (serum PSA).  
 
Handling radical prostatectomy specimen 
 
Several papers have been published regarding the appropriate methods of histological 
sampling(7-9). Although it is not uncommon practice in academic centers to serially section and 
embed the radical prostatectomy specimen in its entirety, a survey of the American Society 
of clinical Pathologist indicated that only 12% of pathologists processed the entire prostate 
specimen for histological review(10). The reason for this is probably because the whole mount 
process is technically demanding requiring time and experience of the technician.  
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This is different in Europe where in a recent survey, through the European Network of 
Uropathologist among 217 pathologists, 72% appeared to process the prostate in its entirety 
(unpublished data, Lars Egevad, personal communication). 
In case of palpable tumors (clinical stage T2) studies suggest that prostates could be partially 
sampled by focusing on the posterior portion of the prostate where the tumor is palpated, 
and submitting gross tumor along with routine margins(9-11). Sedhev et al. studied 10 different 
sampling methods with 78 cT1c prostate tumors(12). They found the most acceptable method 
for partial method is submitting every posterior section plus 1 midanterior section from right 
and left sides. If either of these anterior sections show sizeable tumor, all ipsilateral anterior 
slides are examined. In comparison with total embedding of the prostate this method detects 
98% of tumors with Gleason score > or = 7, 100% of positive margins, and 96% of cases with 
extraprostatic extension. In 32% additional submitting was necessary. In conclusion they 
state that also partial sampling of non-palpable tumors (clinical T1) can detect important 
prognostic parameters but that ultimately the pathologist must decide which sampling 
method to use by balancing the extra time and expense involved to process and examine 
additional sections with the risk of missing important prognostic parameters.  This is in line 
with the recommendations from the consensus meetings in 1999: partial sampling is 
acceptable if a logical approach is followed, whole-mount sections are optional(6).  
 
Category 1 - Gleason score 
 
The Gleason system is the most widely used grading system for prostate cancer(13). This 
system is based on architectural arrangement of the glandular differentiation patterns as 
seen at low magnification (fig.1) . Because prostate cancer is usually heterogeneous, Gleason 
incorporated the most frequent (primary) and the second most frequent (secondary) patterns 
in his system. Both the primary and secondary are assigned a grade between 1 and 5, with 1 
being the most differentiated pattern and 5 the least differentiated. The sum of the primary 
and secondary is the Gleason score (2-10), which is given to each prostate specimen. In cases, 
in which only a single pattern is present, the primary grade is doubled to derive the Gleason 
score. The reproducibility of this scoring system in several studies is in an acceptable range 
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of 70%(14). It has a better intraobserver and interobserver reproducibility than the WHO 
system(15). 
The Gleason score in radical prostatectomy specimen is an important prognostic factor, 
probably the most powerful predictor of disease progression(16;17). Robert et al. found in their 
cohort of 1805 patients in multivariate analysis that Gleason score was one of the 
independent predictors of survival (Hazard Ratio 2.02, p= 0.001) together with positive 
lymph nodes and positive surgical margins(16). Epstein et al. found in their cohort of 617 men 
without lymph node metastases or seminal vesicle invasion in multivariate analysis that 
Gleason score was one of the independent predictors of progression (p<0.0001) together with 
surgical margins (p=0.004) and capsular penetration (p=0.007)(18). In our own cohort of 453 
men without lymph node metastases or seminal vesicle invasion we also could confirm in a 
multivariate analysis that Gleason score (p<0.0001), surgical margins (p<0.0001) and number 
of tumors (p=0.04) were independent predictors of progression (submitted). 
Obviously the importance of the Gleason grading system comes back in the 
recommendations from the consensus meetings in 1999: pathological reports for radical 
prostatectomy specimen should include the Gleason score reported as the composite score 
and its component patterns (e.g. Gleason 3+4=7). The first reported pattern being the most 
frequent pattern and second reported pattern the second most frequent(6). 
 
TNM 
 
Final pathologic stage determined by examination of the RP specimen, predicts the 
likelihood of recurrence much more accurately than factors routinely available pre-
operatively (clinical stage, pre-operative PSA and biopsy Gleason score). The pathologic 2002 
TNM staging categories are given in table 1(19) . 
 
Primary tumor (pT) 
 
T1 
There is no stage pT1 category after radical prostatectomy. Stage T1 is derived from 
incomplete sampling of the prostate e.g. transurethral resection specimen or needle biopsy. 
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pT2 
A cancer completely confined to the prostate is defined as pT2a, b or c. Although subdivision 
of clinical stage T2 disease into stage T2a, T2b and T2c stage makes some sense, a similar 
approach to stage pT2 disease is problematic. 
Chun et al. assessed the prognostic value of pT2 sub stages for the prediction of biochemical 
recurrence after radical prostatectomy(20). In their cohort of 1726 patients they found that 
pathological sub staging did not add to other prognostic information (pre-treatment total 
PSA, surgical margins status and Gleason scores). 
In our own cohort of 542 patients using the TNM 2002 classification we compared 
biochemical outcome of 79 (22%) pT2a and 281(78%) pT2c. No pT2b were found. Here also 
no significant differences were found in biochemical recurrence (log rank test p=0.136) and in 
pathological features (submitted). 
Freedland et al. compared biochemical outcome of men with pT2a and pT2b using the 1997 
TNM staging criteria and found in 1606 men no significant differences in clinical stage or 
recurrence free survival between these subgroups(21). On multivariate analysis biopsy and 
prostatectomy Gleason scores, preoperative serum PSA and clinical stage, but not 
pathological stage (pT2a vs. pT2b) were found to be significant predictors of PSA recurrence, 
concluding that the TNM staging system should be simplified by eliminating 
subclassification of pT2 tumors. Obviously, it makes more sense in organ-confined disease to 
use the generic stage pT2 category with a comment on the amount and distribution of the 
tumor. 
pT3 
A cancer that extends through the prostatic capsule is defined as pT3. This can occur as 
extraprostatic extension (pT3a) and or seminal vesicle invasion (pT3b). 
pT3a extraprostatic extension (EPE) 
The prostatic capsule is not a well defined structure. In the lateral and posterior aspect the 
prostate is sharply demarcated from the adjacent adipose tissue but in other areas this 
demarcation is less evident (apex, anterior surface and bladder neck). When the tumor 
extends beyond the normal confines of the prostate gland the recommended term to be used 
is therefore extraprostatic extension (EPE). If EPE occurs the extent also seems of importance. 
Prostate cancer with only limited or focal extraprostatic extension has a lower rate of PSA 
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recurrence compared to extensive extension. Stephenson et al. also saw this in multivariate 
analysis for the updated post-operative Kattan nomogram.  In a cohort of 1881 patients, EPE 
was a significant variable in the multivariable model (p<0.0001)(22). 
Recommendations from the consensus meetings in 1999 state that reports have indicated that 
some form of quantification of volume and extent of tumor outside the gland in pT3a tumors 
is of prognostic significance(6). 
pT3b seminal vesicle invasion (SVI) 
Seminal vesicle invasion is defined, as tumor infiltrating the muscular coat of the seminal 
vesicle, is commonly associated with EPE, and is considered an independent adverse 
prognostic factor(17;23). The possible routes are: 1) spread along the ejaculatory duct into the 
seminal vesicle, 2) extension into the periseminal vesicle soft tissue and then into the wall of 
the seminal vesicle, and 3) discontinuous metastases. The first two routes are most 
commonly seen(24). Several studies found that SVI is a major adverse factor predicting 
biochemical failure after radical prostatectomy. In a study by Blute et al. in a group of 2518 
patients there was a significant lower 5-year progression-free survival of 52% in patients 
with SVI versus 81% in patients without SVI(25). Secin et al. found in a cohort of 387 patients 
with SVI a 10 year biochemical free survival of 36%(26). 
 
Lymph node 
 
The presence of metastatic prostate cancer in pelvic lymph nodes is a significant adverse 
prognostic factor. In a study by Epstein et al. in a cohort of 721 patients 57 patients were 
found to have lymph node disease and 87% of these men failed at 5 years post surgery and 
all had disease progression at 10 years. In the study for the up-dated postoperative Kattan 
nomogram lymph node involvement was also found to be one of the significant variables in 
the multivariable model (p=0.030)(27). 
The use of pre-operative nomograms for patient selection before radical prostatectomy has 
led to a decreasing rate of positive pelvic lymph nodes(28). Lymph node metastases should be 
assessed by routine microscopy. Identification of a positive lymph node indicates pN1 
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disease, which should be noted in the pathology report. Micro metastases (tumor cell clusters 
>0.2mm and <0.2cm in greatest diameter) should also be reported as pN1 disease(19).  
The recommendations from the consensus meetings in 1999 advice to follow the American 
Joint Committee on Cancer (AJCC)/TNM system for local staging (17;19). 
 
Margin status 
 
A positive surgical margin present in a radical prostatectomy specimen is one of the most 
important prognostic parameters. Presence of tumor cells at the inked margin of resection is 
considered a positive surgical margin. Disease progression is seen significantly more often in 
patient with positive margins after radical prostatectomy compared to those with negative 
margins. Studies with large cohorts of patients have confirmed that positive margins are an 
independent predictor of recurrence. In several studies the 5-year progression-free 
probability following radical prostatectomy ranged from 81-84% for margin-negative disease 
and 58-67% for margin-positive specimens(18;29-32). Vis et al. on the other hand found that 
although a positive surgical margin is a statistically significant prognostic factor it only has a 
limited predictive value for PSA relapse and local recurrent disease (positive margins vs. 
negative margins respectively 33.3% vs. 7.9% and 6.1% vs. 1.4%) stating that cases with a 
positive margin may still be cured(33). 
Other factors that might be of importance could be the location of the tumor(32;34). Blute et al. 
reported a positive margin rate of 26% in 2712 patients and found that positive surgical 
margins are a significant predictor of recurrence(34). This seemed to be site specific with 
prostate base positivity significantly associated with the worst outcome. They found a 5-year 
survival free of a combined end point of clinical or PSA failure for patients with or without a 
positive margin at the prostate base of 56% versus 85%, respectively. Several other studies 
have demonstrated that positive apical margins do not correlate independently with disease 
progression in multivariate analyses(32;35).  
In conclusion a positive surgical margin is an independent predictor of recurrence. A major 
difference with other risk factors is that the surgeon can influence this factor. The surgeon 
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should continue to strive to reduce the rate of positive surgical margins to improve cancer 
control outcomes. 
It seems therefore obvious that the recommendations from the consensus meetings in 1999 
clearly state: Surgical margin status should be a category 1 variable. It is a standard part of 
reporting used in clinical decision making and has been found to be a significant prognostic 
indicator(6).  
 
Category 2 - Tumor volume 
 
The tumor volume of adenocarcinoma of the prostate in RP is clearly associated with 
prognosis. Stamey et al. were the first who found that tumor volume is an independent 
prognostic parameter for prostate cancer progression(36). These findings were also observed 
in other studies(37;38), and confirmed in a more recent study by Chun et al. They found that 
tumor volume and percentage of high grade tumor volume affect the biochemical recurrence 
rate after radical prostatectomy and represent the most powerful predictors of cancer control 
in men treated for localized prostate cancer(39). However, whether it is an independent 
prognostic factor still remains controversial(40). Epstein et al. stated that, although tumor 
volume is a predictor of progression, it did not provide additional information over Gleason 
score and pathological stage(41). This was also found in a study by Salomon et al., where only 
Gleason score and pathological stage were independent factors to predict progression after 
RP. If these parameters were known, tumor volume did not provide any additional 
information(42)ǯȱȱȱ ȱȱȱȱȱȂȱȱȱȱȱ
Gleason score, pathological stage, and positive surgical margins were known. An 
explanation of these conflicting results might be that tumor volume estimations can be done 
with the help of several techniques, as Humphrey and Volmer described earlier(43). The fact 
that several techniques can be used to assess tumor volume is reflected by the way the 
recommendations from the consensus meetings in 1999 are formulated: intraprostatic extent 
of cancer should be evaluated by some standard method so that percent of cancer in the 
sample can be reported(6).  
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Category 3 - Perineural invasion 
 
Perineural invasion is a finding mostly found in radical prostatectomy specimens especially 
in peripheral zone prostate cancers. It often represents a pathway of EPE.  
A study that has shown a positive correlation between perineural invasion and disease 
progression was by Endrizzi et al.(44). In their study with a cohort of 131 patients with pT2 
prostate cancer, 17 (13%) patients had PSA recurrence. Of those with PSA recurrence, 14 had 
PNI, one had no PNI and in two there was no comment on PNI, concluding that in this series 
perineural invasion was the most sensitive predictor of biochemical failure. Others, like Van 
den Ouden et al., suggest that it is not an independent predictor of progression(45).In their 
study of 273 patients they evaluated perineural invasion in radical prostatectomy specimens 
and found that although this was significantly predictive for clinical and biochemical 
progression in the univariate analyses, it was not significant in multivariate analysis or for 
cancer-specific survival.  
The insufficiently proven importance of perineural invasion is reflected by the 
recommendations from the consensus meetings in 1999: This factor requires further study(6).  
 
Future perspectives 
 
Above mentioned pathological variables such as pathological stage, surgical margins and 
Gleason grade are able to predict the rate of biochemical recurrence. However, their accuracy 
is not perfect which drives the search for other predictors like percentage of high grade 
Gleason, maximum tumor diameter and tertiary Gleason pattern. 
 
Percentage of high grade Gleason 
 
Tumors with a high Gleason score are generally aggressive. Stamey et al. therefore advocate 
measuring the percentage of high grade tumor (Gleason patterns 4/5) present within a 
specimen(36). Studies by Cheng et al. and Vis et al. confirmed this and found that the amount 
of high-grade cancer (Gleason pattern 4/5) was a significant predictor of PSA relapse(46;47). 
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Although this is of value in predicting outcome, calculation of this can be difficult and this 
measure is considered investigational. 
 
Maximum tumor diameter 
 
Maximum tumor diameter (MTD) has been suggested as a fast and easy proxy for tumor 
volume. Renshaw et al. noted that simple measurements of the largest diameter of the largest 
tumor from glass slides is a predictor of PSA failure(48). This was supported by Eichelberger 
et al. where they showed that MTD correlates with tumor volume and other potential 
prognostic factors for clinical outcome(49). This is in contrast with our own series where we 
found that maximum tumor diameter was weakly associated with the risk of biochemical 
recurrence and, if adjusted for positive surgical margins, higher Gleason score, advanced 
pathological stage and multiple tumors, maximum tumor diameter did not provide 
additional information (submitted). 
Therefore we need more studies to confirm these results before we can use this as a predictor 
of recurrence. 
 
Tertiary pattern 
 
In his original system Gleason never accounted for the presence of more than two patterns. 
Several studies have assessed the effect of any(50) or high grade(51;52) tertiary Gleason 
component on the risk of PSA recurrence after radical prostatectomy. In all studies the 
presence of a tertiary grade had a significant adverse effect on PSA recurrence. The 5-year 
recurrence free survival rates for men with a tertiary Gleason pattern of any type ranged 
from 19% to 63%  (mean 40%) compared to 59% to 95% (mean 74%) for those without a 
tertiary component(53).  
The consensus of the 2005 International Conference on Gleason Grading of Prostatic 
Carcinoma was that for a radical prostatectomy specimen one assigns the Gleason score on 
the basis of the primary and secondary patterns with a comment as to the tertiary pattern(54). 
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Standardized pathology report 
 
The pathology report of a radical prostatectomy specimen is primarily used for decision 
making if a patient needs adjuvant therapies and for prognostication in the individual 
patient. In radical prostatectomy pathology reports it is important to clearly present the 
relevant prognostic factors, including Gleason score, pathologic stage, and margins status in 
a clear and unambiguous way. Other prognostic factors such as tumor volume, perineural 
invasion, maximum tumor diameter, percentage of high-grade tumor and tertiary Gleason 
pattern are still under debate and require more study. 
 
     Figure 1:  Gleason grades: standard drawing 
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Table 1: 2002 TNM staging Prostate cancer 
 
Clinical Primary Tumor (T) 
Tx  Primary tumor cannot be assessed 
T0  No evidence of primary tumor 
T1  Clinically unapparent tumor not palpable or visible by imaging 
  T1a ȱȱȱȱȱǂśƖȱȱȱ 
  T1b Tumor incidental histologic finding in >5% of tissue resected 
  T1c Tumor identified by needle biopsy 
T2  Tumor confined within prostate 
  T2a ȱȱǂȱȱȱŗȱ 
  T2b Tumor involves >half of 1 lobe but not both lobes 
  T2c Tumor involves both lobes 
T3  Tumor extends through prostatic capsule 
  T3a Extracapsular extension 
  T3b Tumor invades seminal vesicles 
T4 Tumor is fixed or invades adjacent structures other than seminal vesicles; 
bladder neck, external sphincter, rectum, levator muscles, or pelvis wall 
 
Pathologic Primary Tumor (pT) 
pT2  Organ confined 
  pT2a ȱȱǂȱȱȱŗȱ 
  pT2b Tumor involves >half of 1 lobe but not both lobes 
  pT2c Tumor involves both lobes 
pT3  Extraprostatic extension 
  pT3a Extraprostatic extension 
  pT3b Seminal vesicle invasion 
pT4  invasion of bladder, rectum 
 
Regional Lymph Nodes (N) 
Nx  Regional lymph nodes cannot be assessed 
N0  No regional lymph node metastasis 
N1  Metastasis in regional lymph node or nodes 
 
Distant Metastasis (M) 
Mx  Distant metastasis cannot be assessed 
M0  No distant metastasis 
M1  distant metastasis 
  M1a Non-regional lymph nodes 
  M1b Bones 
 M1c Other sites 
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CHAPTER  3  
Does the tertiary Gleason pattern influence the PSA 
progression-free interval after retropubic radical 
prostatectomy for organ-confined prostate cancer?  
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Abstract 
Objectives 
The Gleason sum is an important prognostic parameter for patients treated with radical 
prostatectomy for localized prostate cancer. However, frequently more than two 
predominant Gleason patterns are present in one specimen. In this study we investigated the 
prognostic significance of tertiary Gleason patterns in radical prostatectomy specimens. 
Patients and methods 
Between 1994 and 2001, 277 patients underwent radical retropubic prostatectomy (RRP) for 
clinically localized prostate cancer in our institute. We collected information on Gleason 
score and cancer volume (CV) for all tumor localizations, clinical and pathological stage, 
seminal vesicle invasion (SVI) and extra capsular extension (ECE). In case one pattern was 
seen in more than 95% of the tumor, this pattern was used both for the primary and 
secondary Gleason pattern and any other pattern (actually the secondary pattern) was called 
tertiary. Charts were examined retrospectively for clinical follow up. PSA progression was 
defined as two subsequent rising PSA measurements above 0.10 ng/ml. Kaplan-Meier time to 
PSA progression was compared between patients with and without a tertiary pattern. 
Results 
Overall, of the 223 patients, 106 (48%) were found to have a tertiary pattern, which on 
average, was 7% of the total tumor volume. Patients with a tertiary pattern had a 5-year risk 
of PSA progression of 37.3% versus 12.6% in case no tertiary Gleason pattern was present 
(log rank p = 0.0002). There was no prognostic difference between patients with a higher-
grade tertiary pattern as compared to those with a lower grade tertiary pattern. 
Conclusions 
If present, a tertiary Gleason pattern, whether better or worse than the primary or secondary 
pattern, is an indication for a worse outcome, as indicated by a shorter time to PSA 
progression. This suggests that tumor multifocality, rather than the presence of a higher-
grade tertiary Gleason pattern has prognostic value. 
 
 
 
 
 
 
van Oort IM, Schout BM, Kiemeney LA, Hulsbergen CA, Witjes JA. Does the tertiary Gleason pattern influence the PSA progression-free interval 
after retropubic radical prostatectomy for organ-confined prostate cancer? Eur Urol. 2005 Oct;48(4):572-6. 
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Introduction 
In many countries prostate cancer is the most common cancer in males, and the second cause 
of cancer-related deaths in males after lung cancer(1). The situation in the Netherlands is 
similar with more than 6,500 cases detected yearly(2;3). These numbers will further increase if 
screening will become common practice. Draisma et al. anticipate an increase in incidence of 
prostate cancer of 60Ȯ90% with a population screening program(4). With more men diagnosed 
at an early stage, more men will be treated with curative intent, such as radical 
prostatectomy. However, a substantial number of patients will experience recurrent disease, 
indicating that radical prostatectomy was not curative(5). Identification of these patients 
before surgery would be of great importance to avoid unnecessary surgery or consider early 
adjuvant therapy. With currently available prognostic factors, such as preoperative PSA, 
stage, Gleason grade and surgical margins, whether based on ultrasound, biopsies or 
surgical specimen such a selection cannot be made with sufficient accuracy on an individual 
level. However, the tumor grade seems to be one of the most important prognostic factors6. 
Because prostate cancer often is multifocal(7;8;9), the Gleason system is the most widely used 
grading system for prostate cancer(10). It is based on the glandular differentiation patterns as 
seen at low magnification. The most frequent (primary) and the second most frequent 
(secondary) patterns are each assigned a grade between 1 and 5, with 1 being the most 
differentiated pattern and 5 the least differentiated. The sum of the primary and secondary 
pattern is the Gleason score, which is given to each tumor. Because the original study 
examined primarily biopsy material and transurethral resection specimens the incidence of 
three separate patterns was rare. We now know that many radical prostatectomy specimens 
contain more than two patterns (11-14). There is limited literature concerning the prognostic 
value of the tertiary Gleason pattern. Two recent series addressed this item. Both studies 
suggested an independent negative prognostic value of a higher grade tertiary Gleason 
pattern reflected by a higher stage found at radical prostatectomy and an increased risk of 
progression(15), especially in lower grade disease(16).  
To study the influence of any tertiary Gleason grade on the prognosis of organ confined 
prostate cancer treated with radical prostatectomy, we studied the effect of different Gleason 
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grades in radical prostatectomy specimens on PSA-free survival. Moreover, we looked at the 
prognostic value of several tumor characteristics, tumor multiplicity, the influence of a 4 or a 
5 pattern and the pathologic stage. 
Patients and methods 
Between 1994 and 2001, 277 patients underwent radical retropubic prostatectomy (RP) for 
clinically localized prostate cancer at our institute. Of these patients 54 were excluded from 
analyses because of HIFU treatment, hormonal therapy or irradiation before or immediately 
after RP. Of the remaining 223 patients 13 had incomplete follow-up data. Charts were 
examined retrospectively for clinical and pathological stage including seminal vesicle 
invasion, extra capsular extension and margin status, number of tumors, volume of each 
tumor, and Gleason scores including tertiary Gleason grade. The TNM system was used for 
pathological staging17. All radical prostatectomy specimens were fixed overnight, dyed and 
cut into serial transverse 4 mm. thick slices according to a standard protocol described by 
Ruijter et al.(18). All the specimens were reviewed by the same pathologist (CH). Gleason 
scores were determined as primary and secondary according to their prevalence. The second 
most frequent grade was called secondary if it consisted of more than 5% of the tumor 
volume. It was called tertiary if it consisted of less than 5% of the volume and the secondary 
grade was then given the same grade as the first. PSA progression was defined as two 
subsequent rising PSA measurements above 0.10 ng/ml. We compared the groups with (gl3+) 
ȱ  ȱ ǻřƺǼȱ ȱ ¢ȱ 	ȱ ǯȱ ǰȱ ȱ ȱ  ȱ analyzed 
separately for the presence or absence of a Gleason 4 and/or 5 pattern. We also analyzed 
whether a lower or higher-grade tertiary Gleason pattern modified the risk of PSA 
progression. 
Statistics 
The risk of progression was assessed with the Kaplan-Meier method using the log rank-test 
for the comparison between subgroups. Cox's proportional hazard model was used for 
multivariable analyses. Data were analyzed using SPSS for Windows (version 11.5). 
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Results 
Overall, the 223 eligible patients had a median follow-up of 52 months. 106 patients (48%) 
were found to have a tertiary Gleason pattern, which on average was 7% of the total tumor 
volume. The other 117 patients (52%) only had one or two different Gleason patterns. Time 
to PSA progression was compared between patients with a tertiary pattern (gl3+) and those 
 ȱ ǻřƺǼ(fig. 1). The 5-year risk of PSA progression among patients with a tertiary 
Gleason pattern was estimated to be 37% and in those without a tertiary pattern 13% (log 
rank p = 0.0002). We also compared subgroups with a grade 4 or 5 tertiary Gleason pattern 
(n = 60) to those with a grade 1 to 3 tertiary Gleason pattern (n = 46). An almost similar risk of 
progression was observed in both groups: 5 year risk of progression 38% and 35% 
respectively. The same comparison was made within the group of patients with a total 
Gleason score lower than 7 and the group of patients with a Gleason score 7 or higher. A 
clear difference between patients with a worse or better third Gleason pattern was not 
observed (results not shown). The relation between the third pattern and other potential 
prognostic factors, such as extra capsular extension, seminal vesicle invasion, T-stage and 
tumor volume were also investigated (table 1).  
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   Table 1: Pathological characteristics of radical prostatectomy specimens  
                                                 with (gl3+) or without (gl3ƺǼȱȱ¢ȱ	ȱ 
Histology  
 
Gl3+ (n = 106)  
 
	řƺȱǻn = 117)  
 
p  
 
Extracapsular extension 56.6% 15.4% <0.001* 
Seminal vesicle invasion 17% 6.8% <0.018* 
Margins positive 56.6% 27.4% <0.001* 
pT2 44.3% 80.3% <0.001* 
pT3 53.8% 19.7% 
pT4 1.9% 0 
Tumor volume (mean) 4.5 2.0 <0.001+ 
Gleason score (mean) 6.5 5.7 <0.001+ 
     *Chi-square test 
      +t-test 
Because of these differences Cox proportional hazard regression analysis was performed to 
determine factors predictive of biochemical failure. In these analyses, pT stage (3 or 4 versus 
2) and positive margins were included in addition to the presence or absence of a third 
Gleason pattern. The hazard ratios were HR = 2.34 (95% CI 1.24Ȯ4.42) for stage, HR = 3.95 
(2.04Ȯ7.67) for positive margins and HR = 1.78 (0.91Ȯ3.46) for tertiary Gleason grade. 
Inclusion of capsular penetration or positive seminal vesicles instead of pT stage gave 
comparable results.  
Discussion 
Prostate cancer is the most common cancer in men in the Netherlands. The incidence is 
increasing and more and more men are diagnosed in an early stage. Consequently, the 
number of treatments with curative intent, like radical prostatectomy, is also rising(19). 
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Figure 1:  Kaplan-Meier curves of the PSA progression free interval of patients with a tertiary pattern (gl3+; 
ȱȱǼȱȱȱ ȱȱ¢ȱȱǻřƺǲȱ ȱȱǼǯ 
Although radical prostatectomy is a routine operation with good functional results, there is 
still a substantial percentage of patients that experience a PSA relapse within 5 years. These 
men have not been cured in spite of the previous operation20. Biochemical recurrence is 
observed in approximately 40% of patients who undergo radical prostatectomy, with most of 
the relapses (95%) in the first 5 years5.Prediction of failure is extremely important, but 
remains difficult. The best predictors of PSA failure after radical prostatectomy are Gleason 
score, pathological staging, status of surgical margins and tumor volume21. The Gleason 
score is the most widely used grading system for prostate cancer. The reproducibility of this 
scoring system in several studies is in an acceptable range of about 70%(22;23) with a better 
intraobserver and interobserver reproducibility than the WHO system(24). A potential new 
predictive factor is the presence or absence of a tertiary Gleason pattern. The Gleason 
grading system accounts only for a primary and secondary pattern. A tertiary pattern is not 
evaluated. As prostatic tumors show multiplicity and heterogeneity in many cases, often a 
third and even forth most prevalent pattern can be described. Several studies are published 
Prostate cancer:  
The clinical relevance of pathological findings after radical prostatectomy 
 
 
- 36 - 
 
concerning the prevalence of a tertiary Gleason pattern in prostate cancer. Aihara et al. found 
an average of 2.7 Gleason patterns per case, and more than 50% of the cases containing at 
least three different grades (14). Gleason reported in 1992 that more than 50% of tumors 
contained two or more patterns(13). In an earlier study we found that 16% of all the cancer 
lesions consisted of 3 or more different histological grades(11). In this study 48% of our 
patients had a tertiary grade at histopathological investigation. 
So far only two studies were published dealing with the prognostic significance of the 
tertiary Gleason pattern. In the first study Pan et al. analyzed 114 radical prostatectomies 
with small tertiary patterns. The volumes of the tumor with tertiary components ranged 
from 1% to 15% of the total tumor volume (mean 2%)(15). These were compared to a 
prostatectomy database of 2,276 cases without a tertiary pattern. They defined typical 
Gleason score 5 or 6 tumors as tumors with Gleason scores 2 + 3 = 5, 3 + 2 = 5, 3 + 3 = 6. Both 
typical Gleason score 5 to 6 and Gleason score 7 tumors with worse tertiary patterns revealed 
significantly higher progression rates than typical Gleason score 5 to 6 tumors and Gleason 
score 7 tumors without tertiary patterns. In case of a higher grade tertiary pattern behavior 
was more like typical Gleason score 7 and 8 tumors respectively. Moreover, high-grade 
tertiary patterns were associated with a more advanced pathological stage. They also found 
that tertiary patterns with volumes over 1% of the total tumor volume had a shorter disease 
free survival as compared to cases where the tertiary tumor was less than 1% of the volume. 
In all, Pan et al. concluded that tertiary high-grade patterns adversely influence the 
prognosis, and proposed to modify the Gleason grading system by taking these small 
volumes of patterns 4 and 5 into account. Modifications of the Gleason scoring system based 
on a tertiary pattern were also discussed by Deshmukh and Foster in 1998(25). They described 
how to approach a case with a tertiary pattern. However, there is still no consensus in this 
respect. The second study from Mosse et al. compared the pathological stage of 277 radical 
prostatectomies with tertiary pattern Gleason grade 5 to the pathological stage of 604 radical 
prostatectomies lacking a tertiary pattern(16). The relative effects of a tertiary pattern of 5 were 
largest when the primary and the secondary Gleason grades were low. Even the score of the 
primary pattern was of importance. For example, the impact of a Gleason 5 pattern was 
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much more outspoken in Gleason score 3 + 4 tumors as compared to Gleason score 4 + 3 
tumors. The significance of a tertiary Gleason 5 pattern is obscured in case of higher primary 
and secondary Gleason grades by the already aggressive nature of these advanced primary 
and secondary patterns. They concluded that, except for very high-grade tumors, the tertiary 
pattern at radical prostatectomy should be reported as it has prognostic significance. 
In this study we enrolled only patients with an organ-confined tumor who underwent RRP, 
since that is the group of patients in which the application of an additional prognostic 
marker would be of use, in other words, in whom surgery could have been prevented. We 
found a tertiary Gleason grade in, on average, 7% of the total volume. Our study also 
indicates the importance of a tertiary Gleason pattern. Patients with a tertiary pattern had a 
5-year risk of PSA progression of 37% versus 13% among patients without a tertiary pattern 
(p = 0.0002). There was no difference between patients with a higher tertiary pattern as 
compared to those with a lower tertiary pattern (p = 0.12). So, as we expected, we found a 
worse outcome in the high-grade tertiary pattern cohort, but we also found a worse outcome 
in case of a better tertiary pattern. In comparison to Pan et al. and Mosse et al., we found that 
merely the existence of a tertiary grade, whether low or high grade influences the prognosis. 
The reason for this difference could be that in the studies of Pan et al. and Mosse et al. only the 
largest (index) tumor in the prostate was recorded and small multifocal lower grade tumors 
were not recorded, not taking tumor multifocality and heterogeneity into account. Ruijter et 
al. found in their study that one third of the penetrating tumors in multifocal disease were 
not index-tumors. Furthermore in 9% of the prostate specimens the satellite tumors were 
morphologically more malignant, according to Gleason score, than the index-tumors in the 
same specimens. This indicates that the largest (index) tumor lesion may not be indicative for 
the prognosis(11). In all, we suggest to take into account all tertiary patterns for which 
submission of the entire prostatectomy specimen is needed. 
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Conclusions 
If present, a tertiary Gleason grade, whether better or worse than the primary or secondary 
pattern, is an indication for a worse outcome, as indicated by a shorter time to PSA 
progression. This suggests that tumor multifocality, rather than the presence of a higher-
grade tertiary Gleason pattern has prognostic value. 
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CHAPTER  4  
The prognostic role of the pathological T2 
subclassification for prostate cancer in the 2002 tumor-
nodes-metastasis staging system 
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Abstract 
Objectives 
To evaluate the prognostic role of the 2002 Tumor-Nodes-Metastasis (TNM) pT2 
subclassification for biochemical recurrence (BCR) after radical prostatectomy (RP) for 
prostate cancer. 
Patients and methods 
The 1997 TNM staging system is based on one subdivision for organ-confined prostate 
tumors (T2a, unilateral; T2b, bilateral involvement). The 2002 TNM staging system 
subdivides unilateral involvement into T2a (half of one lobe or less) and T2b (more than one 
half of one lobe), while bilateral involvement is classified as T2c. In all, 542 patients were 
treated with RP at our institute; the RP specimens were completely embedded and 
histopathologically evaluated for Gleason grade, tumor volume and anatomical extent, and 
were staged according to the 2002 TNM staging criteria. Patients were followed for a median 
of 39.5 months. BCR was defined as two subsequent increasing prostate-specific antigen 
(PSA) levels of >0.10 ng/ml. Kaplan-Meier and proportional hazards regression analyses 
were used to evaluate the univariable and multivariable prognostic effect of tumor stage. 
Results 
According to the 2002 TNM staging system, 360 specimens were found to have pT2 tumors; 
79 (22%) of the RP specimens were staged as pT2a and 281 (78%) as pT2c; no pT2b specimens 
were identified. Patients with unilateral involvement (pT2a) had a 5-year risk of BCR of 13%, 
while those with bilateral involvement (pT2c) had a risk of 23% (log rank test, P = 0.056). 
Patients with pT2c disease were more likely to have a larger tumor volume (MannȮWhitney 
U-test P < 0.001) and positive surgical margins (Fishers' exact test, P = 0.001) than those with 
pT2a tumors. MannȮWhitney U-tests showed no differences between the groups for 
preoperative PSA levels (P = 0.167). Also, the RP Gleason score was no different between 
groups (Pearson chi-square, P = 0.807). In the multivariable analyses, positive surgical 
margins appeared to increase the risk of BCR (hazard ratio 4.4, 95% confidence interval 2.5Ȯ
7.9); pT2c versus pT2a had only a marginally (insignificant) additional effect (1.3, 0.6Ȯ2.7). 
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Conclusions 
The absence of a true unilateral pathological T2b tumor in a series of 360 pT2 RP specimens 
questions the relevance of substaging unilateral disease. The limited differences in BCR and 
in pathological features of unilateral versus bilateral pT2 prostate cancer justify modifying 
the TNM staging system to one with no subclassification of pT2 disease, or at most as only 
one subdivision into unilateral (T2a) and bilateral (T2b) disease, combining the T2b and T2c 
sub stages. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
van Oort IM, Witjes JA, Kok DE, Kiemeney LA, Hulsbergen-Van De Kaa CA. The prognostic role of the pathological T2 subclassification for 
prostate cancer in the 2002 Tumour-Nodes-Metastasis staging system. BJU Int. 2008 Aug;102(4):438-41.
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Introduction 
The purpose of any clinical staging system is to provide a reliable estimate of the anatomical 
extent of the disease, to predict prognosis and to guide adequate treatment. Whitmore(1) 
developed the first clinical staging classification system for prostate cancer. In 1992 the TNM 
system for staging prostate cancer was adopted by the fourth edition of the American Joint 
Committee on Cancer (AJCC)(2). The definition of T2 disease was palpable prostate-confined 
tumor, subdivided into three categories; T2a (unilateral tumor involving half of a lobe or 
less), T2b (unilateral tumor involving more than half of a lobe), and T2c (bilateral disease). In 
the 1997 revision the AJCC tried to simplify this by merging T2a and T2b into a single T2a for 
unilateral palpable disease and T2b for bilateral disease(3). In 2002 the AJCC changed this 
again into the three clinical subdivisions(4). 
There remains much controversy about the appropriate subclassification of prostate cancer. 
Most of the discussion is focused on clinical staging, where the three-tiered 1992 clinical 
staging system appeared superior in predicting the outcome in two large series(5;6) . On 
probably the most important aspect, the prognostic value of pathological substaging, fewer 
results are available. 
The purpose of the present study was to assess the prevalence of pT2b tumors and to 
evaluate whether different pT2 AJCC sub stages (TMN 2002) have different risks of 
biochemical progression after radical prostatectomy (RP). 
Patients and methods 
Between 1992 and 2005, 617 patients were treated with RP for clinically localized prostate 
cancer at our institute. Of these patients, 75 were excluded from analyses because of 
treatment with high-intensity focused ultrasound, hormones, or irradiation before RP. The 
medical charts were examined retrospectively for clinical follow-up data. 
All RP specimens were formalin-fixed overnight, inked, and cut into serial transverse 4 mm 
thick slices, perpendicular to the dorsal-rectal surface, according to a standard protocol 
described by Ruijter et al.(7). All slices were macroscopically photographed and subdivided 
into halves or quadrants to fit routine cassettes for further processing. The apex and base 
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were sagittally sectioned to assess the surgical margins. Seminal vesicles were sectioned 
parallel to their junction and embedded in total. After histological staining all specimens 
were evaluated by one experienced urogenital pathologist (C.A.H.K.) and tumors were 
outlined on the microscopic slides and subsequently on the macroscopic photographs to 
allow a reconstruction of tumor extent. Tumors were graded according to Gleason(8). 
Extraprostatic extension was defined as extension of adenocarcinoma in periprostatic 
adipose tissue, and seminal vesicle invasion as invasion beyond the level of their junction 
with the prostate. Surgical margins were considered positive if cancer cells were in the inked 
margin. Tumor volume was calculated as described previously(7). Tumors were initially 
staged according to the TNM classification that was in general use at the time of surgery, but 
retrospectively all pT2 tumors were re-staged according to the 2002 TNM staging criteria (4). 
Patients were followed after RP for a median of 39.5 months. Biochemical recurrence (BCR) 
was defined as two subsequent increasing PSA levels of >0.10 ng/ml. Kaplan-Meier curves 
were used to assess the risk of BCR. In addition, multivariable proportional hazards analyses 
were used to assess the independent prognostic value of stage. Fisher's exact test, MannȮ
Whitney U-tests or chi-square tests were used for comparisons between groups. The 
significance level for all analysis was set at P < 0.05. 
 
             Table 1: The patient and tumor characteristics for pT2 disease (360 men) 
Variable pT2a pT2c P 
No. of patients 79 281  
Mean (SD) age, years 62.1 (6.3) 62.0 (5.6) 0.888 
Median (interquartile range)    
 Preoperative PSA level, 
ng/mL 
6.8 (4.9-10.1) 7.2 (5.0-11.0) 0.168 
Total tumor volume, mL 0.43 (0.16Ȯ1.10) 1.73 (0.75Ȯ3.10) <0.001 
Gleason score, n (%)    
 ǂŜ 51 (65) 187 (67) 0.784 
7 23 (29) 71 (25)  
ǃŞ 5 (6) 22 (8)  
PSM 18 (23) 119 (43) 0.002 
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Results 
Of 542 RP specimens, 360 (66%) were pathologically staged as pT2 and further evaluated; the 
patient and tumor characteristics are summarized in table 1. The mean age was 62.7 years. 
According to the 2002 TNM staging system, 79 (22%) of the RP specimens were staged as 
pT2a and 281 (78%) as pT2c; no specimen was classified as pT2b. Patients with pT2c disease 
were more likely to have a larger tumor volume (1.73 vs. 0.43 mL, MannȮWhitney U-test, 
P < 0.001) and to have positive surgical margins (PSM), than patients with pT2a (23% vs. 
43%, Fisher's exact test, P = 0.002;  table 1). There were no differences between the groups in 
preoperative PSA levels (MannȮWhitney U-test, P = 0.167) or postoperative Gleason score 
(Pearson chi-square, P = 0.784). Patients with unilateral involvement (pT2a) had a 5-year risk 
of BCR of 13%, while patients with bilateral involvement (pT2c) had a risk of 23% (log-rank 
test, P = 0.056; fig. 1). In the multivariate analyses, PSM appeared to increase the risk of BCR 
by more than four times (hazard ration 4.4 95% CI 2.5Ȯ7.9); pT2c versus pT2a had only a 
marginally (insignificant) additional effect (1.3, 0.6Ȯ2.7).  
 
 
 
Figure 1: Kaplan-Meier curves of pT2a and pT2c specimens (upper green line, T2c; lower blue line, T2a). 
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Discussion 
The development of a staging system with both clinical and pathological accuracy is essential 
for determining the prognosis and appropriate treatment. In 1992, the AJCC adopted the first 
TNM staging system for prostate cancer. T2 substaging was primarily based on clinical 
tumor assessment; clinical T2 (cT2) disease was defined by a DRE as palpable organ-confined 
prostate cancer, cT2a involving half a lobe or less, cT2b more than half of one lobe and cT2c 
involving both lobes. In an effort to simplify this TNM system, the 1997 TNM staging system 
combined the 1992 T2a and 1992 T2b into a single subdivision for organ-confined tumors, i.e. 
T2a for unilateral involvement and T2b for bilateral involvement. This new system did not 
gain wide popularity and in 2002 the TNM staging system was revised again into the three-
tiered T2 subclassification of 1992. 
There remains much controversy about the appropriate subclassification of prostate cancer. 
Most of the discussion has been focused on clinical staging criteria in relation to the DRE(5;6). 
Cagiannos et al.(5) reported a comparative analysis of clinical stage T2 prostate cancer in the 
TNM 1992 and 1997 staging system. In a prospective study they analyzed 1755 patients; of 
those with cT2, 37% were classified as cT2a, 43% as cT2b and 20% as cT2c. On univariate 
analysis the recurrence-free survival (RFS) was different for both the 1992 and 1997 cT2a vs. 
cT2b (P < 0.001), but not for the 1992 cT2b vs. cT2c (P = 0.107). However, on multivariate 
analysis they found that the clinical 1992 TNM system (P = 0.005) predicted the biochemical 
outcome after controlling for PSA level and biopsy Gleason score, but not the clinical 1997 
TNM system (P = 0.100). The RFS was 7% higher at 5 years in the 1992 T2a subcategory than 
in the T2b subcategory. In conclusion they stated that the TNM 1992 was better than the 
TNM 1997 system. Staging in this study was done exclusively based on DRE findings and 
not based on pathological examination, and it is well known that the correlation between 
clinical and pathological staging of prostate cancer is poor, with a clinical understaging of up 
to 59%(9). Therefore, it is unclear how many cT2 tumors, especially the larger cT2 tumors, 
would have been re-staged to pT3. 
In a group of 1314 patients with cT2, Han et al.(6) found a significant difference in the RFS for 
patients with 1992 cT2a vs. cT2b tumors (P < 0.001) and 1997 cT2a vs. cT2b tumors (P < 0.001), 
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but not for the 1992 cT2b vs. cT2c tumors (P = 0.117). However, the overall RFS was lower in 
the 1997 cT2a group than in the 1992 cT2a group. They concluded therefore that the 1992 
three-tiered subclassification was preferable or, instead of grouping together the 1992 T2a 
and T2b group, it was better to merge the T2b and T2c stages. Again, this conclusion was 
based on clinical staging only. 
The aim of the present study was to investigate the 2002/1992 T2 subclassification using 
pathologically staged specimens, and not clinical staging, as in all patients treated surgically, 
pathological information is available. Moreover, we evaluated whether distinctions between 
pathological pT2a, pT2b and pT2c subdivisions can predict BCR after RP, the ultimate goal 
of any staging system. In our study we used 360 totally embedded, serially sectioned pT2 RP 
specimens. There were 22% pT2a and 78% pT2c tumors, but we were unable to identify a 
single pT2b tumor (more than one half of one lobe). 
The same result was reported by others who used a pathological assessment(10;11). In the first 
study, RP specimens of 369 patients with prostate cancer were evaluated by complete 
embedding and whole-mount processing(10); no pathological pT2b tumor specimen was 
found. The latter study by Quintal et al.(11) used a point-counting method, i.e. each quadrant 
of each whole-mount section was drawn on paper and contained eight equidistant points. 
The tumor area was drawn on the corresponding quadrant as seen on the paper. Finally, the 
number of positive points represented an estimate of tumor extent. In their series the number 
of points of one lobe of the prostates ranged from 192 for the smallest prostate to 368 points 
for the largest. In their group of 224 men the most extensive unilateral tumor had 68 positive 
points, which is less than half the minimum of total points, showing that it is rather unlikely 
for a large tumor to occupy more than half of one lobe (T2b) and still be confined within this 
lobe, without extension to the opposite site (T2c). In all, tumors that are limited to one lobe, 
but occupy more than half of that lobe, are at least very infrequent, and theoretically, even 
unlikely. 
In the present study there were significant differences between the pT2a and pT2c subgroups 
in tumor volume (0.43 vs. 1.73 mL; P < 0.001) and percentage PSM (23% vs. 43%; P = 0.002), 
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but not in BCR rates (10-year risk of BCR of 15% in pT2a vs. 29% in pT2c, P = 0.087), 
preoperative PSA levels (P = 0.167) or postoperative Gleason score (P = 0.784). 
Only three previous studies have investigated the RFS after pathological substaging. May et 
al. analyzed whether the TNM 1992 or the TNM 1997 can be used to predict RFS (12); in that 
study of 152 men with pT2 disease, there were no significant differences between the 1992 
pT2 subgroups for biochemical 5-year RFS, and thus they supported the two-tiered 1997 
TNM staging system. A limitation of that study was the relatively few patients. Freedland et 
al.(13) examined the biochemical outcome between men with pT2a and pT2b using the 1997 
TNM staging criteria. In that study of 1606 men there were no significant differences in 
clinical stage or RFS between the pT2a and pT2b subgroups. On multivariate analysis, biopsy 
and RP Gleason scores, preoperative serum PSA level and clinical stage, but not pathological 
stage (pT2a vs. pT2b), were significant predictors of PSA recurrence. Recently Chun et al.(14) 
assessed the prognostic value of pT2 substages for predicting BCR after RP. In their group of 
1726 patients they found that pathological substaging did not add to other prognostic 
information (pre-treatment total PSA level, surgical margin status and Gleason scores). 
When adding either the 1997 or 1992/2002 pathological substaging to a multivariate 
nomogram, its accuracy to predict BCR even seemed to decrease. 
The studies discussed above and the present study (table 2) indicate that, although there are 
suggestions that clinical T2 substaging has some prognostic relevance, this  is not sustained 
by its pathological equivalent. This can be explained by the correlation between clinical and 
pathological staging in prostate cancer being disappointing. Clinical staging appears to 
correspond with pathological staging only in 40% of men and up to 59% of clinical 
classifications appear to be understaged(9;15;16). This is a result of the high subjectivity and low 
predictive value of the DRE(17). Probably, most palpable cT2b tumors are already pT2c or pT3 
disease, explaining why clinical staging has a better correlation with prognosis. 
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Table 2:  Details of previous reports comparing TNM systems  
Ref. 
TNM 
comparison Based on Conclusion In favor of TNM 
 
[5] 1992Ȯ1997 Clinical 
staging 
1992 is strongly 
correlated with 
RFS 
1992 
[6] 1992Ȯ1997 Clinical 
staging 
Sign. diff. in RFS 
rate for T2a 92 and 
T2b 92, 
1992 
[12] 1992Ȯ1997 Pathological 
staging 
No sign. diff. in 
RFS rate T2a 92 
and T2b 92 
1997 
[13] 1997 Clinical 
staging  
No sign. diff. T2a 
97 and T2b 97 
A new TNM with no 
subclassification in pT2 
[14] 1997Ȯ2002 Pathological 
staging 
T2 1997 nor 2002 
predictive of 
recurrence 
A new TNM with no 
subclassification in pT2 
[10] 2002 Pathological 
staging 
No T2b was found A new TNM with one or two 
subclassifications in pT2 
Present 2002 Pathological 
staging 
No sign. diff. T2a 
and T2c, No T2b 
was found 
A new TNM with no 
subclassifications, or one or 
two subclassifications 
 
 
 
Therefore, we conclude that the limited differences in BCR rates, in pathological features and 
the absence of a true unilateral 1992/2002 pT2b tumor in a series of 360 pT2 RP specimens, 
justify modifying the TNM staging system to a system with no subclassification of T2 
disease, or at the most into a system with only one subdivision into unilateral (T2a) and 
bilateral (T2b) disease, combining the T2b and T2c substages. 
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CHAPTER  5 
A single institution experience with biochemical 
recurrence after radical prostatectomy for tumors that 
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Abstract 
Objectives 
 Small volume prostate cancers (<0.5 cc, svPC), and insignificant prostate cancers (<0.5 cc and 
Gleason scores <7, InsigPC) are considered clinically insignificant by some investigators. The 
aim of this study is to determine the biochemical recurrence rate (BCR) of svPC and InsigPC 
in prostatectomy specimens. 
Methods 
 In total, 502 patients with prostate cancer, treated with radical prostatectomy (RP) between 
1992 and 2005 and with detailed pathological classification, were included in the present 
study. Patients were postoperatively followed for a median period of 39.5 months (0.6Ȯ150). 
A total of 82 specimens (16.3%) with svPC including 64 (12.8%) with InsigPC were identified. 
BCR was defined as 2 consecutive PSA levels >0.10 ng/ml. 
Results 
 In the total group, the median age at the time of surgery was 62.7 years (42.4Ȯ73.4) and the 
median preoperative PSA level was 8.0 ng/ml. Patients with InsigPC had Gleason scores of 4 
in 7%, 5 in 37%, and 6 in 56%. Positive surgical margins were identified in 13 (15.9%) svPC 
and in 8 (12.7%) InsigPC specimens. The 5-year risk of BCR for the svPC group and the 
insigPC group was 10% (95% CI 2Ȯ18%, 7 and 5 patients, respectively) vs. 35% (95% CI 29Ȯ
41%) in the rest of the cohort (log rank P = 0.001). 
Conclusions 
Patients with svPC and patients with InsigPC have a significantly lower risk of BCR. 
However, even in this seemingly very favorable patient group, 1 in 10 patients will develop a 
BCR after RP. Therefore, new studies are needed to examine what the prognostic relevance is 
of small-volume tumors. 
 
 
 
 
 
 
 
 
 
 
 
 
van Oort IM, Kok DE, Kiemeney LA, Hulsbergen-van de Kaa CA, Witjes JA. A single institution experience with biochemical recurrence after 
radical prostatectomy for tumors that on pathology are of small volume or "insignificant". Urol Oncol. 2008 Jul 12. Epub ahead of print. 
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Introduction 
Prostate cancer is the most commonly diagnosed cancer and the second leading cause of 
cancer death in Western men. Unlike other malignancies, not every prostate cancer poses a 
threat to life and, consequently, need therapy. The wide spread use of prostate specific 
antigen (PSA) testing has led to a spectacular stage migration to smaller and lower stage 
prostate cancers. Small-volume cancers (svPC) are those with a volume of 0.5 cc or less. A 
subset of these tumors is called insignificant prostate cancers (InsigPC). In this case, a 
volume of 0.5 cc or less is combined with a Gleason score of 6 or less(1;2). Expectant 
management is more and more considered to be a reasonable treatment option for these 
small-volume/insignificant prostate cancers. Therefore, for patients with a relatively long life 
expectancy, it is important to know what the biological behavior of these small-volume 
prostate cancers is. However, looking at studies dealing with small-volume prostate cancers, 
nearly all results and conclusions are based on preoperative classifications, nomograms, or 
they are comparing preoperative biopsies with postoperative diagnoses(1-5).To our 
knowledge, the only known analysis looking at the outcome of patients with svPC, in this 
case disease progression, was published by Epstein et al. in 1993(6). They analyzed 185 clinical 
stage B adenocarcinomas of the prostate with a follow-up of 5 years and found that no tumor 
with volume smaller than 0.5 cc (18 patients) was found to have progression following RP.  
In the present series of 502 consecutive radical prostatectomy (RP) patients, we characterized 
and analyzed detailed pathological features of svPC and InsigPC and analyzed the risk of 
biochemical recurrence (BCR) in this group. 
Material and methods 
Study population 
Between 1992 and 2005, 617 patients were treated with RP for clinically localized prostate 
cancer at our institute. Of these patients, 115 were excluded from analyses because of 
preoperative high intensity focused ultrasound (HIFU) treatment, hormonal pretreatment, 
preoperative irradiation, adjuvant treatment (radiation or hormonal), or preoperative 
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transurethral resection of the prostate. Of the remaining 502 patients, 5 had incomplete 
follow-up data. Charts were examined retrospectively for clinical follow-up data. 
Assessment of tumor characteristics 
All RP specimens were fixed overnight, inked, and cut into serial transverse 4 mm thick 
slices according to a standard protocol by Ruijter et al.(7). All slices were macroscopically 
photographed and subdivided into halves or quadrants to fit routine cassettes for further 
processing. Apex and base were sagittally sectioned for assessment of surgical margins. 
Seminal vesicles were sectioned parallel to their junction and embedded in total. After 
histological staining all specimens were evaluated by one experienced urogenital pathologist 
(C.A.H.K.), and tumors were outlined on the microscopic slides and subsequently on the 
macroscopic photographs to allow for reconstruction of tumor extent. Tumor grading was 
performed according to Gleason. Extraprostatic extension was defined as extension of 
adenocarcinoma in periprostatic adipose tissue, seminal vesicle invasion as invasion beyond 
the level of their junction with the prostate. Surgical margins were considered positive if 
cancer cells were in the inked margin. Tumor volume was calculated as described before(7). 
Tumors were initially staged according to the TNM classification that was in general use at 
the time of surgery, but retrospectively all pT2 tumors were restaged according to the 2002 
TNM staging criteria(8). 
Small-volume cancerȱ ȱȱȱȱ ȱȱȱǂȱŖǯśȱǯȱȱȱ
ȱ ȱȱȱȱ ȱȱȱǂȱŖǯśȱȱȱȱ	ȱȱǀȱŝǯȱȱȱ
were obtained before surgery and at every follow-up point. BCR after RP was defined as two 
subsequent PSA levels above 0.10 ng/ml among patients who reached non-measurable levels 
after RP. 
Kaplan-Meier curves were used to assess the risk of BCR. Mann-Whitney U-tests, Log rank 
ȱ ȱ Λ2 test were used for comparisons between groups. The significance level for all 
analyses was set at P < 0.05. SPSS version 14.0 for Windows (SPSS Inc., Chicago, IL) was used 
for all statistical analyses. 
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Results 
In the total group, the median age at the time of surgery was 62.7 years (42.4Ȯ73.4). The 
median preoperative PSA level in this group was 8.0 ng/ml. A total of 82 (16.9%) specimens 
with total tumor volume 0.5 cc or less, including 64 (12.9%) specimens with a total tumor 
volume 0.5 cc or less and a Gleason score < 7 were identified. Tables 1 and 2 and summarize 
pathological characteristics of svPC and InsigPC. In the svPC group, Gleason score was 4 in 
7%, 5 in 37%, and 6 in 56%. Positive surgical margins were identified in 13 (15.9%) svPC and 
in 8 (12.9%) InsigPC specimens. None of these patients had lymph node metastasis. There 
were 7 patients with BCR in the svPC group and in the smaller InsigPC group still 5 patients 
had BCR (table 3). The 5-year risk of biochemical progression for the svPC group and the 
insigPC group was 10% (95% CI 2Ȯ18%, 7 and 5 patients, respectively) vs. 35% (95% CI 29Ȯ
41%) in the rest of the cohort (log rank P < 0.001) (fig. 1). 
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Table 1: Pathological characteristics for small volume prostate cancers (svPC) 
Tumor characteristics 
Cancer volume 
ǂŖǯśȱȱǻƖǼ 
Cancer volume 
>0.5 cc (%) 
P-value 
Na (%) 82 (16.9%) 404 (83.1%) 
Mean cancer volume (SD) 0.25 (0.14) 4.03 (5.07) 
TNMb 2002 (%) 
P < 0.001  
 T2a 37 (45.1%) 34 (8.4%) 
 T2b 0 0 
 T2c 44 (53.7%) 206 (51.5%) 
 T3a 1 (1.2%) 107 (26.6%) 
 T3b 0 45 (11.2%) 
 T4 0 11 (2.7%) 
Gleason scoresc (%) 
P < 0.001  
 ǂŜ 67 (81.7%) 200 (49.9%) 
 7 12 (14.6%) 133 (33.2%) 
 ǃŞ 3 (3.7%) 68 (17.6%) 
Positive surgical margins (%) 13 (15.9%) 231 (57.3%) P < 0.001  
Number of tumors (SD) 2.2 (1.4) 2.2 (1.4) P = 0.81ȕ 
Unifocal tumor (%) 37 (45.1%) 176 (43.6%) 
P = 0.80  
Multifocal tumors (%) 45 (54.9%) 228 (56.4%) 
Biochemical recurrence (5-year risk) 7 (10%) 110 (35%) P < 0.001Ȗ 
a 16 missing 
b 1 missing 
c 3 missing 
 Λ2 test 
ȕ Mann-Whitney U test 
Ȗ Log rank test  
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Table 2: Pathological characteristics of insignificant prostate cancers (InsigPC) 
Tumor characteristics Insignificant cancer (%) 
Cancer volume 
>0.5 cc (%) 
P-value 
Na (%) 64 (12.9%) 434 (87.1%) 
Mean cancer volume (SD) 0.23 (0.14) 3.80 (5.0) 
TNMb 2002 (%) 
P < 0.001  
 T2a 26 (40.6%) 48 (11.1%) 
 T2b 0 0 
 T2c 38 (59.4%) 215 (49.7%) 
 T3a 0 110 (25.4%) 
 T3b 0 48 (11.1%) 
 T4 0 12 (2.8%) 
Gleason scores c (%) 
P < 0.001  
 ǂŜ 64 (100%) 203 (47.1%) 
 7 0 153 (35.5%) 
 ǃŞ 0 75 (17.4%) 
Positive surgical margins (%) 8 (12.5%) 245 (56.6%) P < 0.001  
Number of tumors (SD) 2.2 (1.4) 2.2 (1.4) P = 0.47ȕ 
Unifocal tumor (%) 25 (39.1%) 198 (45.6%) 
P = 0.32  
Multifocal tumors (%) 39 (60.9%) 236 (54.4%) 
Biochemical recurrence (5-year 
risk) 
5 (10.0%) 119 (35%) P = 0.001Ȗ 
a 4 missing 
b 1 missing 
c 3 missing 
 Λ2 test 
ȕ Mann-Whitney U test 
Ȗ Log rank test 
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Table 3: Characteristics of patients with BCR with svPCa and InsigPC 
Patient 
TNM 
2002 
GS SM 
Preop 
PSA 
Number of 
tumors 
Age LND Positive LN TV (cc) 
1 T2c 6 neg 7.32 5 64.9 No ȯ 0.42 
2 T2a 5 neg 15.00 1 67.9 Yes 0 0.16 
3 T2c 5 neg 0.11 3 66.4 No ȯ 0.42 
4a T3a 7 pos 3.68 3 53.4 No ȯ 0.48 
5a T2a 7 pos 1.14 1 68.3 No ȯ 0.40 
6 T2c 6 pos 3.89 4 55.1 No ȯ 0.46 
7 T2c 6 neg 14.27 2 59.3 No ȯ 0.40 
GS = Gleason score; SM = surgical margins; ECE = extra capsular extension; VSI = vesicula seminalis invasion; 
LND = lymph node dissection; TV = total tumor volume. a svPC.  
 
 
Figure 1:  (A) Kaplan Meier curves small volume prostate cancer 
(B) Kaplan Meier curves insignificant prostate cancer  
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Discussion 
The characteristics, which are mostly used to predict progression of prostate cancer after RP, 
are Gleason score, pathological staging, positive surgical margins, and tumor volume(9). The 
tumor volume of adenocarcinoma of the prostate after RP is clearly associated with 
prognosis. However, whether it is an independent prognostic factor still remains 
controversial(10). Epstein et al.(6) stated that although tumor volume is a predictor of 
progression, it did not provide additional information over Gleason score and pathological 
stage. This is in contrast with Stamey et al. who found that tumor volume is an independent 
prognostic parameter for prostate cancer progression(11). These findings were also observed 
in other studies(10;13). 
In accordance with the discussion on the prognostic relevance of total tumor volume, the 
clinical significance of small-volume (less than 0.5 cc) prostate cancer is also controversial. 
Many still consider small-volume prostate cancer to be either clinically insignificant or 
minimally significant. As a consequence, patients with these tumors are considered more 
and more to be good candidates for watchful waiting. This is of growing importance as the 
widespread use of PSA testing leads to overdetection of prostate cancer in general. As a 
consequence of this stage migration, more and more of these small volume prostate cancers 
are detected(14;15). Even when assuming that the relative incidence of insignificant cancers 
remains stable(16-18), the absolute numbers are clearly rising. For instance, in the United States, 
with an average incidence rate of 16% for insignificant cancers (the percentage of 
insignificant cancers is reported to be between 6.4% and 26%(2;17-20)), the absolute numbers 
increased from 28,600 patients in 1999 to 37,500 in 2006(21;22). 
Newer reports suggest that the incidence of these tumors is even higher. In a study by 
Roemeling et al.(16), they found that by using a nomogram recalibrated for a screening setting, 
59% of men were predicted to have indolent prostate cancer(16). In our series, the incidence of 
small-volume prostate cancer was 16.3%, which is comparable to the series of Epstein et al., 
where they found an incidence of 16%. The study by Epstein et al. from 1993 is the first and, 
to our knowledge, the only series that reported on the BCR of these small-volume prostate 
cancers(6). In their cohort of 185 patients with stage B adenocarcinoma, there were 18 patients 
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with a prostate cancer volume less than 0.5 cc. None of these patients were found to have a 
BCR after 5 years of follow-up(6). Nevertheless, small volume prostate tumors can be 
associated with adverse pathological findings. In a subsequent study, Epstein et al.(1) made a 
categorization of these small-volume prostate cancers. They called tumors insignificant if 
tumors were less than 0.2 cc, since they found no capsular penetration and no PSA 
recurrences in a cohort of 21 clinical T2 cases with tumor volumes less than 0.2 cc, after 5 
years of follow-up. However, they categorized tumors with a volume between 0.2 and 0.5 cc 
as minimal tumors and not as insignificant tumors, since 13% of 23 clinical stage T2 tumors 
demonstrated capsular invasion, but still no BCR was seen. Looking at capsular invasion in 
our series, none of the InsigPc patients had capsular invasion, although 5 (10.0%) patients 
had a BCR. In the group svPC we found 1 (1.2%) specimen with capsular invasion and a total 
of 7 (10.0%) patients had BCR. Adverse pathological characteristics in small tumors were also 
seen in a series by Cheng et al.(23). In their series of 371 specimens, they looked at the 
pathological characterization of small-volume tumors in whole-mount specimens and found 
a total of 62 specimens with total tumor volume 0.5 cc or less with a mean tumor volume 0.29 
cc. Tumor multifocality and bilaterality were present in 69% and 37% of cases, respectively. 
Three (5%) had positive surgical margins. The distribution of Gleason scores was 5 in 19%, 6 
in 65%, and 7 in 16%. In this study, unfortunately, no clinical follow-up was given. They did, 
however, conclude that even small-volume tumors have high Gleason grades in 16% of their 
patients and might be considered clinically significant if left untreated. They end with the 
advice that long-term clinical follow-up is warranted to determine the outcome differences 
among patients with and without small-volume prostate cancer. High Gleason grades were 
also present in our series and comparable to the study of Cheng et al. Of the svPC patients 15 
(18.3%) patients had a Gleason score 7 or more and 1 (1.2%) patient had a pathological stage 
more than T2. In table 3, the characteristics of the 7 patients with a BCR are shown. 
Obviously, all patients except patient number 3 have one or more characteristics that might 
explain a BCR such as tumor multifocality, Gleason score, positive surgical margins, or 
preoperative PSA. So, although numbers are small, the similarity in outcome of svPCs and 
InsigPCs is not surprising, although the risk of PSA progression is significantly lower 
compared with the total group (10% vs. 35%, P < 0.001). 
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Limitations exists to the present study, as there is a limited number of patients (82) with 
small volume prostate cancer, but still, to our knowledge, this is the largest cohort of small 
volume prostate cancers with clinical follow-up and BCR. 
Another limitation to our study is that the follow-up of this study is relatively short with a 
median of 39.5 months. Since many prostate cancer deaths occur more than 10 years after 
initial diagnosis(24), with a longer follow-up, a percentage of these patients with a small-
volume cancer could develop not only biochemical recurrences, but even metastatic disease, 
or death. So, with longer follow-up the numbers could even be worse. 
An explanation for the relatively high number of positive surgical margins could be the 
detailed stepwise pathological analysis of the RP specimens. Another possibility is that the 
surgical technique is responsible for the high number of positive surgical margins. However, 
this seems not the case since the BCR rate of the entire cohort of 502 specimens is 21% after 
39.5 months (median), which is comparable to other series (i.e., Renshaw 27% after a median 
of 22.5 months, Dvorak 31% after a median of 64 months)10,25]. 
In an attempt to predict the presence of clinically insignificant prostate cancer before 
definitive therapy, Epstein et al. published a set of 4 PSA- and needle biopsy based criteria(1). 
These consist of a PSA density between 0.1 and 0.15, low or intermediate cancer grade, core 
involvement of less than 3 mm, and involvement of only 1 needle biopsy core. These criteria 
were shown to predict the presence of insignificant tumor defined as 0.5 cc or less and 
confined to the prostate, without a primary or secondary Gleason pattern 4 or 5. Since almost 
all our patients are referral patients and their biopsies are taken elsewhere, we were not able 
to assess these variables in our patient cohort even though we know their predictive value(26). 
Recently, there was a European validation of these criteria by Jeldres et al.(3) where they 
concluded that these Epstein criteria may underestimate the true nature of prostate cancers 
in as many as 24% of European patients. Therefore, knowing the BCR rates of small volume 
prostate cancers in European patients is of considerable clinical importance, since this might 
have great implications in a significant number of patients, and up to now many assume that 
small volume prostate cancers are insignificant because of U.S. data from 1993. 
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This study with detailed pathological analysis is, to our knowledge, the only study with 
clinical follow-up of insignificant prostate cancers from a European center. 
Conclusions 
In conclusion, looking at the current series and the results, we have clearly found that the 
biological behavior of svPC and InsigPC is significantly more favorable than of the general 
group of patients undergoing RP, but it is not, per se, clinically insignificant. More studies 
are needed to examine what the prognostic relevance is of small-volume and insignificant 
prostate cancer, since this is very important for decision making, especially for the large and 
growing group of patients with a relatively long life expectancy. 
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CHAPTER  6 
Maximum tumor diameter is not an independent 
prognostic factor in high-risk localized prostate cancer  
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Abstract 
Objectives 
Previous studies suggest that maximum tumor diameter (MTD), is a predictor of recurrence 
in prostate cancer (PC). This study investigates the prognostic value of MTD for biochemical 
recurrence (BCR) in patients with PC, after radical prostatectomy (RP), with emphasis on 
high-risk localized prostate cancer. 
Methods 
RP specimens of 542 patients were evaluated with a median follow-up of 39.5 months (range 
0.6-150 months). MTD was defined as the largest diameter of the largest tumor; high-risk as 
ǃŘȱȱȱȱǁȱŘŖȱȦȱȱ	ȱȱǃȱŞȱȱȱȱŘȱȱȱȱǁȱŖǯŗŖȱ
ng/ml. Proportional hazards multivariable regression models were composed to determine 
prognostic factors for BCR.  
Results 
Overall, 114 patients developed BCR after RP. The overall 5-year risk of BCR was 25% (95% 
CI=20.4 -29.6), median MTD was 24mm (range 1- 65). MTD in the total and high risk group 
was associated with total tumor volume, volume of the largest tumor, pre-operative PSA 
levels and Gleason score. In a univariable analyses, MTD was weakly associated with risk of 
BCR (HR=1.02 per mm increase, 95% CI=1.002-1.035, p=0.024) in the total group, in the high-
risk group this association was lost (HR=1.01, 95%CI=0.99-1.03, p=0.18). Multivariable 
analyses indicated that positive surgical margins, higher Gleason score, advanced 
pathological stage and multiple tumors were the main prognostic factors for BCR 
irrespective of the risk profile. MTD did not provide additional information. 
Conclusions 
MTD is not an independent prognostic factor for BCR in patients treated with RP, 
irrespective of the risk profile.  
 
 
 
 
 
 
van Oort IM, Witjes JA, Kok DE, Kiemeney LA, Hulsbergen-vandeKaa CA. Maximum tumor diameter is not an independent prognostic factor in 
high-risk localized prostate cancer. World J Urol. 2008 Jun;26(3):237-41. 
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Introduction 
The characteristics mostly used to predict progression of prostate cancer (PC) after  radical 
prostatectomy (RP) are Gleason score, pre-operative PSA level, pathological staging, positive 
surgical margins and tumor volume (TV)(1). The first three are also used to define high-risk 
localized PC(2). TV in the RP specimen is also clearly associated with prognosis. However, 
whether it is an independent prognostic factor both for the total group as for the high-risk 
group still remains controversial(3). 
Epstein et al. stated that, although TV is a predictor of progression, it did not provide 
additional information over Gleason score and pathological stage(4). This was also found in a 
study by Salomon et al., where only Gleason score and pathological stage were independent 
factors to predict progression after RP(5). If these parameters were known, TV did not 
provide any additional information. This is in contrast with Stamey et al. who found that TV 
is an independent prognostic parameter for PC progression(6). These findings were also 
observed in other studies(7-9). None of these studies, however, specifically addressed the high-
risk subgroup. An explanation of these conflicting results might be that TV estimations can 
be done with the help of several techniques, as Humphrey and Volmer described earlier(10). 
Moreover, these techniques are rather complex and time-consuming. Therefore, maximum 
tumor diameter (MTD) has been suggested as a fast and easy proxy for TV. Renshaw et al. 
noted that simple measurements of the largest diameter of the largest tumor from glass 
slides is a predictor of PSA failure(11). This was supported by Eichelberger et al. who showed 
that MTD correlates with TV and other potential prognostic factors for clinical outcome(12). 
However, these studies had respectively a small number of patients with a relative short 
follow-up (57 patients, median follow-ȱŘŝǯŘȱǼȱȱȂȱ ȱ ȱȱ
between MTD and biochemical recurrence (BCR). 
Therefore, in this present study, with a large cohort of 542 RP specimens, a median follow-up 
of 39.5 months, we study the prognostic value of MTD, as a surrogate for tumor volume, for 
BCR in patients with PC, with special attention to the high-risk group.  
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Materials and Methods 
Between 1992 and 2005, 617 patients were treated with RP for clinically localized PC at our 
institute. Of these patients, 75 were excluded from analyses because of HIFU treatment, 
hormonal pre-treatment or irradiation before RP. Of the remaining 542 patients, 5 had 
incomplete follow-up data. Charts were examined retrospectively for clinical follow-up data 
ȱȱȱǯȱȱȱȱ ȱȱȱȱȂ(2). High 
risk  ȱȱȱȱǃȱŘȱȱȱȱǁŘŖȱȦȱȱ	ȱȱǃȱŞȱȱ ȱȱ
ȱ ȱ ȱ ȱ  ȱ ȱ ȱ ȱ ȱ ǻǀȱ Řǰȱ ȱ ȱ ǂȱ ŘŖȱ Ȧȱ ȱ
	ȱȱǂȱŝǼǯ 
All RP specimens were fixed overnight, inked and cut into serial transverse 4 mm. thick 
slices according to a standard protocol by Ruijter et al.(13). In brief, the apical and basal 
margins were amputated to a thickness of 4 mm and sectioned parasagittaly at 4 mm 
intervals. The seminal vesicles were sectioned parallel and entirely submitted. The prostate 
was then sectioned perpendicularly to the long axis (apical to basal) of the gland along the 
posterior rectal surface at 4-mm intervals. Tumor was outlined on the microscopic glass 
slides and schematically drawn on the macroscopically photographed transverse sections in 
order to be able to reconstruct tumor extension and tumor multifocality. Detailed 
pathological analysis, including number of tumors, total volume of all tumors, MTD, 
pathological staging, Gleason score, extracapsular extension and positive margins, was 
performed by a single pathologist (CAHK). Tumors were staged using the American Joint 
Committee on Cancer (AJCC) TNM staging criteria of 2002(14). MTD was defined as the 
largest diameter of the largest tumor. MTD was determined by marking both ends of the 
tumor and measuring the distance at the glass slide directly. If the tumor was present on 
consecutive glass slides, thickness of the slices of the concerning sections was summed. This 
reconstructed diameter was considered as MTD if larger than the diameter visualized 
directly on the glass slides. 
PSA values were obtained before surgery and at every follow-up point. BCR after RP was 
defined as two subsequent PSA levels above 0.10 ng/ml among patients who reached non-
measurable levels after RP. 
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Statistical Analysis 
Baseline characteristics are summarized with median, and interquartile ranges (IQR). 
Associations between MTD and clinical or pathological characteristics were examined by 
univariate regression models. Kaplan-Meier curves were used to assess the risk of BCR. 
Proportional hazards multivariable regression models were composed to determine 
prognostic factors for BCR. SPSS version 12.0.1 for Windows was used for all statistical 
analysis. 
Results 
Patient and tumor characteristics are summarized in table 1. The age of the patients at time of 
RP was 62.7 (IQR 58.4 Ȯ 66.5) years and they had a median Gleason score of 6. In the 
specimens a median MTD of 24.0 (IQR 16.0- 32.0) mm was found. Patients were followed for 
a median period of 39.5 (IQR 17.1 Ȯ 67.3) months. Overall, 114 (21%) of the patients 
developed BCR after RP. The median time to PSA recurrence was 20.3 (IQR 10.3 Ȯ 46.9) 
months. The overall 5-year Kaplan-Meier risk of BCR was 25% (95% CI=20.4 -29.6) for the 
whole group. For the high risk group and low/intermed risk these were respectively 27.4% 
(95% CI=22.2 - 32.6) and 10% (95% CI =2.2-17.8).  432 of the 542 patients fulfilled the criteria 
for high-risk localized PC, 72 patients were low/intermed risk, and 38 patients never reached 
non-measurable PSA levels. Associations between MTD and pathological characteristics are 
summarized in table 2. Overall we found 359 organ-confined (T2) tumors, 116 extracapsular 
extended tumors (T3a) and 52 tumors invaded into seminal vesicles (T3b). Half of all the 
patients (n= 271) had positive surgical margins and 8 patients had lymph node involvement. 
 
Table 1:  Patient and pathological characteristics (n=542) 
 Median IQR 
Age (years) 62.7 58.4 Ȯ 66.5 
Follow-up period (months) 39.5 17.1 Ȯ 67.3 
Pre-operative PSA (ng/ml) 8.0 5.5 Ȯ 13.0 
Gleason score 6 5 Ȯ 7 
Number of tumors (n) 2 1 Ȯ 3 
Index tumor volume (cm3) 1.6 0.6 Ȯ 3.4 
Total tumor volume (cm3) 2.0 0.8 Ȯ 3.9 
Maximal tumor diameter (mm) 24.0 16.0 Ȯ 32.0 
Data are presented as median and interquartile ranges (IQR) 
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Pre-operative PSA levels ranged from 0.1 Ȯ 87.2 ng/ml (median 8.0 ng/ml). Kruskall-Wallis 
tests or Mann-Whitney U test revealed that MTD was significantly associated with 
pathological stage (p<0.001), Gleason score (p <0.001), margin status (p<0.001), number of 
tumors (p<0.001) and pre-operative PSA levels (p<0.001). Positive surgical margins were 
associated with a larger MTD compared to negative surgical margins. Single tumors were 
also found to have a larger MTD than multiple tumors. Extracapsular extension (T3a) and 
invasion to seminal vesicles (T3b) were both associated with larger maximal tumor diameters 
compared to those of organ-confined (T2) tumors. MTD in the high risk group was 
significantly higher than in the low/intermediate risk group (median 24.5 vs.14.0 mm 
p<0.001). We also calculated the correlation coefficient for MTD and all other factors. We 
found that MTD was significantly correlated to index TV (= largest tumor) (r = 0.60, p<0.001) 
and total TV (r= 0.61, p< 0.001) in the total group. In the high risk group these correlations 
were weaker. In addition, significant correlations with MTD were found for Gleason score (r 
= 0.17, p< 0.001), the number of tumors (r = -0.21, p< 0.001) and pre-operative PSA levels (r = 
0.38, p< 0.001).  
Table 2: Associations between MTD and pathological characteristics 
 Maximum tumor diameter 
 No. of 
patients 
Mean Median Range p-value* 
Pathological stage* (2002) 
     T2 
     T3a 
     T3b 
Gleason score* 
     ǂȱŜ 
     3 + 4 
     4 + 3 
     ǃȱŞ 
Margin status# 
     Negative 
     Positive 
Number of tumors# 
     1 
     ǃȱŗ 
Pre-operative PSA* 
     < 4 
     4-10 
     10-20 
     >20  
Risk groups# 
high  
low/intermed 
 
359 
116 
52 
 
301 
136 
22 
80 
 
270 
271 
 
241 
301 
 
56 
289 
123 
70 
 
432 
72 
 
 
21.0 
30.8 
31.1 
 
22.5 
26.2 
25.0 
28.8 
 
20.5 
28.5 
 
27.3 
22.3 
 
17.4 
23.6 
24.5 
34.4 
 
25.8 
14.3 
 
 
20.0 
28.0 
31.0 
 
21.0 
25.0 
24.0 
28.0 
 
20.0 
28.0 
 
26.0 
22.0 
 
15.0 
24.0 
24.0 
35.5 
 
24.5 
14.0 
 
 
1 Ȯ 60 
12 Ȯ 60 
3 Ȯ 55 
 
1 Ȯ 65 
8 Ȯ 60 
3 Ȯ 49 
4 Ȯ 60 
 
1 Ȯ 52 
3 Ȯ 65 
 
1 Ȯ 65 
1 Ȯ 50 
 
3 Ȯ 46 
1 Ȯ 55 
2 Ȯ 55 
10 Ȯ 65 
 
1-65 
1-36 
 
 
<0.001 
 
 
 
<0.001 
 
 
 
 
<0.001 
 
 
<0.001 
 
 
<0.001 
 
 
 
 
<0.001 
 
* p-values were assessed by *Kruskal-Wallis tests or #Mann-Whitney U test 
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Univariable analyses of MTD as a continuous variable revealed that it is weakly associated 
with risk of BCR (HR = 1.02 per mm increase, 95% CI = 1.00 Ȯ 1.04, p=0.024). In the high risk 
group this association was lost (HR=1.01 per mm increase, 95%CI=0.99-1.03, p=0.18). 
In the total group TV, pre-operative PSA levels, pathological stage and Gleason score were 
associated with risk of BCR, as presented in table 2. Proportional hazards multivariable 
regression models were composed to determine significant independent prognostic factors 
(table 3). Positive surgical margins, higher Gleason score, advanced pathological stage and 
multiple tumors were the main prognostic factors for BCR. Neither MTD nor tumor volume 
turned out to be significant in either group. 
 
Table 3: Univariable and multivariable analysis of clinical and pathological characteristics associated with time to BCR 
 
 Univariable Multivariable 
Covariates HR 95% CI  AHR 95% CI  
Pre-operative PSA 1.02 1.01-1.04*     
Pathological stage 
   pT2 
   pT3a 
   pT3b 
 
1.0 
2.12 
3.90 
 
 
1.39-3.23* 
2.33-6.53* 
  
1.0 
1.26 
1.79 
 
 
0.81-1.97# 
1.02-3.13* 
 
Gleason score 
   ǂȱŜ 
   3+4 
   4+3 
   ǃȱŞ 
 
1.0 
2.64 
7.27 
5.68 
 
 
1.64-4.25* 
3.18-16.63* 
3.60-8.97* 
  
1.0 
1.97 
5.71 
3.57 
 
 
1.20-3.23* 
2.47-13.20* 
2.17-5.89* 
 
Extracapsular extension 2.71 1.87-3.94*     
Invasion seminal vesicle 3.07 1.94-4.87*     
Margin status 4.64 3.02-7.12*  3.75 2.36-5.96*  
Number of tumors 1.02 0.88-1.17#  1.18 1.02-1.36*  
Maximal tumor diameter    1.02 1.00-1.04*     
Index tumor volume 1.04 1.02-1.07*     
Total tumor volume 1.04 1.02-1.07*     
HR = Hazard ratio, CI = Confidence interval, AHR = adjusted hazard ratio, * = p<0.05, # = p>0.05 
 
Discussion 
Prediction of outcome after RP in patients with localized PC is important to tailor follow up, 
and for example to consider adjuvant therapy in patients at highȮrisk for recurrence. Several 
studies have assessed the value of morphological and clinical variables in this respect. 
Tumor stage, Gleason score and pre-operative PSA levels are obvious parameters, and also 
used to define patients at high-risk for recurrence(2). MTD, as easy to determine surrogate for 
tumor volume(12), is another potential variable considered as a potential predictor of BCR. In 
our study of 542 patients we found that MTD correlates with index TV, total TV, pathological 
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stage, Gleason score, number of tumors and pre-operative PSA levels irrespective of risk 
classification. However, MTD was not an independent predictor of BCR in the total or in the 
high-risk sub group.  For the whole group these results are in contrast with previously 
reported findings. 
One of the first studies addressing the association of MTD and BCR was by Renshaw et al.(3). 
In this study, with 57 patients undergoing RP, it was found that MTD was strongly 
correlated with total TV. In this small series a high MTD was associated with a slight 
increased risk for BCR (HR 1.12) which was marginally significant. Their subsequent study 
was a larger cohort of 434 patients. The median MTD was 13 mm. The median follow-up was 
12.9 months and 27.2% of patients had PSA failure. This study confirmed that MTD is an 
independent predictor of BCR, even after adjustment for other risk factors(11).  
Their next study by Dvorak et al.(15) had an even larger cohort (781 patients) and longer 
median follow-up (64.8 months). MTD remained the same with a median of 13 mm, and BCR 
in 31% of the patients. Again they found that MTD was significantly associated with time to 
BCR (HR=1.04, p=0.004) adjusted for pre-op PSA, Gleason score and pathological stage. But 
when surgical margin status was added MTD lost statistical significance (p=0.07). One 
important feature of these studies is that the RP specimens were not uniformly processed. 
Therefore we have to be taking into account the variation in evaluation of the prognostic 
factors.  
Another difference with our results is that the median MTD in these three studies (13mm) 
are less than in our study (24 mm). This might be explained by the way we determine our 
MTD. Renshaw et al. limited his measurements to the single focus of tumor that could be 
demonstrated on one slide (slice-MTD). We, on the other hand, take the largest diameter of 
the largest tumor after reconstruction (real-MTD). To see if we could explain this difference 
we also measured the slice-MTD in a part of our cohort. In 250 consecutive cases from 2000 
till 2005 we found a median slice-MTD of 19 mm and a median real-MTD of 24 mm. This 
strongly suggests that part of the difference in MTD is caused by the different way MTD is 
measured.  
The difference that still exist, could be explained by the fact that Renshaw et al. used partially 
submitted prostates, thus missing part of the prostates for evaluation. The only study where 
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they did use uniformly processed specimens is by Eichelberger et al., but this study has a 
very short follow-up. They analyzed the prognostic value of MTD in a cohort of 364 patients 
treated with RP, and found a mean MTD of 17.3 mm and biochemical recurrence in 12 % of 
the patients(16). In this study with a median follow-up of only 12 months they found that 
MTD was a significant predictor of BCR, adjusted for Gleason score and surgical margin 
status ( HR=1.70, p=0.011). In our study we found a median time to BCR of 20.3 months, 
hence a follow-up of 12 months seems not long enough to investigate BCR. 
Another striking difference is the percentage of positive surgical margins. In our study this is 
relatively high (50%) compared to other studies (Renshaw et al. 31% and 26%, Eichelberger et 
al. 23%, Dvorak et al. 27%). Our median BCR rate (21% after 39.5 months), however was 
comparable to the median of these studies (Renshaw 27% (22.5 months), Eichelberger 12% 
(12 months), Dvorak 31% (64.8 months)). An explanation for the high number of positive 
surgical margins, next to surgical techniques, is that by evaluating only partially included 
prostates you miss positive surgical margins.  
The difference between our study and studies like Eichelberger et al., in which the entire 
prostate was histologically examined using whole mount sections, are less easily explained, 
but here the interval at which the prostates were sliced is higher (mean 7.8 mm according to 
the used protocol described by Qian et al.(17)  - personal communication). From this, we can 
conclude, that MTD is not an independent prognostic marker, if surgical resection margins 
are accurately documented.  
Finally, none of the mentioned studies separately looked at the group where prediction 
might be of most importance, the high-risk group. As clearly indicated, in this group neither 
MTD nor TV is of any significant value.  
In all, we do not advice to use MTD as a prognostic factor for BCR, since after proper follow-
up and with adequate pathological techniques it does not add anything to other readily 
available prognostic factors. Moreover, in the high risk group TV is not an independent 
prognostic factor at all.  
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Conclusions 
The results of our study suggest that MTD is positively correlated to total TV, as can be 
expected. MTD was weakly associated with risk of BCR and this association was lost in the 
high risk group. If adjusted for positive surgical margins, higher Gleason score, advanced 
pathological stage and multiple tumors, MTD did not provide additional information.  
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CHAPTER  7 
The length of positive surgical margins correlates with 
biochemical recurrence after radical prostatectomy  
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Abstract 
Objectives 
To evaluate the prognostic role of the length of a positive surgical margin (+SM) for 
biochemical recurrence (BCR) after radical prostatectomy (RP) for prostate cancer.  
Methods 
Consecutive RP specimens (n=267) with +SM were analysed. All RP specimens were 
sectioned at 4-mm intervals and completely embedded. Data were analysed using Kaplan-
Meier survival analysis and proportional hazards models.  
Results 
In 267 patients length of +SM ranged from 0.4 to 174.5 mm (median 11.2 mm) and correlated 
with preoperative PSA (p< 0.001), pathologic stage (p < 0.001), tumour volume (p = 0.001), 
number of +SM (p <0.001), Gleason grade at +SM (p < 0.001) and Gleason score (p = 0.015). 
Patients with detectable postoperative PSA levels (N=34) or adjuvant therapy (N=59) were 
excluded from for BCR-analysis. In the remaining 174 patients the 5-year risk of BCR was 
29%; in patients with +SM ǂȱ ŗŖȱȱȱǁȱ ŗŖȱȱ ȱ ȱ ŘŗƖȱȱ řşƖǰȱ ¢ǯȱ ȱ
ȱ¢ȱȱ ȱȱ ȱȱȱȱȱƸȱǻǂȱŗŖȱȱǯȱǁȱ
10 mm; HR 2.15; 95% CI 1.12-4.15; p = 0.022). 
Conclusions 
The length of +SM is an independent prognostic factor for BCR in patients with undetectable 
PSA after RP.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
van Oort IM, Bruins HM, Kiemeney LA, Witjes JA, Hulsbergen-van de Kaa CA. The length of positive surgical margins correlates with 
biochemical recurrence after radical prostatectomy. Submitted  
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Introduction 
The four most common characteristics used to predict progression of prostate cancer after 
radical prostatectomy (RP) are Gleason score, pathological stage, tumour volume and 
positive surgical margins (+SM)(11) The prevalence of +SM has been reported to range from 
10%-48%(5). Clearly, it is the only prognostic factor that can be influenced by surgical 
technique. Most investigators agree that the presence of a +SM may adversely affect cancer 
control after RP (5, 8, 13, 18, 23). In a recent study by Eastham et al. the risk of progression after 10 
years for patients with +SM is approximately 30-54 % depending on the pathological stage 
compared to 16-22 % for those with negative surgical margins(6). A multi-institutional study 
by Karakiewicz et al. showed a 3.7-fold higher risk of progression for patients with +SM(13). 
Others, however, disagree and state that it has only limited prognostic value for PSA relapse 
and local recurrence(21, 23). 
To our knowledge until now, three studies have investigated the prognostic value of the 
length of positive surgical margins with contradicting results (4, 14, 17). 
Therefore the purpose of this present study was to evaluate the correlation between the 
length of +SM and BCR after RP in a large cohort of 267 patients, with uniformly and 
completely processed specimens.  
Materials and Methods 
Between 1995 and 2005, 267 consecutive patients with +SM in the prostatectomy specimen 
were evaluated. This total group (N=267) was analysed for associations between the length of 
the +SM and different prognostic variables. Of these 267 patients, 34 never reached an 
undetectable PSA level post-operatively, indicating residual disease, and another 59 received 
adjuvant hormonal (N+ disease) or radiation treatment (T4 disease, amongst others). These 
93 patients were excluded from the analysis of risk of BCR, leaving a group of 174 patients 
(analysis of BCR group).   
The medical charts were examined retrospectively for clinical follow-up data. Patients were 
followed at 3-month intervals for the first year and 6-monthly thereafter. Biochemical 
recurrence (BCR) was defined as two subsequent increasing PSA levels of > 0.10 ng/ml. 
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All RP specimens were uniformly processed and entirely submitted for histological 
investigation, according to previously described protocols(12,20). Immediately after surgical 
resection specimens were fixed in 10% neutral-buffered formalin, using fine needle formalin 
injections and fixation overnight. Subsequently, the entire surface was marked with ink 
using three different colours (black for the posterior side, green and red for the right anterior 
and left anterior side, respectively), after which the entire prostate specimen was cut into 
serial transverse 4 mm thick slices, perpendicular to the dorsal-rectal surface and all slices 
were macroscopically photographed.  The apex and base were sagittally sectioned to assess 
the caudal and cranial surgical margins. Seminal vesicles were amputated at their junction 
with the prostate and sectioned parallel to their junction and embedded in total. The 
remaining slices were subdivided into halves or quadrants to fit routine cassettes. After 
histological staining all specimens were evaluated by one expert urological pathologist 
(C.A.H.K.). Tumours were outlined on the microscopic slides and subsequently mapped on 
the macroscopic photographs to allow reconstruction of tumour extent and multifocality (fig. 
1). 
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Figure 1. Schematical drawing on the macroscopic photographs of the radical prostatectomy specimen. Multifocal tumor was 
diagnosed, numbered 1-4. Positive resection margins are indicated. (GS = Gleason score of the entire tumor nodule; EPE = 
extraprostatic extension; SM + = positive surgical margin; VS = seminal vesicles). 
 
Each individual tumour was graded according to the Gleason grading system. Tumours 
were initially staged according to the TNM classification that was in general use at the time 
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of surgery, but retrospectively all tumours were re-staged according to the 2002 TNM 
staging criteria(10). Extraprostatic extension was defined as extension of adenocarcinoma in 
periprostatic adipose tissue or beyond the confines of the normal glandular prostate (15,20)  and 
seminal vesicle invasion as invasion of the seminal vesicle (muscular) wall beyond the level 
of their junction with the prostate. Tumour volume was calculated for each tumour by 
measuring the largest tumour diameter and the diameter perpendicular to the largest 
diameter in all sections containing tumour. Section tumour surface area was calculated from 
these diameters by assuming elliptical tumour shape, was integrated over all sections and 
multiplied by the slice thickness for each slice in which the tumour was present. Surgical 
margins were only considered positive if cancer cells were in the inked margin. The sites of 
margin involvement were marked on the slides. All cases initially reported as +SM were re-
evaluated for total linear length of involvement, number of sites and location of involvement, 
and highest Gleason grade pattern at the involved location (C.A.H.K., H.M.B). The linear 
length of positive margin was measured in mm at each involved site by using the diameter 
of the microscopic field after calibration with an ocular micrometer (Zeiss axioscope: 40 x 
objective = 0.6 mm; 20 x =1.2 mm; 10 x = 2.5 mm; 5 x = 5.0 mm; 2.5 x = 9.0 mm; fig. 2 and 3).  
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Figure 2. Positive resection margin at the apex (HEx100). The tumour is covered with green ink over an area with a diameter of 
one high power field of 40x objective (0.6 mm; represented by the circle). 
 
For each site involving more than one slice, the measurements were summed. Sites were 
recorded separately if they were at least 4 mm apart from each other. The locations of the 
+SM were classified and recorded as apical, posterior, posterolateral, anterior, bladder neck 
and at the site of seminal vesicle. For each location the total linear length of involvement was 
summed.  
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Figure 3. Positive resection margin at dorsal site (HEx50). Tumour reaches in the inked surface over a large area (8 mm; slightly 
less than one low power field of 2.5x objective). 
 
Statistical analysis 
ȱ ȱ ȁȱ Ȃȱ ǻƽŘŜŝǼȱ ȱ ¢ȱ ¢ȱ ȱ ȱ ǻǼȱ ȱȱ ȱ ȱ
ȱȱȱȱƸȱ ȱȱȱȱȱǯȱȱȱȁ¢s 
ȱȱȂȱǻƽŗŝŚǼȱ-Meier curves were used to assess the risk of BCR. In addition, 
multivariable proportional hazards analyses were used to assess the independent prognostic 
value of the length of the +SM. The significance level for all analyses was set at p < 0.05. 
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Results 
The baseline characteristics of the study population are listed in table 1.  
 
Table 1. Patient characteristics 
Variable Total group 
 
N=267 
Group for 
BCR follow 
up* 
N=174 
Group  
did not reach 
undetectable 
PSA 
N=34 
Group  
direct 
adjuvant 
therapy 
N=59 
Preoperative PSA (ng/ml) 
median (range) 
8.7 (0.1-87.2) 8.1  (0.1-79.2) 11.7 (3.4-81.0) 11.0 (1.0-87.2) 
       
Follow-up (months) median 
(range) 
26  (0-141) 36   (0-141) - # - # 
     
Pathologic stage (%)     
  pT2a/c 142 (53.2) 104 (59.8) 14 (41.2) 24 (40.7) 
  pT3a 83   (31.1) 56   (32.2) 8   (23.5) 19 (32.2) 
  pT3b/4 42   (15.7) 14   (8.0) 12 (35.3) 16 (27.1) 
     
Gleason score (%)     
  <7 101 (37.8) 73   (42.0) 11 (32.4) 17 (28.8) 
  7 107 (40.1) 76   (43.7) 13 (38.2) 18 (30.5) 
  >7 59   (22.1) 25   (14.4) 10 (29.4) 24 (40.7) 
     
Tumour volume (cm3) median 
(range) 
3.2  (0.2-35.0) 3.2  (0.2-25.0) 4.0 (0.46-35.0) 3.3 (0.2-24.0) 
     
Total linear length +SM (mm) 
median (range) 
11.2 
(0.4-174.5) 
8.0   
(0.4-151.0) 
32.7  
(2.0-163.0) 
16.5  
(0.5-174.5) 
     
Number of +SM (%)     
  1 161 (60.3) 123 (70.7) 10 (29.4) 28 (47.5) 
  >1 106 (39.7) 51   (29.3) 24 (70.6) 31 (52.5) 
     
Gleason grade at +SM (%)     
  ǂȱř 150 (56.2) 112 (64.4) 13 (38.2) 25 (42.4) 
  > 3 117 (43.8) 62   (35.6) 21 (61.8) 34 (57.6) 
 
* Group excluding patients who did not reach undetectable PSA after RRP and patients who received direct adjuvant therapy 
# No follow-up, direct biochemical evidence of residual tumour after prostatectomy 
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In the total group (N=267) the length of positive margins ranged from 0.4 to 174.5 mm 
(median 11.2 mm; mean 21.9 mm). The distribution of the locations of positive margins was 
posterior (42.7%), anterior (34.8%), apical (33.0%), posterolateral (20.6%), basal (19.5%) and at 
the seminal vesicles (5.2%). 
The length of +SM was associated with preoperative PSA (p< 0.001), pathologic stage (p < 
0.001), tumour volume (p = 0.001), number of positive sites (p <0.001), Gleason grade pattern 
at the +SM (p < 0.001), and with Gleason score (p = 0.015) (table 2).  
 
Table 2. Patient characteristics and extent of positive margin in the total group of 267 radical prostatectomy specimens. 
Characteristic N Extent of positive margin in mm, 
(mean, (95% CI))  
p* 
Preoperative PSA (ng/ml)    
  < 10 151 14.0 (11.3-16.7) <0.001 
  ǃȱŗŖ 113 33.0 (25.6-40.5)  
    
Pathologic stage    
  pT2a/c 142 15.9 (12.1-19.6) <0.001 
  pT3a 83 22.6 (16.1-29.2)  
  pT3b/4 42 41.4 (27.8-55.0)  
    
Gleason score     
  <7 101 15.8 (11.6-19.9) 0.015 
  7 107 23.6 (17.8-29.2)  
  >7 59 29.7( 19.1-40.5)  
    
Tumour volume (cm3)    
  < 3.0 128 14.6 (11.0-18.1) <0.001 
  ǃȱřǯŖ 139 28.8 (22.8-34.9)  
    
Number of +SM    
  1 161 12.1 (9.6-14.7) <0.001 
  >1 106 37.0 (29.4-44.6)  
    
Gleason grade at +SM    
  ǂȱř 150 14.9 (11.5-18.3) <0.001 
  > 3 117 31.1 (24.2-38.0)  
*ANOVA test 
 
A total of 93 patients were excluded for BCR analysis because of a PSA that did not drop to 
zero (N=34), indicating residual disease, or because of immediate post surgical adjuvant 
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hormonal or radiotherapy treatment (N=59). In this group of 93 patients the median length of 
positive margins was significantly greater than the rest of the total group (32.7 mm vs. 16.5 
mm; p < 0.001).  
The remaining group of 174 patients with +SM was analysed for BCR. The mean follow-up of 
this group was 43 months (range 0-141, median 36 months). The 5-year risk of biochemical 
recurrence was 29%. There was a significant difference between patients with a +SM less or 
equal to 10 mm with a 5-year risk of BCR of 21% and patients with a +SM of more than 10 
mm with a 5-year risk of BCR of 39% (fig 4; p=0.011).  
Follow-up (months)
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Fig. 4:  Kaplan-ȱ ȱ ȱ ȱ ȱ ǀȱ ŗŖȱȱ ȱ ȱǰȱ  ȱ ȱ ȱ ǃȱ ŗŖȱȱ ȱ ȱ
margin. 
 
Using univariable Cox regression for time to PSA recurrence, length of +SM was a significant 
predictor for PSA recurrence (HR=2.26; 95% CI: 1.19-4.31; p=0.013) (table 3). Other pathologic 
features including preoperative PSA, pathological stage, location of the positive margin, and 
tumour volume were not significantly predictive for PSA recurrence. Multivariable analyses 
revealed that risk ȱȱ ȱȱ ȱȱȱȱƸȱǻǂȱŗŖȱȱǯȱǁȱŗŖȱȱ
HR=2.15; 95% CI: 1.12-4.15; p = 0.022), but not with preoperative PSA, pathological stage, 
Gleason score, tumour volume, localization of the +SM or Gleason grade pattern at the 
resection margin. 
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Table 3. Factors associated with time to PSA recurrence in 174 radical prostatectomy specimens. 
 Univariable Multivariable 
Characteristic HR (95% CI) p HR (95% CI) p 
Preoperative PSA (ng/ml)     
  < 10 (reference category)     
  ǃȱŗŖ 1.03 (0.54-1.98) 0.94   
     
Pathologic stage     
  pT2a/c (reference category)     
  pT3a 1.45 (0.75-2.85) 0.27 1.13 (0.56-2.28) 0.73 
  pT3b/4 1.94 (0.65-5.70) 0.23 1.35 (0.44-4.17) 0.60 
     
Gleason score      
  < 7 (reference category)     
  7 1.68 (0.82-3.44) 0.15 1.52 (0.72-3.2) 0.27 
  >7 1.82 (0.72-4.63) 0.20 1.70 (0.65-4.42) 0.28 
     
Tumour Volume (cm3)     
  < 3.0 (reference category)     
  ǃȱřǯŖ 1.03 (0.54-1.92) 0.94   
     
Location of +SM     
  Apex 1.02 (0.52-2.02) 0.95   
  Posterior 1.25 (0.66-2.4) 0.49   
  Posterolateral 1.21 (0.55-2.62) 0.64   
  Ventral 1.15 (0.59-2.24) 0.68   
  Bladder neck 1.11 (0.49-2.52) 0.80   
  Seminal vesicle 0.048 (0.00-523.1) 0.19   
     
Number of +SM     
  1 (reference category)     
 >1 1.46 (0.76-2.79) 0.24   
     
Length positive margins      
<10mm (reference category)     
ǃȱŗŖ 2.26 (1.19-4.31) 0.013 2.15 (1.12-4.2) 0.02 
     
Gleason grade at +SM     
  ǂȱřȱǻȱ¢Ǽ     
  > 3 1.60 (0.87-2.97) 0.13   
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Discussion 
 
In this study of men with positive surgical margins (+SM) and undetectable PSA levels after 
radical prostatectomy we found that the length of +SM is the only factor that is significantly 
associated with BCR in univariable and multivariable analysis. 
Several studies have investigated the relationship between the extent of positive margins and 
BCR. Most of these studies categorized the extent of positive margins instead of using 
continuous measurements of the extent of positive margins. In a study by Epstein et al. 
tumour extension was categorized in equǰȱ ȱ ǻȱ ȱ ȁthe involved site(s) 
were limited and pȱȱ¢ȱȱȱ ȱȂ) or extensive (multiple areas). They found 
a significant difference in risk of recurrence between men with focal +SM and men with 
extensive +SM, with a 5-year recurrence-free survival of 60 % for focally positive margins 
and 35 % for extensive positive margin patients (7, 9). 
Others, however, found no significant association with recurrence when using comparable 
categorizations of +SM as Epstein et al.(23, 25). It is possible that the use of categories based on 
terminology like focal and extensive gives a higher interobserver variation as compared to 
the use of a continuous variable to determine +SM. This is more likely to be accurate and 
objective and therefore more useful in clinical practice and for comparing results between 
institutions.  
To our knowledge there are only three recent studies in which the continuous length of the 
+SM was used to assess its prognostic value for the risk of BCR. The first one, conducted by 
Marks et al. found that the linear extent of margin positivity, measured in millimetres, is not 
an independent prognostic factor for PSA recurrence(14). In this study comprising 174 
patients, the linear extent of margin positivity (dichotomised at 5 mm) was associated with 
tumour volume but not with pre-operative PSA levels, pathologic stage, Gleason score, extra 
prostatic extension or PSA recurrence. The RP specimens in this study, however, were not 
completely embedded, which may have resulted in an underestimation of the total linear 
length of +SM. This could be an explanation for the differences in results with our study of 
267 patients in which RP specimens were completely embedded, and in which the linear 
length of +SM was associated with preoperative PSA (p< 0.001), pathologic stage (p < 0.001), 
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tumour volume (p = 0.001), and Gleason score (p = 0.015). In the subgroup of 174 patients 
with an undetectable postoperative PSA level and no direct adjuvant therapy, we found a 
significant association of the length of the +SM with BCR (HR 2.15; 95% CI 1.12-4.15; p = 
0.022). This association is supported by findings in a study by Ochiai et al.(17) in which a 
smaller patient series (117 patients) showed a significant difference in BCR in patients with a 
ƸȱǁȱřȱȱǯȱǂřȱȱȱśřȱƖȱȱŗŚƖǰȱ¢ǯȱȱȱ¢ȱ¢ȱȱ
that only a Gleason score 8 or greater and a margin of 3 mm or greater were independent 
prognostic factors. This study used a 3 mm cut off because of a previous study that indicated 
that the risk of biochemical failure was significantly higher in pT2 tumours when the length 
of +SM was more than 3 mm(1). 
In a study by Chuang et al. (4) the length of positive surgical margin was evaluated in areas of 
capsular incision (exposure of benign or malignant glands to the inked surgical margin(2). 
They evaluated only pT2 specimens and used 3 mm as a cut-off level. They found that the 5-
year risk of biochemical progression was 20% if the surgical margin positivity was less than 3 
mm compared to 55% if this was 3 mm or more. 
In our study there was no clear cut-off point of length of +SM above which the risk of BCR 
was significantly higher.  This is illustrated in fig. 5 where a ROC curve of +SM length vs. 
BCR does not show a clear cut-off point, but a gradual increase of risk.  
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Figure 5. ROC curve total length positive surgical margin and PSA recurrence without taking into account the follow-up. 
 
We used 10 mm as a cut-off point for practical reasons, i.e. simplicity in a clinical setting, and 
because it is very close to the median value of 11mm. By using the length of +SM as a 
dichotomous variable we found that it is an independent prognostic variable for BCR. The 
results for length of +SM as a continuous variable were comparable (HR=1.013; 95%CI 1.009-
1.017; P<0.001 for each mm increase). 
One major difference between our study and the studies mentioned above is that we 
excluded the patients in which PSA did not drop to zero after RP. The decision to exclude 
these patients is because of the definition of recurrence, a return of disease after complete 
resection of the tumour confirmed by an immeasurable PSA after radical prostatectomy. In 
patients with a +SM, in which PSA does not drop to zero after RP, there is per definition 
ȱȱǯȱȱȱȱ¢ȱȱȱȁȱȱȂȱǯȱ 
Several other studies state that the localization of the +SM is also a prognostic factor. Blute et 
al., in his series of 253 margin positive patients and Öbek et al. in 151 +SM patients found that 
the impact of positive margin status on recurrence-free survival is location dependent, with a 
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positive margin at the prostate base having the worst outcome (3, 16). A recent study done by 
Eastham et al. (275 margin positive patients) showed that the most common locations, when 
one positive margin was involved, were the apex (37 %) and posterolateral site (35%) with 
the posterolateral site being significantly associated with increased risk of biochemical 
recurrence(6). In our study the most common sites were posterior (42.7%), anterior (34.8%) 
and the apex (33.0%). In univariable analysis there was no significant difference in the risk of 
BCR for the location of the positive margin. The large number of anterior positive sites is 
probably caused by the learning curve of our laparoscopic prostatectomies where we used to 
grasp the specimen at the anterior site causing a transsection of intraprostatic tumour 
(capsular incision), as reported in literature(19). 
The lack of significance in univariable and multivariable analysis of the known prognostic 
factors such as Gleason score, pathologic stage, and tumour volume is remarkable. An 
explanation for this might be that we have selected a group of patients with a relatively good 
prognosis by excluding patients who underwent direct adjuvant therapy or whose PSA did 
not drop to zero. This is illustrated by the fact that in the total group of patients (N=267), 22% 
had a Gleason grade of 8-10. Among these 22%, 69% had stage pT3 disease. In the group of 
patients that was used for the analyses (N=174), 14% had Gleason grade 8-10 and only 56% of 
them had stage pT3. In the total group of patients, this led to a 5-year risk of BCR of 35% and 
65% for patients with Gleason grade < 7 and 8-10, respectively (log rank p-value = 0.002). In 
the group selected for analyses, the 5-year risk of BCR was 20% and 33% for patients with 
Gleason grade < 7 and 8-10, respectively (log rank p-value = 0.28).  
In conclusion, the length of positive surgical margins was significantly associated with a 
higher risk of recurrence in men who had undergone RP, in whom the postoperative PSA 
became zero, and had no direct additional therapy. This information should therefore be 
included in the prostatectomy pathology report. In the first place, this will give feedback to 
the urologist who should strive for negative surgical margins, and secondly stratification 
ȱ ȱ ȱ ǻƸȱ ǂȱ ŗŖȱȱ ȱ ǁȱ ŗŖȱǰȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ ȱ
recurrence) may aid in deciding to start direct adjuvant therapy after radical prostatectomy. 
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CHAPTER  8 
Prognostic relevance of number and bilaterality 
of positive surgical margins after radical 
prostatectomy 
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Abstract 
Objectives 
Positive surgical margin (PSM) status following radical prostatectomy (RP) is a well 
established prognostic factor. However, there is a persisting need to identify subsets of 
patients at high risk for biochemical recurrence, to tailor adjuvant therapy following RP. The 
aim of the present study is to evaluate whether number of PSMs or bilaterality of PSMs 
might have prognostic significance for biochemical recurrence (BCR) in the population with 
a PSM status following RP. 
Patients and Methods 
We evaluated 1395 RP pathology reports from our centre between 1980 and 2006. All cases 
that underwent (neo)-adjuvant therapy were excluded, leaving a cohort of 1009 patients, 
with 249 (24.7%) subjects having one or more PSM. Median follow-up was 39.9 months 
(range 0.1- 258 months). BCR was defined as any rise in PSA above or equal to 0.2 ng/ml. 
Results 
ȱȱŘŚşȱȱ ȱȱȱȱȱȱ ȱŘşǯŚƖȱȱȱȱǻǃŘȱ), 
while 13.6% had bilateral PSMs. Of patients with a PSM status 41% (95% CI: 33-49%) 
developed BCR within five years, compared to 12% (95% CI: 9-15%) in the population 
without a PSM. The difference in risk of BCR between single and multiple PSM status and 
between unilateral and bilateral PSM status was not significant. Patients with bilateral PSM 
progressed to BCR earlier during follow-up, leading to significantly different survival 
curves. Multivariable analysis identified PSA at diagnosis and RP Gleason score as 
independent predictive factors for BCR. The presence of bilateral PSMs did add prognostic 
information regarding estimated time of BCR, but could not predict the occurrence of BCR. 
Conclusions 
In patients with a PSM, the number of positive sites or bilaterality of PSM status does not 
add prognostic information on risk of BCR. Survival curve slopes were different for patients 
with bilateral PSM, showing a significant tendency to progress to BCR earlier during follow-
up than patients with unilateral PSM. 
 
D.M. Somford, I. M. van Oort, J-P. Cosyns, J.A. Witjes, L. A.L.M. Kiemeney, B. Tombal. Prognostic relevance of number and bilaterality of positive 
surgical margins after radical prostatectomy. Submitted. 
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Introduction 
Radical prostatectomy (RP) remains the standard treatment of localized prostate carcinoma. 
The 5- and 10-year overall survival rates are excellent(1), leading to significant survival benefit 
compared to watchful waiting(2). In absence of extraprostatic extension and positive surgical 
margins (PSM), the rates of biochemical recurrence (BCR) are low(3) . This, however, does not 
stand true for patients with a PSM, a common pathological feature following RP, with an 
incidence varying between 5-43% in different series(4,5). Several studies have shown PSM to 
be one of the most important prognostic factors for BCR following radical prostatectomy(4-13). 
The EORTC 22911 trial(14) established that adjuvant external irradiation after RP improves 
local control and biochemical progression-free survival in patients with a PSM, extraprostatic 
extension, or invasion of the seminal vesicles. Whether this translates into an overall survival 
benefit could not be detected due to a relative short follow-up. In this series 43.7% of the 
patients in the wait and see arm experienced biochemical or clinical progression or death. 
This percentage was reduced to 26.1% in the irradiation arm. However, if all patients in this 
series would have received immediate radiotherapy, more than 50% would have received 
intervention without ever progressing to biochemical recurrence at the cost of radio 
therapeutic toxicity. Therefore, characterization of patients at high risk of (biochemical) 
progression after RP would be of great help to identify those patients benefiting most of 
immediate postoperative radiotherapy. Re-evaluation of the EORTC 22911 data by van der 
Kwast et al.(15) stressed that amongst patients with adverse pathological features on 
prostatectomy, those with PSM benefit most from immediate radiotherapy, preventing 291 
PSA recurrence events for every 1,000 treated. We hypothesized that the number of PSMs or 
bilaterality of PSMs could be an additional risk factor of BCR in patients with a PSM, and 
could indicate who would be ideal candidates for adjuvant postoperative radiotherapy. The 
number of PSMs has not extensively been reported in the literature before and to our 
knowledge we present the first series addressing the prognostic value of bilateral PSM 
status. 
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Materials and Methods 
Study population and data retrieval 
The pathological reports of 1395 RP procedures performed at the Department of Urology, of 
the Université Catholique de Louvain, Brussels, between 1980 and 2006 were retrospectively 
evaluated for PSM status. Patient and tumour characteristics were retrospectively reviewed 
for all subjects with a PSM. All subjects who were treated with neo-adjuvant and/or adjuvant 
hormonal therapy, or immediate postoperative radiotherapy were excluded. Data on 
number and bilaterality of PSM, as well as pathological stage (pT2 versus pT3), RP Gleason 
score, presence of perineural invasion (PNI) and pathological lymph node status were 
obtained from the original pathological reports. Charts were retrospectively reviewed for 
PSA at diagnosis and follow-up data. The median follow-up was 39.9 months (range 0.1-258 
months). The standard follow-up protocol was fairly consistent over time starting with PSA 
measurements and DRE every 3 months after RP, gradually decreasing in frequency to once 
a year. BCR was defined as any rise in PSA (ng/ml) above or equal to 0.2 ng/ml. Local 
recurrence was not documented separately. When BCR became evident patients were treated 
ȱ ȱ ȱ ¢Ȃȱ ȱ ȱ  ȱ ȱ ȱ ȱ ȱ ¢ȱ ȱ ȱ
analysis. 
 
Pathological Processing 
All RP specimens were uniformly processed and evaluated. The left and right sides of the 
prostate gland were identified by a longitudinal incision into the right anterior half. 
Following fixation in buffered 10% formaldehyde, the 5 mm thick proximal and distal 
transections of the prostate were serially sectioned at 2 mm intervals parallel to the urethra. 
The tips of the vasa deferentia were transected and the seminal vesicles were longitudinally 
sectioned until at their junction with the prostate. The remaining prostate gland was then 
serially sectioned perpendicularly to the apical-basal axis at 5 mm intervals to perform whole 
mount sections. In some cases, each cross-section of the prostate was divided so as to fit into 
a cassette and designated in a manner that permitted localization of each section within the 
prostate. The external surface of surgical radical prostatectomy specimens was covered with 
ink since 1990. Surgical margins were considered as positive or negative when the malignant 
Prostate cancer:  
The clinical relevance of pathological findings after radical prostatectomy 
 
 
- 101 - 
 
cells were separated without any or with any amount of benign tissue from the inked edge of 
the surgical resection of the gland, respectively. The paraffin embedded tissues were recut if 
necessary until visualization of the inked margin. When the margins had not been inked, the 
paraffin blocks were if necessary recut until that the whole circumference of the tissue 
sample was mounted on the slide. The edges of the artifactual disruptions of prostatic or 
extraprostatic tissue were not considered as surgical margins. 
 
Statistical Analysis 
For statistical analysis we used SPSS software (SPSS, version 16.0.01, Chicago, Illinois, USA). 
Kaplan-Meier survival analysis was performed with BCR free survival as outcome for both 
single versus multiple PSM and unilateral versus bilateral PSM. The log-rank test was used 
to detect significant differences in BCR free survival rates between groups. The Wilcoxon 
signed-rank test was used to detect differences in the slope of survival curves. Multivariable 
Cox proportional hazards regression models were composed to determine prognostic factors 
for BCR. As multiple PSMs will represent a large subgroup of bilateral PSMs, we performed 
multivariable analysis for both factors separately. Statistical significance in our study was set 
at p<0.05. With the numbers of single and multiple PSM cases in our series, and an assumed 
40% 5-year risk of BCR, we had an 80% power to detect a Hazard Ratio (HR) of 1.5. Likewise, 
we had a power of 80% of detecting a HR = 1.7 for the comparison between unilateral and 
bilateral PSM.  
 
Results 
We found sufficient data on surgical margin status for 1314 patients to include them in our 
study. Of these 378 (27.1%) had one or more PSMs. Those who received immediate 
postoperative radiotherapy (n=181), neo-adjuvant (n=171) or adjuvant hormonal therapy 
(n=18) were excluded, leaving a cohort of 1009 patients, with 249 (24.7%) subjects having one 
or more PSMs. Of 723 patients with a pT2 status 122 (16.9%) had a PSM, compared to 123 
(46.2%) patients of the cohort of 266 with a pT3 status, 8 patients had pT4 tumour, of which 4 
displayed BCR (50.0%). Seven patients had pT0 status upon RP, and in 5 patients the 
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pathological stage could not be established. Of 249 patients with a PSM status, 115 were 
initially included in the wait-and-see arm of the EORTC 22911 trial on immediate 
postoperative radiotherapy versus salvage radiotherapy. The mean age was 63.8 years (range 
46-77) for all PSM subjects and did not differ significantly between groups with single versus 
multiple and unilateral versus bilateral PSMs. Mean PSA at diagnosis was 11.7 ng/ml (SD ± 
9.7) for all PSM subjects (range 0.9-68.3), with mean PSA for single and multiple PSMs being 
10.7 ng/ml (SD ± 7.8) and 12.9 ng/ml (SD ± 12.8), respectively. PSA did not differ significantly 
between the groups with unilateral and bilateral PSM status, with mean levels of 11.4 ng/ml 
(SD ± 8.4) and 11.8 ng/ml (SD ± 13.1), respectively. In this cohort of 249 patients with one or 
more PSMs, we found sufficient data on number of PSMs in 218 pathology reports, and in 
191 subjects sufficient data were reported to determine PSM bilaterality. Of these, 70.6% had 
a single PSM, while the remaining 29.4% had two or more PSMs. In all documented cases, 
86.4% of the PSMs were unilateral and the remaining 13.6% bilateral. In the total cohort with 
PSM, 122 (49.8%) had pathological stage pT2, and 123 (50.2%) pT3, and in four cases the 
definitive pathological stage could not be determined. In the RP specimen 173 (69.8%) had a 
	ȱȱǂŜǰȱŜŜȱǻŘŜǯŜȱƖǼȱȱȱ	ȱore 7, while 9 (3.6%) had a Gleason score equal 
to or higher than 8. Pathological stage differed significantly between single and multiple 
PSM status (p=0.04) and unilateral versus bilateral PSM status (p=0.03), with patients with 
multiple or bilateral PSMs having higher pathological stages. RP Gleason score did not differ 
significantly among groups. Table 1 summarizes all relevant patient characteristics as 
identified in our series. 
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Table 1:  Patient characteristics 
Variable PSM Single 
PSM 
Multiple 
PSM 
Unilateral 
PSM 
Bilateral 
PSM 
Number of subjects 249 154/218 64/218 165/191 26/191 
Age (mean±SD) 63.8±6.9 63.6±6.9 64.7±6.1 63.8±6.5 64.3±7.0 
PSA at diagnosis 
(mean±SD) 
11.7±9.7 10.7±7.8 12.9±12.8 11.4±8.4 11.8±13.1 
Pathological 
Stage 
pT2 122 (49.8%) 82 (53.9%) 25 (40.3%) 80 (49.7%) 10 (38.5%) 
 pT3 123 (50.2%) 70 (46.1%) 37 (59.7%) 81 (50.3%) 16 (61.5%) 
RP Gleason 
score 
ǂŜ 173 (69.8%) 110 (71.4%) 41 (64.1%) 118 (71.5%) 15 (57.7%) 
 7 66 (26.6%) 40 (26.0%) 18 (28.1%) 41 (24.8%) 9 (34.6%) 
 8-10 9 (3.6%) 4 (2.6%) 5 (7.8%) 6 (3.6%) 2 (7.7%) 
BCR (95% CI) 41%  
(33-49%) 
43%  
(32-54%) 
46%  
(31-61%) 
45%  
(35-55%) 
46%  
(24-68%) 
 
Excluding subjects that underwent (neo)adjuvant therapy, 41% (95% CI: 33-49%) of all 
subjects with a PSM developed a BCR within 5 years, compared to 12% (95% CI: 9-15%) in 
the population without a PSM. When subdivided into single and multiple PSMs, these 
percentages were 43% (95% CI: 32-54%) versus 46% (95% CI: 31-61%), respectively, which 
was non-significant (log-rank p=0.31). Also, the difference between unilateral and bilateral 
PSMs was not significant (log rank p=0.34), with 5-year BCR rates of 45% (95% CI: 35-55%) 
versus 46% (95% CI: 24-68%), respectively. Patients with data missing on number of PSMs 
had a 5-year BCR rate of 24% (95% CI: 6-42%), while those with missing data on bilaterality 
had a 5-year BCR rate of 30% (95% CI: 16-44%). Kaplan-Meier survival analysis with BCR as 
outcome for these data is displayed in figure 1 and 2.  
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       Figure :. Kaplan Meier BCR Free Survival Curves for single (upper blue line) and multiple (lower green line) PSM 
 
 
 
Month  0 12 24 36 48 60 
Single 
number of 
events 
0 13 27 37 41 44 
 number at risk 154 121 85 59 40 25 
Multiple 
number of 
events 
0 15 19 22 23 24 
 number at risk 64 43 31 20 19 12 
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       Figure 2: Kaplan Meier BCR free survival curves for unilateral (upper line) and bilateral (lower line) PSM 
 
 
 
When we used the Wilcoxon signed-rank test to detect differences in the slope of the survival 
curves, we found that single versus multiple PSM status did not display significant 
difference in survival curve slope (p=0.077). However, survival curve slopes for unilateral 
versus bilateral PSM did differ significantly (p=0.029), as the bilateral PSM cohort did 
progress to BCR earlier during follow-up, with the curves closing in later on. Univariable 
analysis identified PSA at diagnosis, pathological stage, RP Gleason score and perineural 
invasion (PNI) as possible predictors of BCR after RP in this PSM status cohort and these 
were consequently included in the multivariable analysis. Positive lymph node status (pN+) 
Month  0 12 24 36 48 60 
Unilateral 
number of 
events 
0 16 31 42 47 51 
 number at risk 165 134 92 65 45 28 
Bilateral 
number of 
events 
0 9 10 10 10 10 
 number at risk 26 12 10 9 9 7 
Prostate cancer:  
The clinical relevance of pathological findings after radical prostatectomy 
 
 
- 106 - 
 
was not significantly associated with BCR on univariable analysis. Bilateral PSM status and 
multiple PSM status had no prognostic value for BCR on univariable analysis. Multivariable 
analysis identified PSA at diagnosis and RP Gleason score as independent prognostic factors 
for BCR. Bilateral PSM status and number of PSMs did not add prognostic information, see 
table 2. 
Table 2: Univariable and Multivariable Analysis of Prognostic Factors for BCR in a PSM cohort 
Variable Univariable Analysis HR 
(95% CI) 
Multivariable Analysis HR 
(95% CI) 
Age at RP 1.00 (0.97-1.03) N/A 
PSA at diagnosis 1.04 (1.02-1.05) 1.04 (1.02-1.06) 
Pathological Stage (pT2 vs. 
pT3) 
2.36 (1.47-3.79) 1.40 (0.75-2.60) 
RP Gleason Score 1.42 (1.15-1.76) 1.33 (1.05-1.68) 
PNI 2.20 (1.40-3.44) 1.44 (0.82-2.53) 
Bilateral PSM 1.28 (0.79-2.07) 1.50 (0.60-3.73) 
Multiple PSM 1.37 (0.72-2.64) 0.85 (0.41-1.76) 
 
Discussion 
It has been demonstrated in several series that PSM status in itself influences the risk of BCR 
and local recurrence. BCR rates in these series vary with 19-64.3 % of patients with a PSM(6-9), 
in most series defined as a rise in PSA above a value in the range of 0.1-0.4 ng/ml. Data on 5-
year risk of BCR for PSM patients following RP are somewhat more consistent in the 
literature and are reported between 25-47%(5,10-12), However, in the series reporting a 25% risk 
of BCR, 37% of the patients with a PSM underwent adjuvant therapy in some form and were 
consequently deleted from analysis(10)ǰȱȱȱȱȱȃȱȄȱǯȱȱȱȱ
prostate cancer-specific survival or overall survival has been determined, obviously because 
the available follow-up does not suffice to detect these differences if present. Vis et al.(8) also 
documented a significant increase in local recurrence in their PSM group. We found a five 
year risk of BCR of 41% in our series following PSM at RP, comparable to these earlier 
reports. Pre-operative PSA, RP Gleason score and pathological stage are well-established 
predictors of BCR following RP(3,16-19). In correspondence with other series we identified RP 
Gleason score as a prognostic factor for BCR in the population with a PSM(5,7,9,11). All these 
earlier reports identified pathological stage as a prognostic factor for BCR as well, which we 
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could only confirm in our series on univariable analysis. When present in prostate biopsy 
specimen, perineural invasion (PNI) has been identified by several investigators as a 
predictor of BCR following external beam radiotherapy(19,20), however much debate remains 
over the prognostic value of PNI in RP specimens(21,22). In our subset of patients with PSMs 
we could not identify PNI as an independent prognostic factor for BCR on multivariable 
analysis. Furthermore, we could not identify pN+ status as an independent prognostic factor 
for BCR in our series, even on univariable analysis. This is probably due to the very low 
incidence in our series, with 18 out of 249 (7.2%) subjects having positive lymph nodes upon 
RP. 
Five studies address the number of PSMs in detail in populations that did not receive 
immediate postoperative therapy, with contradictory results. In a subset of 80 PSM patients 
analyzed by Lowe and Lieberman a significant increase in BCR for patients with multiple 
PSMs compared with single PSM was found(23), a finding confirmed in another series by 
Sofer et al. with 210 patients with PSM(24). Both series did not include pathological stage in 
their multivariable analyses which may have led to biased results as one might hypothesize 
that extraprostatic extension (pT3) is far more common in the subgroup with multiple PSM 
status. In our series we could confirm that pathological T3 stage was significantly more 
common in the multiple and bilateral PSM cohorts compared with the single PSM cohort. 
This hypothesis is supported by a larger series by Blute et al. of 697 pT2 patients with a PSM 
in which only a slightly higher rate of BCR was found for patients with multiple PSM when 
compared with those with a single PSM (25). Also, a more recent report on PSM status in 354 
patients with extraprostatic carcinoma (pT3a/b) on RP could also not detect a significant 
difference in BCR between patients with single and multiple PSMs(11). Therefore we think 
that any report on PSM status should include pathological stage in the multivariable analysis 
in order to be able to assess the independent prognostic value of PSM status properly. 
Furthermore, as patients with multiple or bilateral PSMs tend to experience BCR earlier on 
follow-up with Kaplan Meier curves closing in later on, the relative short follow-up of 22 
months by Sofer et al.(24) could lead to a false impression of increased BCR for multiple PSMs 
in the long term when processing Kaplan Meier curves on these data. This is supported by 
the difference in calculated 5-year BCR rates for multiple PSMs between ours and their 
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series, 41% versus approximately 60% (read from the Kaplan-Meier curve) respectively. 
Although we are not informed upon the 95% CI of this estimate, a very wide 95% CI range 
would support this statement. Our results support the thesis that patients with bilateral PSM 
progress to BCR earlier during follow-up, but are not at greater risk for BCR in the long-
term. A series by Jayachandran et al. reporting on 902 patients with PSM and/or pT3 disease 
could not identify pathological stage as an independent predictor of BCR on univariable 
analysis and thus did not incorporate this factor in their multivariable analysis(26). 
Consequently they found number of PSM to be significantly associated with BCR on 
univariable and multivariable analysis, a finding we could not confirm. In their series they 
did however exclude a substantial number of patients (n=205) with seminal vesicle invasion, 
which could account for a large number of BCR subjects in our series as these are relative 
poor-risk subjects within the pT3 subgroup. Another series reporting on 829 patients with a 
PSM following RP, retrospectively evaluated from CaPSURE, found no difference between 
single and multiple PSM. However, in this series patients with a multiple PSM status 
received immediate postoperative radiotherapy more frequently, which could compensate 
for any difference in BCR between single and multiple PSM status(6). 
We did not take the extent or length and site of PSM into account. Contradictory reports 
have been published on this issue, some finding length of PSM as a prognostic marker for 
BCR(27), while others could not identify extent of PSM as a prognostic marker(8,28). Most series 
did not find site of PSM to be predictive of BCR (24,28). Only Blute et al.(25) identified the 
prostate base as the only anatomic site of PSM predictive for recurrence at that specific 
anatomic site with a significant effect on 5-year risk of BCR, this increased from 15% to 44% 
in case of a PSM at the prostate base. 
To our knowledge no study on bilaterality of PSM status has been published before. 
Nevertheless one might hypothesize that bilateral PSM status might influence BCR free 
survival, as it might express more extensive tumour involvement of the prostate bed after 
RP. However, we could not identify an independent prognostic value of bilateral PSM status 
on multivariable analysis in our series. Patients with bilateral PSM tend to progress to BCR 
earlier during follow-up, with survival curves closing in at about 5-years of follow-up.  
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As far as pre-operative decision-making is concerned we think our report suggests that 
bilaterality of tumour near the prostatic pseudo-capsule or even suspicion of bilateral 
ȂȂ extraprostatic extension in itself should not be an absolute contra-indication for 
RP in experienced hands, as even patients with more extensive PSM will show 5-year BCR 
rates below 50%. This point is underscored by a review of literature by Grossfeld et al.(29) who 
found high probability of undetectable PSA in patients with a PSM status that did not 
receive immediate postoperative radiotherapy and this observation has consistently been 
reported by other investigators(4-12), with 5-year risk of BCR for patients in PSM cohorts 
between 25-47%. However the risk of a PSM and its future implications should be 
meticulously discussed with patients, and, as it is the only prognostic factor for BCR 
following RP that the urologist can influence, it is obvious that at all times maximum effort 
should be undertaken to avoid a PSM. In the near future pre-operative mapping of prostate 
cancer using sophisticated imaging techniques might prove to be of great help in minimizing 
PSM status after RP. 
The main limitation of our series is the retrospective data collection, which led to a 
substantial number of missing data in which we could not establish the details of PSM status 
on number and bilaterality. Interestingly patients with missing data did better as far as BCR 
rates are concerned, which might be attributed to less detailed pathological reporting on 
number and bilaterality of PSM in case of a single or limited multiple PSM status. Another 
concern might be the possible underpowering of our series to detect differences between 
groups; this is mainly an issue in the comparison of unilateral versus bilateral PSM, as only 
26 subjects were documented to have bilateral PSM. 
Also, the stretched time-frame in which our series was performed is a potential source of bias 
as we cannot exclude the influence of the well-documented effect of Gleason score migration 
over the last decades of the twentieth century(30,31), which has a profound effect on 
prognosis(31,32).The retrospective exclusion of subjects who underwent (neo) adjuvant 
hormonal therapy and/or immediate postoperative radiotherapy could have led to the 
exclusion of relative poor-risk subject that were treated with any of these measures at their 
ph¢Ȃȱǯȱ
 ȱ ȱ ȱ ȱ ȱ ȱȱ ȱ ȱ ǻŗŗśȱ ȱ ŘŚşǼȱ
were randomized to the wait-and-see arm of the EORTC 22911 trial on immediate 
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postoperative radiotherapy and consequently included in our series will at least diminish 
that effect. Furthermore, the EORTC 22911 included a centralized pathology review and is 
therefore acting as an external audit for this series. 
 
We conclude that number or bilaterality of PSM are not independent predictors of BCR in 
our series, however patients with bilateral PSMs did show a significant tendency to progress 
to BCR earlier during follow-up compared to patients with unilateral PSMs. For conclusive 
evidence future prospective series addressing this issue are needed. The search for more 
valid prognostic markers for disease recurrence following RP needs to continue for better 
risk stratification and decision-making regarding timing of adjuvant radiotherapy in post-
prostatectomy subjects. 
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CHAPTER  9 
The prognostic value of E-cadherin and the cadherin-
associated molecules D-, E-, J-catenin and  p120ctn in 
prostate cancer specific survival: a long-term follow-up 
study 
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Abstract 
Objectives 
To determine the value of loss of expression of E-cadherin and cadherin associated molecules 
as prognostic markers for prostate cancer patients in a long-term follow-up study. 
Methods 
Sixty-five prostate cancer specimens, obtained from patients with different stages of prostate 
cancer who underwent a radical prostatectomy or TUR-P between 1987 and 1991, were used 
for immunohistochemical analysis of the expression pattern of E-cadherin, D-, E-, J-catenin and 
p120ctn. Clinical records of these patients were studied for follow-up data and the prognostic 
value of expression of these adhesion molecules was determined by Kaplan-Meier survival 
analyses and multivariable proportional hazard regression analysis. 
Results 
Normal staining patterns were found in 36 cases (55.4%) for E-cadherin, 37 cases (56.9%) for 
D-catenin, 40 cases (61.5%) for E-catenin, 25 cases (38.5%) for J-catenin, and 40 cases (61.5%) 
for p120ctn. Overall, a strong correlation was found between the expression of E-cadherin 
and other cadherin-associated molecules. The 5-years survival rates for each staining were as 
follows: E-cadherin (normal 79.2%, aberrant 26.8%), D-catenin (normal 79.2%, aberrant 
26.8%), E-catenin (normal 73.1%, aberrant 27.3%), J-catenin (normal 86.4%, aberrant 37.1%), 
and p120ctn (normal 72.8%, aberrant 30.0%). There was a significant difference in survival 
between normal and aberrant expression in each staining (log rank p<0.0001). The 
proportional hazard regression model including tumor stage and Gleason score revealed D-
catenin expression as the best prognostic marker for patients with prostate cancer. 
Conclusions 
Our data revealed a strong correlation between E-cadherin expression and other cadherin-
associated molecules. Among these markers, alpha-catenin seems the best prognostic marker 
for prostate cancer specific survival. Larger studies are needed to confirm this result. 
 
 
 
 
van Oort IM, Tomita K, van Bokhoven A, Bussemakers MJ, Kiemeney LA, Karthaus HF, Witjes JA, Schalken JA. The prognostic value of E-
cadherin and the cadherin-associated molecules alpha-, beta-, gamma-catenin and p120ctn in prostate cancer specific survival: a long-term follow-
up study. Prostate. 2007 Sep 15;67(13):1432-8. 
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Introduction 
Prostate cancer is the most commonly diagnosed solid cancer and the second leading cause 
of cancer related deaths in American and European men(20;21). Although surgery and 
radiation therapies are effective for the treatment of organ confined cancer, a substantial 
number of patients will experience recurrent disease(3).   
Currently available prognostic factors such as preoperative PSA, stage, Gleason grade, and 
surgical margins have limitations, i.e. an inability to indicate metastatic potential. Therefore, 
more accurate markers are required to predict clinical course. One of these is the epithelial 
cell adhesion molecule E-cadherin(4). 
Functional E-cadherin adhesion complexes are necessary to maintain the normal 
differentiated phenotype in epithelial cells(5-7). In prostate cancer, dysfunction of molecules in 
these complexes is associated with an invasive phenotype(8-11). In functional E-cadherin 
complexes, which are located in the adherens junctions, E-cadherin is linked to the 
cytoskeleton via E- or J- catenin, D-catenin and p120ctn. Loss of functioning of E-cadherin 
and/or D-catenin in cancer cells is thought to be a poor prognostic factor in patients with 
prostate cancer(12-14). 
Aberrant expression of E-cadherin, D-, E-, and J-catenin molecules is correlated with 
pathological features such as capsular invasion(22). One recent study showed that reduced D- 
or E-catenin expression is related to malignant phenotype in localized prostate cancer and 
predicts shortened recurrence-free survival(18). p120ctn expression in prostate cancer has also 
been correlated with a shorter recurrence-free survival(19). However, all these studies have a 
relative short follow-ȱ ȱ Ȃȱ ȱ ȱ ȱ  ȱ ȱ ¡ession of E-
cadherin, D-, E-, and J-catenin, p120ctn and prostate cancer specific survival. In this present 
study, with a long median follow-up of 50 months, we report on the expression of E-
cadherin, D-, E-, J-, and p120ctn in human prostate cancer specimens by immunohistochemical 
staining and analyze the correlation between expression of these molecules with long term 
prostate cancer specific survival. 
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Material and methods 
Patients 
Sixty-five patients with carcinoma of the prostate who underwent radical prostatectomy or 
desobstructing TUR-P at the Radboud University Nijmegen Medical Centre or Canisius-
Wilhelmina Hospital between 1987 and 1991 were included in this study. Clinical records 
were studied for follow-up data. Treatment for localized disease was radical prostatectomy 
or curative radiation therapy. Treatment for locally advanced or metastatic disease was 
hormonal therapy. Patients were controlled every 3 months for the first year and every 6 
months after that until June 2006, death, or loss to follow-up. 
 
Immunohistochemistry 
Upon radical prostatectomy or transurethral resection, prostatic adenocarcinoma specimens 
were snap-frozen in liquid nitrogen. Four Pm serial sections were used for 
immunohistochemical analysis. One of the serial sections was stained with hematoxylin & 
eosin to determine the histopathological grading using the Gleason score(20).  
Frozen prostate carcinoma materials (4 Pm) were fixed by paraformaldehyde (10 min.) for E-
cadherin, D-, E-, J-catenin and p120ctn staining. Upon preincubation with normal sheep serum 
(diluted 1:20 in PBSE) for 30 min., the sections were incubated for 1 hour at room temperature 
with primary antibody. A standard immunohistochemical avidin-biotin step was applied 
 ȱ ȱ Ȃȱ ȱ (Vectastain ABC kit, Vector Laboratories Inc., 
Burlingame, USA). Diaminobenzidine (DAB) was used for detection. Antibodies against E-
cadherin (HECD-1 - mouse monoclonal antibody Ȯ Takara,Otsu, Shiga, 520-2193, Japan), D-
catenin (C2081 - rabbit polyclonal antibody, Sigma BioSciences, Missouri,63103 USA), E-catenin 
(mouse monoclonal antibody, Transduction Laboratories Lexington, Kentucky, 40510-1100 
USA), J-catenin (PG5.1 - mouse monoclonal antibody, Progen Biotechnik GmbH , D69123 
Heidelberg, Germany), and p120ctn (mouse monoclonal antibody, Transduction Laboratories) 
were used at a dilution of 1:100, 1:1000, 1:400, 1:25, and 1:200, respectively. Two independent 
observers (K.T., A.v.B.) performed the evaluation of staining patterns without prior 
knowledge of the tumor stage and patient profile. Patterns were scored as either normal 
(membrane staining - fig. 1a) or aberrant (negative or heterogeneous staining (= mixed 
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populations of positive and negative cells Ȯ(fig. 1b) as previously described by Schipper(21) and 
Umbas(22). 
Statistical analyses 
Chi-square tests were used to determine the correlation of staining and tumor grade or stage. 
Correlations between E-cadherin expression and expression of the other molecules were 
ȱȱȂȱǯȱȱ -up was calculated as the number of months from 
treatment until prostate cancer death, death from other causes, end of the study period, or 
loss to follow-up. Prostate cancer death was used as the event variable in Kaplan-Meier 
survival analyses. Differences in survival between subgroups were tested using the log-rank 
test. The proportional hazard regression model was used to test the independent effects of 
stage, grade, and staining pattern for E-cadherin, D-, E-, J-catenin, and p120ctn on prostate 
cancer death. Statistical significance of the resulting hazard ratios was tested with the 
likelihood ratio test. Statistical significance for all tests was set at p<0.05. All analyses were 
performed using the SPSS (Statistical Package for Social Sciences) software version 12.01. 
 
Results 
The mean and median age at presentation was 69.0 years (range 42-87yr). The median 
follow-up was 50 months. Gleason score ranged from 5 to 10. During follow-up 40 of 65 
patients died of prostate cancer, 10 died of other causes and 4 were lost to follow-up (table 1). 
 
Table 1: Characteristics of 65 study participants 
Age at diagnosis, median (IQR) 69.0 (64-76) 
Follow-up in months, median (IQR) 50 (21,5-104,5) 
Gleason score, n ( %) 5-6 19 (29%) 
7 6 (9%) 
8-10 40 (62%) 
Stage, n (%) T2 20 (31%) 
T3-4 45 (69%) 
Metastasis, n (%) M0 30 (46%) 
M1 26 (40%) 
Mx 9 (14%) 
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Membrane staining for cadherin-associated molecules was found in normal glands, while 
both normal and aberrant expression was found in cancer areas. Pathological stage, Gleason 
score and staining pattern is summarized in table 2.  
 
Table 2: Aberrant staining proportions for cadherin adhesion molecules by pathological stage and  
Gleason score. 
 n E-cadherin 
% aberrant 
D-catenin 
% aberrant 
Ά-catenin 
% aberrant 
·-catenin 
% aberrant 
p120ctn 
% aberrant 
All patients 65 44.6 43.1 38.5 61.5 38.5 
Stage T2 20 30 30 30 40 30 
T3-4 45 51 49 42 71 42 
     Λ2* p  0.11 0.16 0.35 0.17 0.35 
Gleason 
score 
5-6 19 5.3 0 5.3 21.1 0 
7 6 0 0 33.3 50.0 0 
8-10 40 70.0 70.0 55.0 82.5 62.5 
     Λ2* p  <0.001 <0.001 0.001 <0.001 <0.001 
ȘȱȱȱΛ2 test for differences in proportions between normal and aberrant staining by stage and grade. 
 
The most prevalent abnormal membrane staining is not a complete absence of catenin 
expression but a heterogeneous immunoreactivity. 
Overall, a good correlation was found between E-cadherin expression and other cadherin 
adhesion molecules (table 3), except for J-catenin that had a higher proportion of aberrant 
expression.  
 Table 3: Correlation of E-cadherin expression with ΅-, Ά-, ·-catenin, and p120ctn expression. 
             E-cadherin  
Molecules   Normal  Aberrant p-value* 
 
΅-catenin normal     35         2     1.00 
   aberrant      1        27  
 
Ά-catenin normal     33          7     0.34 
   aberrant      3        22 
 
·-catenin normal     24         1     0.003 
   aberrant     12        28 
 
p120ctn  normal     35         5     0.22 
   aberrant      1        24 
   
However, in 19 of 65 cases discrepancies in this correlation between E-cadherin and other 
cadherin adhesion molecules were noted. This included aberrant E-cadherin staining with 
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normal staining for one or more catenins in 8 cases, and normal E-cadherin staining with 
aberrant staining for at least one catenin in 12 cases. Survival analysis showed that aberrant 
expression of all antigens was associated with poorer survival compared to cases with 
normal expression (table 4).  
 
Table 4: Correlation of E-cadherin and catenin expression with cancer specific survival (log- rank test)   
 
 
 
 
 
 
 
 
 
 
The survival curve for E-cadherin is shown in figure 2. The curves for the associated 
molecules are all very similar. When the analysis was restricted to only men with a Gleason 
score of 8 or higher, the results were still significant and aberrant staining remained an 
indicator of poor prognosis. We compared cases with discrepancies between E-cadherin and 
catenins expression to cases without discrepancies on survival.  
 
Among patients with aberrant E-cadherin staining there is no significant difference between 
normal staining for one or more catenins (8 cases) and aberrant staining for all catenins (21 
cases) (fig.3) However, among patients with normal E-cadherin staining there was a difference 
between aberrant staining for at least one catenin (12 cases) and normal staining for all 
catenins (24 cases) (p=0.087) (fig 4). Proportional hazard regression (table 5) suggests that D-
catenin is the best prognostic marker for patients with prostate cancer among E-cadherin-
associated molecules. 
variable All patients Patients with Gleason score 8 
or higher 
n 5-yr survival 
rate (%) 
p-value n 5 yr survival 
rate (%) 
P value 
E-cadherin normal 36 79.2 <0.0001 12 80.0 0.21 
 aberrant 29 26.8 28 26.7 
΅-catenin normal 37 79.2 <0.0001 12 80.0 0.04 
 aberrant 28 26.8 28 26.6 
Ά-catenin normal 40 73.1 0.002 18 63.0 0.04 
 aberrant 25 27.3 22 24.6 
·-catenin normal 25 86.4 <0.0001 7 80.0 0.16 
 aberrant 40 37.1 33 34.2 
P120ctn normal 40 72.8 <0.0001 15 62.2 0.50 
 aberrant 25 30.0 25 30.0 
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    Table 5: Proportional hazard regression model for each variable 
Variable Univariable 
HR 
CI Multi- 
Variable HR 
CI 
Stage: locally advanced and/or metastasized vs. localized  
1.87 
 
0.77-4.50 
 
2.00 
 
0.82-4.84 
Gleason grade: 7 vs. 2-6 0.55 0.10-3.09 0.50 0.09-2.84 
Gleason grade: 8-10 vs. 2-6                         3.54 1.21-10.37 1.49 0.40-5.49 
E-cadherin aberrant vs. normal 2.71 0.85-4.89   
΅-catenin: aberrant vs. normal 3.73 0.88-5.09 10.41 2.40-45.21 
Ά-catenin: aberrant vs. normal 2.17 0.82-4.68   
·-catenin: aberrant vs. normal 2.77 0.74-4.23   
P120ctn : aberrant vs. normal 2.34 0.87-5.00 0.34 0.10-1.18 
     In both the univariable and multivariable models, stage and Gleason grade were forced into the model. In the multivariable 
    model, all other factors were evaluated with a stepwise procedure with p=0.15 for entry and exit criteria. 
 
Discussion 
It has become clear that the loss of E-cadherin-mediated adhesion is associated with 
progression of many carcinomas. We previously found that decreased E-cadherin and D-
catenin expression correlates with a decreased recurrence-free survival for patients with 
prostate cancer(23;24). 
 
Because proper anchorage to the cytoskeleton is necessary for E-cadherin function, a lack of 
expression or defect of the molecules involved in this anchorage can also be responsible for 
cancer cell invasion. We thus studied catenin expression and compared it with E-cadherin 
expression to determine which specific prognostic information can be obtained from each 
antigen in prostate cancer patients with emphasis on prostate cancer specific survival with 
long term follow-up. We showed that in prostate cancer, decreased expression of each 
catenin including p120ctn is significantly correlated with lower cancer specific survival, 
independent of conventional factors like stage and Gleason grade. 
In 8 cases, aberrant staining for E-cadherin was found, combined with D-, E-, J-catenin 
normally expressed. Because it has been demonstrated that both D-, and J-catenins are 
unstable in L-cells lacking cadherin, and that they can be stabilized by either desmosomal 
cadherins or E-cadherin[7-23], the staining pattern found in these 8 cases indicates that catenins 
stabilized by molecules other than E-cadherin. There is no significant prognostic difference 
between these cases and cases with aberrant expression of all molecules, suggesting that E-
cadherin expression is very important in a functional complex. 
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In 12 cases, the opposite observation was made; E-cadherin staining was normal, whereas 
catenin immunoreactivity indicated that no functional complexes were present. There is a 
borderline significant prognostic difference between these cases and cases with normal 
expression of all molecules (p=0.087). This suggests that in addition to a normal E-cadherin 
expression normal expression of all catenins is needed to keep the E-cadherin adhesion 
complex functioning. 
The correlation between E-cadherin expression and p120ctn is not as strong as the correlation 
between E-cadherin and catenin expression. Function of p120ctn in the E-cadherin complex is 
not yet well understood. It has been shown that p120ctn can interact with E-cadherin but not 
with D-catenin(24), suggesting that p120ctn does not occupy a place similar to its structural 
homologues E- and J-catenin that bridge E-cadherin to D-catenin. 
Although p120ctn, D- and E- catenin has been studied in prostate cancer with recurrence-free 
survival, long-term follow-up is missing. Data on the expression of E-cadherin, D-, E-, J-
catenin, and p120ctn and prostate cancer-specific survival are also missing.  
To our knowledge, this is the first report correlating E-cadherin, D-, E-, J-catenin, and p120ctn 
expression to cancer-specific survival in prostate cancer. Only one study has been published 
concerning expression of D- and E-catenin and recurrence-free survival. Aaltomaa et al. 
analyzed D- and E-catenin expression in 181 patients with prostate cancer, who underwent a 
radical prostatectomy with a mean follow-up of 7.3 years(18). They found that D- and E-
catenin were highly significant interrelated. Strong D-catenin was related to low Gleason-
grade, low pT category, cancer-free seminal vesicles and low preoperative PSA level. Strong 
E-catenin membrane expression was related to low Gleason-grade and cancer-free seminal 
vesicle status. In a survival analysis low expression of D-catenin and E-catenin predicted 
shortened recurrence-free survival. In all, Aaltomaa et al. concluded that reduced D- or E-
catenin expressions are related to malignant phenotype in local prostate cancer and predict 
PSA failure as well as shortened survival. In our study we found that reduced expression of 
all molecules studied here correlates with poor survival. A significant inverse correlation 
was found between immunoreactivity for members of the E-cadherin complex and clinical 
metastasis and Gleason score but not with pathological tumor stage. Our data also revealed a 
good correlation between E-cadherin expression and other cadherin-associated molecules. 
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However, the proportional hazard regression model revealed D-catenin is the best prognostic 
marker among E-cadherin-associated molecules for patients with prostate cancer. Because 
this result is based on small numbers, it needs conformation by other studies. 
 
Conclusions 
Our data revealed a good correlation between E-cadherin expression and other cadherin-
associated molecules. A significant inverse correlation was found between immunoreactivity 
for members of the E-cadherin complex and Gleason score which is significantly associated 
with cancer specific survival. Alpha-catenin seems to be the best prognostic marker for 
patients with prostate cancer and adds significant information to predict survival in prostate 
cancer patients.  
       Figure 1a: normal membrane staining 
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          Figure 1b: aberrant membrane staining 
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Figure 2: Kaplan-Meier survival curves showing prostate cancer-specific survival for all patients according to E-cadherin 
staining. Upper line = normal staining, lower line= aberrant staining.  
Figure 3: Difference between all catenins aberrant (= blue line) and at least one catenin normal (= green line) among patients 
with aberrant E-cadherin staining. 
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Figure 4: Difference between normal staining of all catenins (=upper blue line) and at least one catenin aberrant (=lower green 
line) among patients with normal E-cadherin staining. 
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CHAPTER 10  
Summary 
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Approximately 680,000 men are diagnosed with prostate cancer worldwide each year. This 
number will increase with more widespread serum PSA testing. The increase in prostate 
cancer detection has introduced a sharp increase in the number of treatments for localized 
disease, like radiotherapy, brachytherapy, cryotherapy, and of course also radical 
prostatectomy. The popularity of surgical treatment over radiotherapy is in part due to 
improvements in the surgical techniques that decrease the risk of impotence, i.e. nerve-
sparing prostatectomy. 
  
With the increasing use of prostatectomy as treatment with curative intent, there is a rise in 
the number of prostatectomy specimens that has to be evaluated. Since there is also a stage 
and grade shift, as described in the introduction, the average prostatectomy specimen 
nowadays is different from that of 15 years ago, and different aspects of pathology have 
become less (like stage and resection margin) or more (like tumor volume) important. This 
clearly results in an increasing importance of the pathological classification, and therefore 
one of the main issues for pathologists and urologists is the identification of those prognostic 
factors in RP specimens that accurately predicts patient outcome. This thesis addresses the 
clinical relevance of pathological findings that are found in prostatectomy specimens after 
radical prostatectomy. 
Pathological information derived from the radical prostatectomy specimen such as Gleason 
score, pathological stage and margin status are powerful prognostic indicators that are used 
in prediction tables like the Kattan ȱȱȱȱȂȱȱȱȱ
free survival. Moreover, this pathological information is of importance to decide whether a 
patient needs to receive adjuvant radiotherapy or hormonal treatment. Therefore, it is 
important to get appropriate pathological information from the pathologist. In chapter 2 we 
review the results of published prognostic factors derived from radical prostatectomy 
specimens. It is important that pathology reports clearly present the relevant prognostic 
factors including Gleason score, pathological stage, and margin status. Other prognostic 
factors such as tumor volume, perineural invasion, maximum tumor diameter, percentage of 
high-grade tumor, and tertiary Gleason pattern are still under debate and require more 
study. This is the basis for this thesis. 
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In chapter 3 the value of the tertiary Gleason score is studied. The Gleason system is based 
on the glandular differentiation patterns seen at low magnification. The most frequent 
(primary) and the second most frequent (secondary) patterns are each assigned a grade 
between 1 and 5 with 1 being the most differentiated pattern and 5 the least differentiated. 
The sum of the primary and secondary pattern is the Gleason score, which is given to each 
tumor. However, many radical prostatectomy specimens contain more than two patterns. In 
this study we investigate the prognostic significance of the tertiary Gleason pattern in 277 
radical prostatectomy specimens obtained between 1994 and 2001. In these radical 
prostatectomy specimens 48% were found to have a tertiary pattern, which on average was 7 
% of the total tumor volume. Patients with a tertiary pattern had a 5-year risk of PSA 
progression of 37.3% versus 12.6% in case no tertiary Gleason pattern was present. Based on 
these data we conclude that the presence of a tertiary Gleason pattern has prognostic 
significance, as indicated by a shorter time to PSA progression. Since this was even found in 
those cases where the tertiary pattern was better differentiated than the primary and 
secondary Gleason score we think that not only a tertiary pattern but also the presence of 
multifocality of prostate cancer has prognostic significance for biochemical recurrence, 
Chapter 4 describes the prognostic role of the pathological T2 subclassification for prostate 
cancer in the 2002 Tumor-Node -Metastasis staging system. The TNM2002 defined pT2 
prostate cancer into three clinical subdivisions, T2a (unilateral tumor involving one-half of a 
lobe or less), T2b (unilateral tumor involving more than one-half of a lobe), and T2c (bilateral 
disease), where in 1997 it was a division in two categories (unilateral vs. bilateral). There is 
still a lot of controversy regarding the appropriate subclassification of prostate cancer. Only 
very few results are available on probably the most important aspect, the prognostic value of 
pathological substaging. In this study we looked at the prevalence of pathological T2b 
tumors in 360 pT2 specimens. We identified 79(22%) pT2a and 281(78%) pT2c but no pT2b 
specimens. The 5-year risk of biochemical recurrence was 13% vs. 23% (p=0.056) (pT2a vs. 
pT2c), respectively. In a multivariable analysis pT2c versus pT2a there was only a marginally 
(insignificant) increase in the risk of biochemical recurrence for pT2c tumors t (HR=1.3 95% 
CI=0.6-2.7). Therefore, we conclude that the limited differences in biochemical recurrence for 
the substages pT2a and pT2c,  and the inability to identify a pT2b tumor it is justified  to  
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modify the TNM staging system into one with no subclassification of pT2 disease, or with  
only one subdivision, unilateral (T2a) and bilateral (T2b) disease, combining the pT2a and 
pT2b substages. 
In chapter 5 the small volume prostate cancers and insignificant prostate cancers are 
investigated. Small-volume cancers (svPC) are those with a volume of 0.5cc or less. Tumors 
are called insignificant prostate cancers (InsigPC), in case of a volume of 0.5cc or less 
combined with a Gleason score of 6 or less. For these small-volume/insignificant prostate 
cancers expectant management is more and more considered to be a reasonable approach. 
Therefore, for patients with a relatively long life expectancy it is important to know what the 
biological behavior of these small-volume prostate cancers is. We studied this biological 
behavior in our own cohort of 502 patients. All of these patients were treated with radical 
prostatectomy between 1992 and 2005. A total of 82 specimens (16.3%) with svPC including 
64 (12.8%) with InsigPC were identified. The 5-year risk of biochemical recurrence for the 
svPC group and the insigPC group was 10% (95% CI 2-18%, 7 and 5 patients, respectively) 
vs. 35% (95% CI 29-41 %) in the rest of the cohort (log rank p=0.001). These results show that 
patients with svPC and patients with InsigPC have a significantly lower risk of biochemical 
recurrence. However, even in this seemingly very favorable patient group 1 in 10 patients 
will develop a biochemical recurrence after radical prostatectomy. Therefore new studies are 
needed to examine what the prognostic relevance is of small-volume tumors. 
Chapter 6 describes the prognostic value of maximum tumor diameter in localized prostate 
cancer. Tumor volume in the radical prostatectomy specimen is also associated with 
prognosis. However, it is controversial whether it is an independent prognostic factor for the 
total group or for the high-risk group. Maximum tumor diameter (a simple measurement of 
the largest diameter of the largest tumor from glass slides) has been suggested as a fast and 
easy to measure parameter for tumor volume. In our own cohort with a median follow-up of 
39.5 months we found a median maximum tumor diameter of 24mm (range 1- 65). The 
overall 5-year risk of biochemical recurrence was 25% (95% CI=20.4 -29.6). In univariate 
analyses, maximum tumor diameter was weakly associated with risk of biochemical 
recurrence in the total group (HR=1.02 per mm increase, 95% CI=1.002-1.035, p=0.024), in the 
high-risk group this association was lost (HR=1.01, 0.99-1.03, p=0.18). Multivariate analyses 
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indicated that positive surgical margins, higher Gleason score, advanced pathological stage 
and multiple tumors were the main prognostic factors for biochemical recurrence 
irrespective of the risk profile. Therefore the conclusion of this study is that maximum tumor 
diameter is not an independent prognostic factor for BCR in patients treated with RP, 
irrespective of the risk profile. 
In chapter 7 and 8 two studies from two different patients cohorts are presented concerning 
the prognostic value of a positive surgical margin. Chapter 7 is a study of our own cohort 
where we analyze the correlation of the length of the positive surgical margin with 
biochemical recurrence. The presence of positive surgical margins is the only prognostic 
factor that can be influenced by the surgical technique. Most investigators agree that a +SM 
may adversely affect cancer control after RP; others disagree and state that it has only limited 
predictive value for PSA relapse and local recurrence. Stratification of men with a +SM is 
essential in determining who might benefit from adjuvant therapy after RP. Early 
identification of these patients can have significant clinical impact. One of these factors for 
stratification could be the length of the positive margin. In our cohort of 267 patients with a 
positive surgical margin, the total linear length of +SM ranged from 0.4 to 174.5 mm. In 174 
patients with an immeasurable postoperative PSA value (median follow-up of 36.3 months) 
the 5-years risk of BCR was 29%. The risk of BCR for these patients was 21% in case of a +SM 
ǂȱ ŗŖȱ ȱ ȱ ȱ ȱ řşƖȱ  ȱ ȱ Ƹȱ  ȱ ǁȱ ŗŖȱ ǯȱ ȱ ȱ ¢ȱ
biochemical recurrence was associated with an increasing length of +SM (HR 2.15 for 
>10mm; 95% CI 1.12-4.15; p = 0.022), but not with preoperative PSA, pathological stage, 
Gleason score, tumor volume or Gleason grade at the resection margin. This indicates that 
the length of +SM is an independent predictive factor for PSA recurrence.  
In Chapter 8 we evaluated whether the number of +SMs or bilaterality of +SMs were 
prognostic markers for biochemical recurrence (BCR) since these parameters are easier to 
assess for the pathologist than length of positive surgical margin. Therefore we evaluated, in 
a cohort of 1009 patients who had had a radical prostatectomy in Brussels at the university 
de Louvain, a subgroup of 249 patients with +SM. A single +SM was found in 70.6%, 29.4% 
ȱȱƸȱǻǃŘȱǼǰȱŞŜǯŚƖȱ ȱǰȱ ȱŗřǯŜƖȱȱȱƸǯȱȱ
was no difference in biochemical recurrence between these groups. Multivariate analysis 
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showed that PSA at diagnosis and Gleason score were independent predictive factors for 
biochemical recurrence. Thus the presence of multiple and/or bilateral +SMs did not add 
prognostic information.  
 
 The above-mentioned factors still have limitations in their ability to predict whether the 
disease will metastasize. Therefore, more accurate markers are required to predict clinical 
outcome. One of these markers is the epithelial cell adhesion molecule E-cadherin. 
Functional E-cadherin adhesion complexes are necessary to maintain the normal 
differentiated phenotype in epithelial cells. In prostate cancer, dysfunctions of molecules in 
these complexes are associated with an invasive phenotype. In functional E-cadherin 
complexes, which are located in the adherens junctions, E-cadherin is linked to the 
cytoskeleton via E- or J- catenin, D-catenin and p120ctn. Loss of functioning of E-cadherin 
and/or D-catenin in cancer cells is thought to be a poor prognostic factor in patients with 
prostate cancer. Aberrant expression of E-cadherin, D-, E-, and J-catenin molecules is 
correlated with pathological features such as capsular invasion. In chapter 9, we studied a 
cohort of 56 patients with a median follow-up of 50 months, and analyzed the correlation 
between expressions of these molecules with long-term prostate cancer specific survival. The 
5-year survival rates for each staining showed a significant difference in survival between 
normal and aberrant expression of each marker (log rank p<0.0001). Multivariate analysis 
revealed D-catenin expression as the best prognostic marker for patients with prostate 
cancer, although larger studies are needed to confirm this result. 
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Samenvatting 
Wereldwijd worden jaarlijks ongeveer 680.000 mannen gediagnosticeerd met 
prostaatkanker. Dit aantal zal bij een groter gebruik van de PSA test ongetwijfeld toenemen. 
De toename van de detectie prostaatkanker heeft een grote toename veroorzaakt in het 
aantal behandelingen voor gelokaliseerd prostaatkanker, zoals radiotherapie, 
brachytherapie, cryotherapie en uiteraard ook radicale prostatectomie. De populariteit van 
de chirurgische behandeling is deels te danken aan de verbetering van de operatietechniek, 
die het risico van impotentie door een zenuwsparende benadering verkleint. 
Met de toenemende populariteit van de in opzet curatieve radicale prostatectomie, zien wij 
ook een toename in het aantal prostatectomie preparaten die onderzocht en geëvalueerd 
worden. Aangezien er ook een verandering is in stadiëring en gradering zal het pathologisch 
verslag van het gemiddelde prostatectomie preparaat nu anders zijn dan 15 jaar geleden. 
Sommige aspecten van de pathologie zijn minder relevant geworden (zoals stadium en 
resectievlak) en andere zijn meer relevant geworden (zoals tumorvolume). Dit resulteert in 
een toenemende waarde van de pathologische classificatie en identificatie van de 
prognostische factoren in RP preparaten. De evaluatie van RP preparaten zijn daardoor een 
van de belangrijkste onderwerpen voor pathologen en urologen om tot een nauwkeuriger 
prognose voor patiënten te komen. 
Dit proefschrift verwijst naar de klinische relevantie van pathologische bevindingen die 
worden gevonden in preparaten van radicale prostatectomieën. Pathologische informatie 
afkomstig uit een preparaat van een radicale prostatectomie, zoals Gleason score, 
pathologisch stadium en resectievlakken zijn sterk prognostisch indicatoren die kunnen 
worden gebruikt in voorspellende tabellen zoals de Kattan nomogrammen. Deze 
nomogrammen kunnen de prognose voor ziektevrije overleving voorspellen. Bovendien is 
deze pathologische informatie van belang bij de het nemen van een besluit of een patiënt 
adjuvante radiotherapie of een hormonale behandeling wordt geadviseerd. Het is derhalve 
van groot belang om uitgebreide pathologische informatie te verkrijgen van de patholoog. 
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In hoofdstuk 2 worden de resultaten van prognostische factoren uit de literatuur besproken, 
die afkomstig zijn uit pathologische onderzoeken van radicale prostatectomieën. Het is van 
klinisch belang dat pathologierapporten duidelijk de relevante prognostische factoren 
weergeven zoals Gleason score, pathologisch stadium en resectievlakken. Andere 
prognostische waarden, zoals tumor volume, perineurale invasie, maximale tumor diameter, 
percentage van hooggradigheid van de tumor en tertiair Gleason patroon, staan nog ter 
discussie en behoeven meer onderzoek. Dit is de basis voor dit proefschrift.  
In hoofdstuk 3 wordt de waarde van de tertiaire Gleason score bestudeerd. Het Gleason 
gradering systeem is gebaseerd op het differentiatiepatroon van de klieren dat bij lage 
uitvergroting wordt gezien. De meest voorkomende (primaire) en de op één na meest 
ȱǻǼȱȱȱȱȱȱŗȱȱśǰȱ ȱȃŗȄ het meest 
ȱȱȃśȄȱȱȱȱȱǯȱȱȱȱȱȱȱ
de secundaire patroon is de Gleason score, die aan ieder tumorpreparaat wordt gegeven. 
Echter veel preparaten van radicale prostatectomieën bevatten meer dan twee patronen. In 
deze studie wordt de prognostische waarde van het tertiaire Gleason patroon bestudeerd in 
277 preparaten van radicale prostatectomieën die tussen 1994 en 2001 zijn uitgevoerd in het 
Radboud Ziekenhuis Nijmegen. In 48% van de preparaten werd een tertiair Gleason patroon 
gevonden, wat overeenkomt met 7% van het totale tumorvolume. Patiënten met een tertiair 
Gleason patroon hadden een 5-jaar risico op PSA progressie van 37.3% versus 12.6% in 
gevallen waarin geen tertiair Gleason patroon aanwezig was. Aan de hand van deze data 
kan worden geconcludeerd dat de aanwezigheid van een tertiair Gleason patroon 
prognostische waarde heeft, zelfs in die gevallen waarin het tertiaire patroon beter was 
gedifferentieerd dan de primaire en secondaire Gleason score. 
Hoofdstuk 4 beschrijft de prognostische rol van de pathologische T2 subclassificatie voor 
prostaatkanker in het 2002 TNM graderingsysteem. Sinds 2002 heeft het AJCC pT2 
prostaatkanker in drie klinische subdivisies onderverdeeld: pT2a (unilaterale tumor van een 
halve kwab of minder), pT2b (unilaterale tumor van meer dan een halve kwab) en pT2c 
(bilaterale ziekte), terwijl er in 1997 slechts een onderverdeling was in twee categorieën 
(unilateraal versus bilateraal). Er bestaat nog altijd een grote controverse ten aanzien van de 
juiste subclassificatie van prostaatkanker.  
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Over het belangrijkste aspect, te weten de prognostische waarde van de pathologische 
subgradering, zijn minder resultaten beschikbaar. In deze studie is gekeken naar de 
prevalentie van pathologische T2b tumoren in preparaten van in totaal 360 pT2 materiaal, 
waar 79 (22%) pT2a en 281(78%) pT2c preparaten konden worden vastgesteld, maar geen 
pT2b preparaten werden gevonden. Het 5 jaar risico op biochemisch recidief was 
respectievelijk 13% versus 23% (p=0.056) (pT2a vs. pT2c). In een multivariabele analyse gaf 
pT2c versus pT2a slechts een marginaal (insignificant) toegevoegd effect in de toename van 
biochemisch recidief (HR=1.3 95% CI=0.6-2.7). Derhalve is geconcludeerd dat de beperkte 
verschillen in biochemisch recidief en in pathologische eigenschappen van unilateraal versus 
bilateraal pT2 prostaatkanker het wijzigen van het TNM graderingsysteem rechtvaardigt in 
een systeem zonder subclassificatie van pT2 ziekte, of met de subclassificatie van unilateraal 
(T2a) en bilateraal (T2b) prostaatkanker, waarbij de T2a en T2b substadia worden 
gecombineerd. 
In hoofdstuk 5 worden de kleinvolume prostaatkankers en insignificante prostaatkankers 
onderzocht. Kleinvolume prostaatkankers (svPC) zijn carcinomen met een volume van 0.5cc 
of minder. Tumoren worden insignificante prostaatkankers (InsigPC) genoemd bij een 
volume van 0.5cc of minder, gecombineerd met een Gleason score van 6 of minder. 
Waakzaam wachten wordt steeds vaker als een adequate benadering beschouwd voor deze 
prostaatkankers. Daarom is het voor patiënten met een relatieve lange levensverwachting 
belangrijk te weten wat het biologische gedrag van deze kleine prostaatkankers is. Dit 
biologische gedrag is bestudeerd in een eigen patiëntencohort van 502 patiënten. Deze 
patiënten ondergingen tussen 1992 en 2005 een radicale prostatectomie. In totaal werden er 
82 preparaten (16.3%) met svPC geïdentificeerd waarvan 64 (12.8%) InsigPC. Het 5 jaar risico 
op biochemisch recidief voor de svPC groep en de insigPC groep was 10% (95% CI 2-18%, 
respectievelijk 7 en 5 patiënten) versus 35% (95% CI 29-41 %) in de rest van de 
patiëntencohort (log rank p=0.001). Deze resultaten tonen aan dat patiënten met svPC en 
patiënten met InsigPC een beduidend lagere kans hebben op biochemisch recidief. Echter 
zelfs in dit ogenschijnlijk zeer gunstige patiëntencohort zullen 1 tot 10 patiënten na een 
radicale prostatectomie een biochemisch recidief ontwikkelen. Om deze reden zijn er nieuwe 
studies noodzakelijk om de prognostische waarde van kleine tumoren te onderzoeken. 
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Hoofdstuk 6 beschrijft de prognostische waarde van de maximale tumor diameter bij 
gelokaliseerd prostaatkanker. Tumorvolume in het radicale prostatectomie preparaat is ook 
onmiskenbaar geassocieerd met de prognose. Echter, of het een onafhankelijke prognostische 
factor is voor zowel de totale groep als voor de hoogrisicogroep blijft nog altijd omstreden. 
Een uitleg voor deze conflicterende resultaten kan zijn dat schattingen van tumorvolume 
worden gedaan met behulp van verschillende technieken. Daarom wordt de maximale 
tumordiameter (eenvoudige metingen van de grootste diameter van de grootste tumor van 
preparaatglaasje) gesuggereerd als een snelle en makkelijk te meten parameter voor 
tumorvolume. In ons eigen patiëntencohort (N= 502) met een gemiddelde follow-up van 39.5 
maand vonden wij een gemiddelde maximale tumordiameter van 24mm (interval 1- 65). Het 
5 jaar risico op biochemisch recidief in de gehele groep was 25% (95% CI=20.4 -29.6). In 
univariate analyses werd in de totale groep een zwakke relatie gevonden tussen de 
maximale tumordiameter en de kans op biochemisch recidief (HR=1.02 per mm toename, 
95% CI=1.002-1.035, p=0.024), in de hoogrisicogroep was deze relatie verdwenen. (HR=1.01, 
0.99-1.03, p=0.18). Multivariabele analyses toonden aan dat positieve snijvlakken, een hogere 
Gleason score, een vergevorderd pathologisch stadium en multipele tumoren de 
belangrijkste factoren voor biochemisch recidief waren, Deze bevinding is ongeacht het 
risicoprofiel. Daarom is de conclusie van deze studie dat de maximale tumordiameter geen 
onafhankelijke prognostische factor is voor biochemisch recidief in patiënten die ongeacht 
het risicoprofiel een radicale prostatectomie hebben ondergaan. 
In hoofdstuk 7 en 8 worden twee studies gepresenteerd in twee verschillende cohorts over 
de prognostische waarde van een positief snijvlak. 
Hoofdstuk 7 is een studie van ons eigen cohort waarin de correlatie van de lengte van het 
positieve snijvlak met het biochemisch recidief (BCR) wordt geanalyseerd. De incidentie van 
positieve chirurgische snijvlakken(+SM) is de enige prognostische factor die kan worden 
beïnvloed door de chirurgische techniek. De meeste onderzoekers zijn het er over eens dat 
een +SM de ziektecontrole ongunstig kan beïnvloeden na radicale prostatectomie. Anderen 
zijn het hiermee oneens en beweren dat het slechts een beperkte voorspellende waarde heeft 
voor PSA- en lokaal recidief. Stratificatie van mannen met een +SM is essentieel om vast te 
stellen wie in aanmerking zou kunnen komen voor adjuvante therapie na radicale 
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prostatectomie. Vroege detectie en voorspelling van deze patiënten kunnen een belangrijke 
klinische impact hebben. Een van deze factoren voor stratificatie zou de lengte van het 
positieve snijvlak kunnen zijn. In ons cohort van 267 patiënten met een positief snijvlak, 
varieerde de lengte van +SM van 0.4 tot 174.5 mm. In 174 patiënten met een onmeetbare 
postoperatieve PSA waarde (gemiddelde follow-up van 36.3 maanden) was het 5 jaar risico 
op BCR 29Ɩǯȱ
ȱȱȱȱȱ£ȱºȱ ȱŘŗƖȱȱȱȱȱȱƸȱǂȱŗŖȱ
mm vergeleken met 39% waarbij de +SM > 10 mm was. In een multivariabele analyse werd 
biochemisch recidief geassocieerd met een toenemende lengte van +SM (HR 2.15; 95% CI 
1.12-4.15; p = 0.022), maar niet met preoperatieve PSA, pathologisch stadium, Gleason score, 
tumorvolume of Gleason stadium bij het snijvlak. Dit betekent dat de lengte van +SM een 
onafhankelijke voorspellende factor is voor PSA recidief.  
In hoofdstuk 8 worden het aantal +SM en de bilateraliteit van de +SM geëvalueerd als 
prognostische marker voor biochemisch recidief. Dit zou namelijk een eenvoudiger te 
evalueren parameter zijn voor de patholoog in plaats van het meten van de lengte van het 
positieve snijvlak. We hebben hiervoor in een cohort met 1009 patiënten een subgroep van 
249 patiënten met een positief snijvlak geëvalueerd die een RP hebben ondergaan in het 
Universiteit ziekenhuis de Louvain in Brussel. In 70.6% werd een enkel positief snijvlak 
gevonden, 29.4% had multipele positieve snijvlakken, 86.4% was unilateraal en 13.6% had 
bilaterale snijvlakken. Er werd geen verschil gevonden in biochemisch recidief tussen deze 
groepen. Multivariate analyse liet zien dat preoperatief PSA en Gleason score onafhankelijke 
voorspellende factoren waren voor biochemisch recidief. De aanwezigheid van multipele 
en/of bilaterale snijvlakken gaf geen extra prognostische informatie. 
 
Alle bovengenoemde factoren hebben hun beperkingen in hun capaciteit om de kans op 
metastasering aan te geven. Daarom zijn er meer accurate markers nodig teneinde de 
klinische consequenties te kunnen bepalen. Een van deze markers is het epitheel 
celadhesiemolecuul E-cadherine. Functionele E-cadherine adhesiecomplexen zijn 
noodzakelijk voor het behoud van het normaal gedifferentieerd fenotype in epitheel cellen. 
In prostaatkanker, zien wij dat disfunctie van moleculen in deze complexen verbonden zijn 
met een invasief fenotype. In functionele E-cadherine complexen, die zich in de adherente 
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juncties bevinden, is E-cadherine gelieerd aan het cytoskelet via E- of J- catenine, D-catenine 
en p120ctn. Verlies van de functie van E-cadherine en/of D-catenine in kankercellen wordt 
gezien als een slechte prognostische factor in patiënten met prostaatkanker. Afwijkend 
expressie van E-cadherine, D-, E-, en J-catenine moleculen worden in verband gebracht met 
pathologische eigenschappen zoals kapsel doorbraak.  
In hoofdstuk 9, wordt een cohort van 56 patiënten bestudeerd met een gemiddelde follow-
up van 50 maanden en wordt naar de correlatie gekeken tussen expressies van deze 
moleculen met lange termijn prostaatkankerspecifieke overleving. De 5 jaar 
overlevingsaantallen voor elke molecuul toonde een significant verschil in overleving tussen 
normale en atypische expressie in elke marker (log rank p<0.0001). Een multivariabele 
analyse toonde aan dat D-catenine expressie de beste prognostische marker is voor patiënten 
met prostaatkanker, dit zal echter in grotere studies moeten worden bevestigd. 
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Future perspectives 
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Radical prostatectomy 
The fundamental basis of the type of studies as presented in this thesis is the radical 
prostatectomy specimen. Without these specimens in our database analysis of prognostic 
indicators would not be possible. The way in which this specimen is obtained is by radical 
prostatectomy of which several different techniques have evolved in the last decade. 
Although not the main subject of this thesis, discussion of these techniques seems 
appropriate in a thesis on prostate cancer in the year 2009. The open radical prostatectomy 
(RRP) is the reference standard for the surgical management of localized prostate cancer. In 
ȱȱşŖȂȱȱȱȱǻǼȱȱ¢ǯȱȱique is a complex 
ȱȱ ȱȱȱȱȱȱȱǰȱȱȱ¡Ȃȱǰȱ
it is safe and effective. Since the beginning of this millennium, the robotic assisted 
laparoscopic prostatectomy (RALP) has become popular. The intention was to decrease the 
steep learning curve of LRP while accomplishing the advantage of a minimally invasive 
technique. Advantages of the RALP technique include the 3-dimensional stereoscopic 
visualization, finger-controlled movements and improved ergonomics achieved by a 
comfortably seated surgeon.  
With the greater availability of these minimally invasive radical prostatectomy techniques, 
there is, at the same time, a debate ongoing, regarding what will be the standard treatment 
for the management of localized prostate cancer in the near future. Intermediate term follow-
up of large series show similar oncological results for RRP, LRP and RALP, but 
unfortunately there are no prospective randomized studies comparing the three techniques. 
In our own database we saw that the learning curve of the LRP resulted in an increase in 
positive surgical margins.  To achieve optimal cancer control, it is important for the surgeon 
to use the technique that will give the best oncological outcome. This is, however, highly 
dependent on the experience of the surgeon.  An experienced surgeon, who uses the open 
technique and who has a good oncologic and functional outcome, should not try to convert 
at all costs to the newer techniques. Others, challenged to start with these new techniques, 
have to reckon with a temporary increase in the number of positive surgical margins, and 
therefore have to make sure that this learning curve will be as short as possible, e.g. by using 
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laparoscopic training facilities. For that reason the preferentially minimally invasive 
technique will be the RALP with a shorter learning curve than the LRP.  
To solve the question on what will be the standard treatment for the management of 
localized prostate cancer, we will need large prospective randomized trials with long term 
follow up. Not earlier can we make assumptions on what technique will be the best. Only 
with these trials we can compare the different surgical techniques and evaluate the influence 
of these techniques on biochemical recurrence and prostate cancer. But unfortunately, since 
Ȃȱȱȱȱ ȱȱȱǻȱvs. laparoscopic) the chance of this kind of trial is 
very small. 
 
Diagnosing the disease 
Staging systems are used to predict prognosis and guide adequate treatment. Staging 
systems are divided into a clinical system (pre-operative) and a pathological system (post-
operative). Better staging should start with better clinical staging. An accurate assessment on 
tumor extent and progression is important to estimate the risk of progression after treatment. 
Currently this is done by serum prostate specific antigen (PSA), digital rectal examination 
(DRE), transrectal ultrasound (TRUS) and TRUS- guided biopsies. DRE shows poor 
performance especially in the lower PSA ranges, where currently most patients are coming 
from. TRUS is the most commonly used imaging modality for the prostate, not because of its 
good sensitivity but mostly for guiding the prostate biopsies.   
For primary diagnostic imaging more is expected from MRI and MRI modalities 
(Conventional T2-weighted MRI with the addition of MR-spectroscopy, dynamic contrast 
ȱȱ ǻȃȄ-MRI), and diffusion weighted MR imaging). This combination 
outperforms any other imaging technique. We therefore expect to have a better positive 
biopsy rate with fewer biopsies taken and maybe even an indication of the aggressiveness of 
the tumor (Gleason score). Future studies will have to confirm this(25). 
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PSA and prostate cancer specific markers 
PSA is organ specific but not cancer specific. It has a low specificity, especially in the serum 
PSA gray zone of 3 to 15 ng/mL, resulting in a negative biopsy rate of 70% to 80%. To 
improve the clinical use several other methods have been developed such as PSA velocity, 
PSA density, PSA doubling-time and free to total PSA ratio, but none have made an 
undisputable improvement. As a result, there is an urgent need for prostate cancer specific 
markers that can improve the specificity in prostate cancer diagnosis and can prevent 
unnecessary prostate biopsies. With a negative predictive value of 90% the PCA3 urine test 
has shown to have diagnostic value and great potential in reducing the number of 
unnecessary biopsies(26). Another improvement and promise for the future is the TMPRSS2-
ERG fusion transcript. These transcripts can also be detected in the urine sediment after 
DRE.  With a high positive predictive value of 94% of TMPRSS2-ERG fusion transcripts, this 
test could give an even better indication which patients require repeat biopsies and which 
patients do not(27). Therefore, it is expected that in the near future, after confirmation of these 
results in larger trials, the decision to perform prostate biopsies in patients will be made by 
using a combination of the prostate cancer-specific biomarkers TMPRSS2-ERG and PCA3. 
When these test show that biopsies are needed the patient will have TRUS guided biopsies. If 
after a single procedure of 10-12 biopsies prostate cancer has not been diagnosed MRI and 
MRI guided biopsies will be the following step in trying to diagnose this disease. 
 
Staging the disease 
After diagnosing the disease and performing a radical prostatectomy the patient is staged 
according to the TNM classification. This classification had already been revised twice with 
intervals of 5 years. The reason for these revisions is that there are regularly new additional 
data, which can be used to fine-tune the prognosis in the different stage categories. Since the 
last revision it has become more evident that the three subclassifications in the T2 stage (the 
most found T-stage in radical prostatectomy cohorts) are not necessary. Analysis of our 
database confirmed this, where no T2b (more than one half of one lobe) was found at all. It is 
also rather unlikely for a large tumor to occupy more than half of one lobe and still be 
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confined within this lobe, without extension into the opposite site. Since even no significant 
difference was found in our study in risk of biochemical recurrence in the two other 
subclassifications, we advise that in the upcoming new TNM classification the T2 
classification will be one with no subclassification or at most 2 subclassifications. This will 
not only be easier for the urologists who have to interpret the information and inform the 
patient, but also for the pathologist.  
 
Tertiary Gleason pattern  
One of the prognostic factors that has the potential to give us more information about the 
aggressiveness of the tumor is the tertiary Gleason score. The results of our own cohort 
showed that the presence of a tertiary Gleason is an indication for worse outcome in patients 
with prostate cancer. This was also confirmed in a systematic review and meta-analysis in 
2007(28). Since a better tertiary Gleason score is also associated with a worse outcome, one 
might hypothesize that multifocality or a larger volume of prostate cancer, more than a 
tertiary Gleason score per se, is the reason for a worse prognosis. We therefore strongly 
advise the pathologist to report all tertiary patterns found in a radical prostatectomy 
specimen. 
 
Volume of prostate cancer 
With the use of all these new diagnostic modalities and the increased awareness of prostate 
cancer of the general population there is a dramatic shift towards smaller and earlier stage 
prostate cancer. To find out whether active surveillance is a reasonable treatment for these 
small volume cancers, we analyzed our own database and found that, although less than in 
the rest of the cohort, even small/insignificant prostate cancers have the ability to develop 
biochemical recurrence. This means that volume of prostate cancer has some prognostic 
value, but that more studies and larger series are necessary to evaluate the biological 
behavior of these small/insignificant cancers. Only then we will be able to make good 
decisions about which men are suitable for active surveillance.  
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The previous results illustrate the importance of prostate cancer volume.  The measurement 
of this volume by the pathologist is rather time-consuming. The suggestion was, that 
measurement of the maximum tumor diameter on a glass slide, was an easy parameter to 
measure tumor volume and therefore for biochemical recurrence. Unfortunately, in our 
cohort we could not find the association of maximum tumor diameter with biochemical 
recurrence to be significant. We therefore do not advise to measure maximum tumor 
diameter but still promote to measure the total tumor volume, so that in the future, with 
larger cohort studies, more information about tumor volume as a prognostic factor can be 
analyzed. 
 
Resection margins 
Of all the prognostic factors surgical margins is the only one, which is influenced by the 
surgeon. Whether it affects cancer control is still controversial and better stratification of 
these patients is necessary to determine who needs direct adjuvant therapy. We therefore 
investigated the length of the positive surgical margin in our own cohort. Our results 
showed an association between the length of the positive surgical margins and the risk of 
biochemical recurrence, with a higher chance of recurrence in patients with a positive 
surgical margin of > 10 mm. Since it is easier for the pathologist to report only the total 
number of positive surgical margins or even the bilaterality of the positive surgical margins, 
we looked at a different cohort of radical prostatectomies from Brussels to see if there was an 
association of these variables with biochemical recurrence. Unfortunately this was not the 
case. We therefore advise pathologist to measure the total positive surgical margin in 
millimeters and include this in the pathology report and not only the number of positive 
surgical margins or the number of sides. 
 
Molecular markers 
All of the factors mentioned above, still do not indicate the metastatic potential of prostate 
cancer. Molecular markers like the epithelial cell adhesion molecule E-cadherin and the 
cadherin-associated molecules could be markers for the future. In a cohort of prostate cancer 
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patients we found that alpha-catenin was best associated with cancer specific survival. Since 
this was only a small cohort we advise to conduct more studies on cancer specific survival 
towards this potential marker for the risk of metastasis and prostate cancer death.  If this is 
confirmed in larger studies, the status of these adhesion molecules is important for the 
urologist and the patient. If biochemical recurrence occurs in patients with a loss in cell 
adhesions molecules direct adjuvant therapy (i.e. hormonal therapy or early chemotherapy) 
could be given instead of watchful waiting until the systemic recurrence is evident. 
 
Future prognostic factors 
With all these already known prognostic factors and some of the others discussed in this 
thesis, there are still a lot of factors that show promises or have some scientific evidence (i.e. 
tumor volume, perineural invasion, percentage of high grade Gleason etc.). These prognostic 
factors need more evaluation in the future before we can use them to predict our Ȃ 
disease free survival. Therefore we need more information from radical prostatectomy 
databases, preferably multi centric, and prospectively evaluated by uropathologists.  
 
Uropathologist 
The fundamental basis of this thesis as mentioned earlier is the radical prostatectomy 
specimen. Without these specimens analysis of prognostic indicators would not be possible. 
To get the best evaluation of the radical prostatectomy specimen we need dedicated 
uropathologist.  In this way we are sure that the handling of the specimen will be by the 
same guidelines, making it easier to use and compare this information.  
 
In all, pathological information remains to be very important to predict outcome after radical 
prostatectomy, but additional factors and fine-tuning seems possible and necessary. 
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Toekomstverwachtingen 
Radicale prostatectomie 
Het uitgangspunt van de in deze thesis gepresenteerde studies is het radicale prostatectomie 
preparaat. Zonder deze preparaten in onze database is analyse van prognostische factoren 
niet mogelijk. Dit preparaat wordt verkregen door pathologisch onderzoek van de radicale 
prostatectomie. In de laatste decennia zijn hiervoor verschillende operatiemethoden 
ontwikkeld. Hoewel dit niet het onderwerp van dit proefschrift is lijkt discussie van deze 
technieken gepast in het kader van deze thesis over prostaat kanker in het jaar 2009. 
De open radicale prostatectomie (RP) is de referentie standaard voor alle chirurgische 
behandelingen voor gelokaliseerd prostaat kanker. Laat in de jaren negentig werd de 
laparoscopische radicale prostatectomie (LRP) populairder. Deze techniek is een complexe 
procedure en is geassocieerd met een lange leercurve en slechte ergonomie. In handen van 
de expert is het echter een veilige en effectieve procedure. Sinds het begin van dit 
millennium is de robot geassisteerde laparoscopische prostatectomie (RALP) populairder 
geworden. Het doel was om de leercurve van de LRP te verkleinen met de voordelen van 
een minimaal invasieve techniek. De voordelen van de RALP techniek bestaan uit het 3-D 
stereoscopische zicht, vinger gecontroleerde bewegingen en verbeterde ergonomie 
gecomplementeerd met een comfortabele zittende chirurg. 
Met de toegenomen beschikbaarheid van deze minimale invasieve radicale prostatectomie 
technieken is er op hetzelfde moment ook een discussie gaande over wat de standaard 
techniek voor het gelokaliseerde prostaat carcinoom in de toekomst zal zijn. Middellange 
follow-up studies van grotere series laten een vergelijkbaar oncologische resultaat zien voor 
de RP, LRP en de RALP maar helaas zijn er geen prospectieve gerandomiseerde studies die 
deze technieken daadwerkelijk vergelijken. In onze database zagen we dat de leercurve van 
de LRP in het begin resulteerde in een toename van aantal positieve resectievlakken. Om een 
optimale kanker controle te verkrijgen is het belangrijk voor de uroloog om een techniek te 
gebruiken die de beste oncologische uitkomst zal geven. Dit is echter zeer afhankelijk van de 
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ervaring van de uroloog. Een uroloog met ervaring in het gebruik van de open procedure en 
hiermee goede oncologische en functionele resultaten heeft, zou niet ten koste van alles 
moeten proberen om over te gaan op de andere nieuwere techniek. Andere urologen, die wel 
worden uitgedaagd om met de nieuwe technieken te starten, moeten rekening houden met 
een tijdelijke toename in het aantal positieve resectievlakken. Er wordt geadviseerd wordt 
ervoor te zorgen dat de leercurve zo kort mogelijk is door bijvoorbeeld gebruik te maken van 
laparoscopische trainingsfaciliteiten. 
De techniek die de voorkeur verdient, is dan ook de RALP omdat die een kortere leercurve 
heeft dan de LRP. Om antwoord te kunnen geven op de vraag wat de standaard techniek zal 
zijn voor de toekomst zullen grote prospectieve studies nodig zijn met een lange follow-up. 
Niet eerder kunnen we conclusies trekken over welke techniek de beste zal zijn. Alleen door 
deze studies te verrichten kunnen we de verschillende chirurgische technieken vergelijken 
en evalueren, om te evalueren wat de invloed is op het biochemisch recidief bij 
prostaatkanker. Helaas is een er grote kloof tussen aanhangers van beide benaderingen 
(open versus laparoscopisch) en daarmee de kans op deze studie beperkt.  
 
Prostaatkanker diagnostiek 
Stadieringssystemen worden gebruikt om prognose van de patiënt te voorspellen en de 
behandeling te begeleiden. Deze systemen zijn onderverdeeld in een klinisch deel 
(preoperatief) en een pathologisch deel (postoperatief). Een betere stadiering moet beginnen 
met een adequate klinische stagering. Een accurate vaststelling van de uitgebreidheid van de 
tumor en de mate van progressie is hierbij belangrijk om het risico van progressie na de 
behandeling te kunnen voorspellen. Dit wordt tegenwoordig gedaan door de combinatie van 
PSA, rectaal toucher (RT), echo prostaat (TRUS) en echogeleide puncties. RT heeft een lage 
specificiteit speciaal in de lage PSA waarden waarin de meeste patiënten tegenwoordig 
zitten. TRUS is de meest gebruikte beeldvorming modaliteit voor de prostaat, niet vanwege 
de goede sensitiviteit maar vooral ten behoeve van de geleiding van de prostaat biopten. 
Voor de primaire diagnostische beeldvorming wordt er meer verwacht van de MRI en de 
MRI modaliteiten (conventionele T2 gewogen MRI met de MR spectroscopie, dynamische 
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contrast versterkende MRI (= perfusie-MRI) en de diffusie gewogen MRI). Deze combinatie 
is beter dan enig andere beeldvormingtechniek. Wij verwachten dat met deze technieken het 
percentage positieve biopten hoger zal zijn en dat daarvoor een minder aantal biopten 
genomen zal worden. De verwachting is ook dat de MRI modaliteiten misschien zelfs een 
indicatie van de agressiviteit van de tumor (Gleason score) kunnen geven. Dit zal moeten 
worden bevestigd in toekomstige studies. 
 
PSA en prostaatkanker specifieke tumormarkers 
PSA is orgaan specifiek maar niet kanker specifiek. PSA heeft een lage specificiteit, speciaal 
in de grijze PSA zone tussen 3 en 15. Dit resulteert in een negatieve biopteratio van 70 % tot 
80%. Om dit klinisch gebruik te verbeteren zijn er verschillende andere methoden 
ontwikkeld zoals PSA-snelheid, PSA dichtheid, PSA verdubbelingstijd en vrije/totale PSA 
ratio maar geen van deze methoden hebben een duidelijke verbetering gegeven. Hierdoor 
bestaat er nog steeds een noodzaak voor prostaatspecifieke markers die de specificiteit in 
diagnostiek kunnen verbeteren en het onnodig nemen van biopten kan verminderen.  
Met een negatieve voorspellende waarde van 90% heeft de PCA3 test bewezen van 
diagnostische waarde te zijn en heeft daarmee een grote potentie om het aantal biopten te 
verminderen. Een andere potentiële verbetering en een belofte voor de toekomst is de 
TMPRSS2-ERG fusie transcripts. Deze transcripts kunnen ook in urine sediment worden 
gedetecteerd na RT. Met een hoge positieve voorspellende waarde van 94% van TMPRSS2-
ERG fusie transcript kan deze test zelfs een betere indicatie geven welke patiënt 
herhalingsbiopten nodig heeft. Daarom wordt verwacht dat in de nabije toekomst, na 
bevestiging van deze resultaten in grotere studies, de beslissing om tot prostaat biopten over 
te gaan zal worden genomen op basis van een combinatie van de prostaat kanker specifieke 
biomarkers TMPRSS2-ERG en PCA3. Alleen wanneer deze tests positief zijn zal er worden 
overgegaan tot echogeleide biopten. Als na een enkele biopt serie van 10-12 biopten geen 
prostaatkanker kan worden gediagnosticeerd zal worden overgegaan tot MRI en MRI 
geleide biopten om tot een diagnose te komen. 
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Stadiëring van de ziekte 
Na de diagnose van de ziekte en de uitgevoerde radicale prostatectomie zal de patiënt 
worden gestadieerd volgens de TNM classificatie. Deze classificatie is met een interval van 5 
jaar al twee keer gereviseerd. De reden van deze revisie is dat er steeds nieuwere gegevens 
beschikbaar komen die weer gebruikt wordt om de prognose te verfijnen in de verschillende 
categorieën van stadia. Sinds de laatste revisie is het duidelijker geworden dat de 3 
subcategorieën in de T2 classificatie (het meest gevonden T stadium in radicale 
prostatectomie cohorts) niet noodzakelijk zijn. Analyse van onze database bevestigt dit 
aangezien er geen T2b (tumor die meer dan de helft van een lob beslaat) werd gevonden. Het 
lijkt ook weinig waarschijnlijk dat een grote tumor meer dan een helft van een lob in zal 
nemen en daarbij niet over de mediaan lijn komt. Daarnaast werd er in onze studie geen 
significant verschil gevonden in de twee andere subclassificaties (pT2a en pT2c) en kans op 
biochemisch recidief. Daarom adviseren we om in de aankomende vernieuwde TNM 
classificatie het T2 stadium alleen te laten bestaan uit één dan wel ten hoogste twee 
subclassificaties. Dit zal niet alleen makkelijker zijn voor de uroloog die de informatie moet 
interpreteren en de patiënt informeren, maar ook voor de patholoog. 
 
Tertiaire Gleason patroon 
Een van de prognostische factoren die potentie heeft om ons meer informatie te geven over 
de agressiviteit van de tumor is de tertiaire Gleason score. Het resultaat van ons eigen cohort 
laat zien dat de aanwezigheid van een tertiaire Gleason patroon een indicatie geeft van een 
slechte prognose bij patiënten met prostaatkanker. Dit wordt ook bevestigd in een meta-
analyse in 2007(28). Aangezien een betere Gleason score ook is geassocieerd met een slechtere 
prognose kunnen, wij veronderstellen dat multifocaliteit en/of een groter volume, eerder dan 
de tertiaire Gleason score, de reden is voor de slechte prognose. Daarom willen we de 
patholoog adviseren om alle tertiaire patronen die gevonden worden in radicale 
prostatectomie preparaten te rapporteren. 
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Prostaat tumor volume 
Met het gebruik van de eerder besproken nieuwe diagnostische modaliteiten en de 
toegenomen bewustzijn van prostaatkanker bij de bevolking is er een dramatische 
verandering naar de detectie van kleinere tumoren en tumoren in een vroeger stadium. Om 
te beoordelen of waakzaam wachten een goede behandeling is voor deze kleinvolume 
kankers hebben we onze database geanalyseerd. Hierbij hebben we gevonden dat in deze 
cohort zelfs kleinvolume/insignificante tumoren de mogelijkheid hebben om een 
biochemisch recidief te ontwikkelen. Het biochemisch recidief was wel minder dan in rest 
van de totale cohort. 
Dit betekent dat het volume van prostaatkanker een prognostische waarde heeft, maar dat er 
meer en grotere studies nodig zijn om het biologische gedrag van deze kleinvolume en 
insignificante tumoren te bestuderen. Alleen dan kunnen we goede beslissingen nemen over 
welke patiënten geschȱ£ȱȱȁ £ȱ Ȃǯ 
Het voorgaande resultaat illustreert het belang van prostaatkanker volume. Het meten van 
dit volume door de patholoog kost veel tijd. Het idee was dat het meten van de maximale 
tumor diameter op een preparaatglaasje van de patholoog een makkelijk te meten parameter 
zou zijn voor de tumor diameter en daardoor ook voor het biochemisch recidief. Helaas 
werd in ons cohort niet een significante associatie gevonden tussen tumor volume en het 
biochemisch recidief. Daarom adviseren wij om niet de tumor diameter te meten maar om 
nog steeds het totale tumor volume te meten zodat in de toekomst met grotere cohort studies 
meer informatie over tumor volume als prognostische factoren kan worden geanalyseerd.  
 
Resectie vlakken 
Van alle prognostische factoren is het resectievlak de enige die door de chirurg is te 
beïnvloeden. Of dit de kanker controle beïnvloedt is nog steeds controversieel en betere 
stratificatie van deze patiënt is noodzakelijk om vast te stellen wie er direct adjuvante 
therapie nodig heeft. Daarom hebben we gekeken naar de lengte van de positieve 
resectievlakken in ons eigen cohort. In onze resultaten zagen we een associatie tussen de 
lengte van het positieve resectievlak en kans op biochemisch recidief waarbij patiënten met 
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een resectie vlak > 10 mm een hogere kans hebben op recidief. Aangezien het makkelijker is 
voor de patholoog om het aantal positieve resectievlakken of zelfs alleen de bilateraliteit van 
de resectievlakken te bekijken hebben wij een cohort van radicale prostatectomieën 
geanalyseerd uit Brussel om te zien of er sprake was van een associatie met biochemisch 
recidief. Helaas was dit niet het geval. Daarom adviseren wij de patholoog om de totale 
lengte in millimeters te meten en dit in het pathologie rapport te zetten en niet het aantal 
positieve resectievlakken of het aantal positieve zijden. 
 
Moleculaire markers 
Al deze factoren hierboven genoemd geven beperkt inzicht in het metastatisch potentieel 
van de tumor. Moleculaire markers zoals het epitheliale cel adhesie molecuul E-cadherine en 
de cadherine geassocieerde moleculen kunnen deze markers voor de toekomst zijn. In ons 
cohort van prostaat kanker patiënten vonden we dat alfa-catenine het beste geassocieerd is 
met kanker overleving. Aangezien het maar een klein cohort was adviseren we om meer 
studies te verrichten om deze potentiële marker te onderzoeken op de kans op metastase en 
prostaatkanker overlijden. Als dit in groter studies wordt bevestigd zal de entiteit van deze 
cel adhesie moleculen belangrijk worden voor de uroloog en de patiënt. Als er biochemisch 
recidief ontstaat bij patiënten, die bekend zijn met een verlies in cel adhesie moleculen, zal er 
direct begonnen worden met adjuvante therapie (zoals hormonale therapie of vroege 
chemotherapie) in plaats van waakzaam wachten totdat een systemisch recidief duidelijk is. 
  
Toekomstige prognostische factoren 
Met al deze reeds bekende factoren en andere factoren, die in deze thesis worden 
bediscussieerd, zijn er nog een aantal waarbij sommige al deels wetenschappelijk zijn 
bewezen, dan wel een belofte voor de toekomst zouden kunnen zijn (hierbij zijn te noemen: 
het tumorvolume, perineurale invasie, percentage hoge Gleason graad). Deze factoren 
behoeven in de toekomst meer evaluatie voordat we ze kunnen gebruiken om ziekte vrije 
overleving te kunnen voorspellen. Om die reden hebben we meer informatie nodig uit 
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radicale prostatectomie databases. Deze databases, bij voorkeur multicentrisch, zullen 
prospectief geëvalueerd moeten worden door uropathologen.  
 
Uropathologen 
De basis van deze thesis, zoals al eerder vermeld, is het radicale prostatectomie preparaat. 
Zonder dit preparaat is een analyse van prognostische factoren niet mogelijk. Om de beste 
evaluatie te krijgen van het preparaat hebben we op dit specifieke terrein toegewijde 
uropathologen nodig. Op deze manier weten we zeker dat elke evaluatie zal gebeuren 
volgens dezelfde richtlijnen, waardoor het eenvoudiger wordt om deze informatie te 
gebruiken en te vergelijken.  
In conclusie kunnen we stellen dat pathologische informatie erg belangrijk blijft om de 
klinische consequentie te voorspellen na radicale prostatectomie. Verfijning van deze 
prognostische factoren blijft mogelijk en wordt aanbevolen voor de toekomst. 
Prostate cancer:  
The clinical relevance of pathological findings after radical prostatectomy 
 
 
- 153 - 
 
References 
1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin 2006 Mar;56(2):106-30. 
2. Kiemeney L, Lemmers F, Verhoeven R, Aben K, Honing C, de Nooijer J, et al. De kans op kanker voor Nederlanders. Ned 
Tijdschr Geneeskd 2008. 
3. Franks LM. Latent carcinoma of the prostate. J Pathol Bacteriol 1954 Oct;68(2):603-16. 
4. Sakr WA, Grignon DJ, Crissman JD, Heilbrun LK, Cassin BJ, Pontes JJ, et al. High grade prostatic intraepithelial neoplasia 
(HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo 1994 
May;8(3):439-43. 
5. Scardino PT. Early detection of prostate cancer. Urol Clin North Am 1989 Nov;16(4):635-55. 
6. Scardino PT, Weaver R, Hudson MA. Early detection of prostate cancer. Hum Pathol 1992 Mar;23(3):211-22. 
7. Association of Cancer centres. www.ikcnet.nl.  2005.  
8. Nadler RB, Loeb S, Roehl KA, Antenor JA, Eggener S, Catalona WJ. Use of 2.6 ng/ml prostate specific antigen prompt for 
biopsy in men older than 60 years. J Urol 2005 Dec;174(6):2154-7, discussion. 
9. Naughton CK, Miller DC, Mager DE, Ornstein DK, Catalona WJ. A prospective randomized trial comparing 6 versus 12 
prostate biopsy cores: impact on cancer detection. J Urol 2000 Aug;164(2):388-92. 
10. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, et al. EAU guidelines on prostate cancer. Eur Urol 2008 
Jan;53(1):68-80. 
11. Cagiannos I, Karakiewicz P, Graefen M, Eastham JA, Ohori M, Rabbani F, et al. Is year of radical prostatectomy a predictor 
of outcome in prostate cancer? J Urol 2004 Feb;171(2 Pt 1):692-6. 
12. Cooperberg MR, Lubeck DP, Mehta SS, Carroll PR. Time trends in clinical risk stratification for prostate cancer: 
implications for outcomes (data from CaPSURE). J Urol 2003 Dec;170(6 Pt 2):S21-S25. 
13. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of 
prostatic cancer. JAMA 1995 Jan 25;273(4):289-94. 
14. Draisma G, Boer R, Otto SJ, van dC, I, Damhuis RA, Schroder FH, et al. Lead times and overdetection due to prostate-
specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer 
Inst 2003 Jun 18;95(12):868-78. 
15. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, et al. Combination of prostate-specific antigen, 
clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. 
JAMA 1997 May 14;277(18):1445-51. 
16. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, et al. The use of prostate specific antigen, clinical stage and 
Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993 Jul;150(1):110-4. 
17. Smith DS, Catalona WJ. Interexaminer variability of digital rectal examination in detecting prostate cancer. Urology 1995 
Jan;45(1):70-4. 
18. Wingo PA, Guest JL, McGinnis L, Miller DS, Rodriguez C, Cardinez CJ, et al. Patterns of inpatient surgeries for the top four 
cancers in the United States, National Hospital Discharge Survey, 1988-95. Cancer Causes Control 2000 Jul;11(6):497-512. 
19. Takeichi M. The cadherins: cell-cell adhesion molecules controlling animal morphogenesis. Development 1988 
Apr;102(4):639-55. 
20. Hellerstedt BA, Pienta KJ. The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 2002 May;52(3):154-
79. 
21. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin 2005 
Jan;55(1):10-30. 
22. Morita N, Uemura H, Tsumatani K, Cho M, Hirao Y, Okajima E, et al. E-cadherin and alpha-, beta- and gamma-catenin 
expression in prostate cancers: correlation with tumour invasion. Br J Cancer 1999 Apr;79(11-12):1879-83. 
23. Umbas R, Isaacs WB, Bringuier PP, Schaafsma HE, Karthaus HF, Oosterhof GO, et al. Decreased E-cadherin expression is 
associated with poor prognosis in patients with prostate cancer. Cancer Res 1994 Jul 15;54(14):3929-33. 
24. Umbas R, Isaacs WB, Bringuier PP, Xue Y, Debruyne FM, Schalken JA. Relation between aberrant alpha-catenin expression 
and loss of E-cadherin function in prostate cancer. Int J Cancer 1997 Aug 22;74(4):374-7. 
25. Heijmink SW, Futterer JJ, Hambrock T, Takahashi S, Scheenen TW, Huisman HJ, et al. Prostate cancer: body-array versus 
endorectal coil MR imaging at 3 T--comparison of image quality, localization, and staging performance. Radiology 2007 
Jul;244(1):184-95. 
26. van Gils MP, Hessels D, van HO, Jannink SA, Peelen WP, Hanssen SL, et al. The time-resolved fluorescence-based PCA3 
test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. 
Clin Cancer Res 2007 Feb 1;13(3):939-43. 
27. Hessels D, Smit FP, Verhaegh GW, Witjes JA, Cornel EB, Schalken JA. Detection of TMPRSS2-ERG fusion transcripts and 
prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res 2007 Sep 
1;13(17):5103-8. 
28. Harnden P, Shelley MD, Coles B, Staffurth J, Mason MD. Should the Gleason grading system for prostate cancer be 
modified to account for high-grade tertiary components? A systematic review and meta-analysis. Lancet Oncol 2007 
May;8(5):411-9. 
Prostate cancer:  
The clinical relevance of pathological findings after radical prostatectomy 
 
 
- 154 - 
 
Prostate cancer:  
The clinical relevance of pathological findings after radical prostatectomy 
 
 
- 155 - 
 
 
DANKWOORD 
Prostate cancer:  
The clinical relevance of pathological findings after radical prostatectomy 
 
 
- 156 - 
 
Prostate cancer:  
The clinical relevance of pathological findings after radical prostatectomy 
 
 
- 157 - 
 
 
Waarschijnlijk is dit gedeelte het meest gelezen deel van het proefschrift en vaak ook het 
gedeelte dat als eerste wordt gelezen.  
 
Hiermee wil ik een ieder bedanken die op een of andere manier heeft bijgedragen aan dit 
alles. Wetende dat ik niet volledig kan zijn, verontschuldig ik mij alvast en zeg tegen 
diegene, die zichzelf hierin niet terug kan vinden, dat ik dat wel had gewild, dat ik ook jouw 
hulp, vriendschap, ondersteuning etc. op prijs heb gesteld. 
 
Prof.dr. J.A. Witjes, beste Fred, zoals ik al wel eens eerder heb gezegd wist ik een paar dingen 
zeker toen ik naar de opleiding urologie solliciteerde:  ik zou niet mijn opleiding in Nijmegen 
volgen, zou nooit academisch gaan werken en zeker niet promoveren! Dat dit alles anders is 
verlopen is deels te danken aan jou (en gewoon omdat ik een vrouw ben, zou jij zeggen!).Je 
niet aflatende enthousiasme voor de oncologische urologie en de wetenschap heeft ertoe 
bijgedragen dat dit boekje nu af is. Bedankt voor je begeleiding tijdens het schrijven van de 
manuscripten, je begeleiding en adviezen op de OK, je snelle verbeteringen, je vriendschap, 
ondersteuning, luisterend oor en kritische blik.  
 
Prof.dr. L.A.L.M. Kiemeney, beste Bart, bedankt voor de begeleiding op statistisch gebied. Ik 
weet dat je af en toe gek werd van mijn mailtjes. Van jou heb ik geleerd dat het niet uitmaakt 
wat anderen doen op statistisch gebied maar dat wij het vooral goed moeten doen, ook als de 
uitkomsten dan niet zijn wat wij verwachten. Onvergetelijk zijn het gezucht en gemompel als 
je het toch niet echt met mij eens was over een bepaalde uitleg van uitslagen. Ook je grote 
hoeveelheden rode strepen en commentaar, als ik weer een manuscript van je terug kreeg, 
hebben indruk gemaakt. Maar ondanks dit alles, of waarschijnlijk dankzij dit alles, ligt hier 
nu het resultaat!  
 
Dr. C.A. Hulsbergen-van de Kaa, beste Christina, bedankt voor alle prostatectomie preparaten 
die jij met zo veel zorg analyseert waardoor uiteindelijk dit proefschrift mogelijk is 
Prostate cancer:  
The clinical relevance of pathological findings after radical prostatectomy 
 
 
- 158 - 
 
geworden. Onze database is dan wel niet een van de grootste maar wel een van de meest 
nauwkeurige, en zeer goed bekend in binnen- en buitenland. Daarnaast bedankt voor je 
kritische blik bij elk nieuw manuscript. Natuurlijk eindigt onze samenwerking en database 
hier niet en gaan we op voor de 1000! 
 
Drs. D.E.G. Kok, beste Dieuwertje, bedankt voor je hulp met de database. Dankzij je inzet was 
het mogelijk om de database te vervolmaken. Je kwam net op een punt dat ik het even niet 
meer zag zitten om naast mijn klinisch werk ook nog alle ontbrekende statussen door te 
worstelen. Door jouw doorzettingsvermogen en precisie hebben we uiteindelijk een groot 
aantal abstracts geschreven wat uiteindelijk heeft geresulteerd in een groot deel van de 
artikelen in dit boekje. Nu jij nog! 
 
Prof.dr. J.A. Schalken, beste Jack, beste Sjaak. Het begin van mijn interesse voor de wetenschap 
werd in het CWZ gelegd nadat ik door Herbert aan je werd voorgesteld. Dat jij zei dat de 
DD3 test een grote ontdekking zou worden heb ik in het begin maar met een korreltje zout 
genomen. Ik vond het gewoon leuk om eraan mee te doen, hoewel je me in het begin wel 
consequent Ingrid bleef noemen (nog steeds trouwens!). Maar dankzij de DD3 test (nu PCA3 
test) en dus mijn eerste publicatie werd ik enthousiast voor het onderzoek. Ik kijk dan ook 
uit naar een langdurige samenwerking, jij het basaal wetenschappelijke deel en dan ik de 
klinische uitwerking. Ingrid/Inge. 
 
Dr. H. Karthaus, beste Herbert, bedankt voor het begeleiden van mijn eerste stapjes op het 
gebied van de urologie en de wetenschap. Dank zij jou ben ik in contact gekomen met Jack 
en werd ik medeauteur bij het artikel over PCA3. Daarmee is de kiem gelegd en zie hier het 
resultaat. 
 
Ȃǰ zoals jullie hierboven hebben gelezen lag het nooit in mijn planning om in de 
academie te blijven. Dat ik er toch ben gebleven is onder andere omdat er naast het 
interessante werk ook een goede sfeer heerst. En altijd is er naast het serieuze werk tijd voor 
een lach. Reden genoeg om nog even te blijven. 
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Rik en Max, bedankt voor jullie samenwerking.  
Rik, ik hoop dat je de ingeslagen weg doorzet en dat jij binnenkort ook een mooi proefschrift 
hebt, waarbij ik je natuurlijk waar mogelijk graag wil ondersteunen.  
Max, ik hoop dat er ook voor jou een mooie urologische carrière in het verschiet ligt. 
 
Prof.dr. Tombal, dear Bertrand, thank you for sharing your database with me. Hopefully this 
will be the start for a good and long cooperation between Brussels and Nijmegen. 
 
Dr. E. van Lin, beste Emile, bedankt voor de samenwerking, in het bijzonder in het Prostaat 
Kanker Centrum. We hebben er een mooie multidisciplinaire poli van gemaakt en ik hoop 
dat wij nog lang kunnen samenwerken en daarbij de behandeling van de prostaatkanker 
patiënt optimaliseren. 
 
Prof.dr. Barentsz, beste Jelle, ook jij bent een essentieel onderdeel van het Prostaat Kanker 
ǯȱȱȱȱȱȱȂǯȱȱȱ £ȱȱȱȱºȱ
die wij nog hebben op het gebied van onderzoek en diagnostiek. 
 
Medewerkers van de afdeling radiotherapie en radiologie (Aswin, Jurgen, Thomas, Derya, Caroline), 
bedankt voor de samenwerking, op naar heel veel meer!  
 
Sanna, bedankt voor je ondersteuning bij dit proefschrift met als resultaat deze hele mooie 
lay-out. Het is schitterend geworden! 
 
Marion en Els, bedankt voor de ondersteuning in tijden van nood! 
 
Afdeling urologie, bedankt voor de ondersteuning in de afgelopen jaren. Een aantal van jullie 
heeft mij nog zien ploeteren toen ik daar begon als zaalarts en heeft mij toen goed geholpen. 
Nu ondersteunen jullie de patiënten en zorgen ervoor dat ze weer snel op de been zijn. 
Bedankt! 
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OK assistenten van de urologie. De donderdagen en/of vrijdagen waarop wij samen opereren 
zijn altijd gezellig. Ik ga dan ook met plezier naar de Centrale OK. Dankzij jullie 
ondersteuning is elke OK dag een feestje, waarbij jullie al weten dat Skyradio moet worden 
gemeden. Bedankt!  
 
Poli urologie, vooral te noemen de dames van de oncologie Anita, Jose, Suzanne en Judith. 
Bedankt voor jullie ondersteuning op de altijd ȱȂǯȱ£ȱ ȱ ȱȱȱ
stuk aangenamer.  
Anita moet ik natuurlijk even apart benoemen. Je bent, zoals ik altijd tegen patiënten zeg, 
mijn linker- en rechterhand in mijn contacten met de patiënten. Door je niet aflatend 
enthousiasme voor al mijn nieuwe ideeën hebben we al heel veel nieuws samen opgericht en 
het einde daarvan is nog niet in zicht. Bedankt! 
 
Vrienden en familie, hoewel het waarschijnlijk niet altijd duidelijk was waar ik nu mee bezig 
was, bedankt voor de afleiding, ondersteuning en vriendschap. Fijn om naast de urologie 
ook heel vaak met andere dingen bezig te kunnen zijn. 
 
Martha en Marinus, bedankt voor de steun die jullie Harry, Stein, Ariënne en mij hebben 
gegeven. Het is fijn om even alles achter je te kunnen laten en gewoon te genieten van jullie 
gezelschap en van het Groninger landschap. 
 
Bart en Julie, Nils en Jojanneke, lieve broertjes en nu ook zusjes. Ik had me geen betere kunnen 
wensen! Jammer dat we zover uit elkaar wonen maar gelukkig kunnen we ook nog skypen! 
 
Pap en mam, bedankt voor jullie onvoorwaardelijke steun. Jullie hebben mij geleerd om door 
te zetten ook als het tegen zit. Daarnaast was het voor jullie altijd duidelijk dat ik alles kon 
worden wat ik maar wilde en zie hier het resultaat. Ik hou van jullie. 
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Stein en Ariënne, lieve moppies, gelukkig zijn er altijd weer jullie stralende gezichtjes aan het 
einde van de dag. Dan weet ik weer wat belangrijk is!  
 
Lieve Harry, somȱ£ȱ ȱȱȱǳ 
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CURRICULUM VITAE 
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Inge Mariël van Oort  ȱȱŝȱȱŗşŜşȱȱȱ	ǯȱȱȱȁȂȱȱ
zij daar haar HAVO en Atheneum doorlopen in Groningen en daarna van 1991 tot 1997 aan 
de Universiteit van Groningen haar Geneeskunde opleiding gevolgd. De coschappen werden 
ook vlak bij de Martinitoren gelopen in het Academisch Ziekenhuis te Groningen, nu het 
UMCG.  
 
In 1996 trouwde zij met Harry Dijkstra. Na het artsexamen in 1997 is zij een jaar Agnio 
Chirurgie geweest in het Sophia Ziekenhuis te Zwolle. Aldaar werd duidelijk dat niet de 
Chirurgie maar de Urologie haar hart had gestolen.  
 
Na dat jaar in Zwolle werd er gedurende een aantal maanden onderzoek verricht bij dr. E.A. 
Rodrigues Pereira in het Rijnstate Ziekenhuis te Arnhem en in dat jaar werd Stein geboren 
(1999). 
 
In datzelfde jaar werd zij aangenomen voor de opleiding Urologie, en geplaatst in Nijmegen. 
De vooropleiding chirurgie werd gestart in het Canisius Wilhelmina Ziekenhuis te Nijmegen 
in de herfst van 1999.  
 
Net voor de start van het perifere deel van haar opleiding Urologie ook in het Canisius 
Wilhelmina Ziekenhuis (CWZ) te Nijmegen (opleider dr. H. Karthaus), werd Ariënne 
geboren (2001). In de jaren in het CWZ (2002-2004) werden de eerste voetstappen gezet op 
het terrein van het wetenschappelijk onderzoek (DD3 test, nu PCA3 test). 
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De laatste 2 jaar van haar opleiding (2004-2006) vonden plaats in het UMC St Radboud 
(opleider prof.dr. J.A. Witjes). Daar werd duidelijk dat de Oncologische Urologie haar 
meeste interesse had en werd een begin gemaakt met het opzetten van de radicale 
prostatectomie database.  
 
Vanaf 2006 werd met een fellowship Oncologische Urologie (2006-2008) een vervolg gegeven 
aan haar opleiding (opleider prof.dr J.A. Witjes) en werd zij staflid van de afdeling Urologie 
van het UMC St Radboud. Na afronding van het fellowship werd zij aangesteld als 
Oncologisch Uroloog in het UMC St Radboud. Een van de specifieke aandachtspunten zijn 
de prostaatkankerpatiënten waarvoor zij een multidisciplinaire prostaatkankerpoli heeft 
opgezet. 
 
Dit jaar (2009) viert zij ook haar 12½ jarig huwelijk en haar 40e verjaardag. 
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